CDK2 inhibitors and uses thereof

Selective CDK2 inhibitors, as described by specific compound structures, address the lack of targeted CDK2 therapies by reducing toxicities and improving treatment outcomes for cancers with deregulated CDK2 activity.

WO2024243485A1PCT designated stage expired Publication Date: 2024-11-28ODYSSEY THERAPEUTICS INC

Patent Information

Application Number
PCT/US2024/030933
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current CDK inhibitors targeting CDK2 are not selectively effective, leading to significant hematopoietic and gastrointestinal toxicities due to their broad inhibition of CDK family members, and no agents specifically targeting CDK2 have been approved for clinical use.

Method used

Development of compounds with specific structures, such as those according to Formula (I), (II), (III), and (IV), or listed in Table 1, which are selectively inhibitory to CDK2 over other CDKs, reducing toxicity and enhancing therapeutic efficacy.

Benefits of technology

These compounds demonstrate selective inhibition of CDK2, potentially reducing toxicities associated with broader CDK inhibition and providing a targeted approach for treating cancers with deregulated CDK2 activity, including those resistant to platinum-based treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
Patent Text Reader

Abstract

The present disclosure relates to compounds and pharmaceutical compositions, and methods for inhibiting the activity of CDK enzymes, in particular CDK2, with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK2 signaling with the compounds and compositions of the disclosure.
Need to check novelty before this filing date? Find Prior Art

Description

CDK2 INHIBITORS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 468,888, filed May 25, 2023, the disclosure of which is herein incorporated by reference in its entirety.FIELD OF INVENTION

[0002] The present disclosure relates to compounds and pharmaceutical compositions capable of inhibiting the activity of CDK enzymes, in particular CDK2.BACKGROUND OF THE DISCLOSURE

[0003] Cyclin-dependent kinases (CDKs) are a family of serine / threonine kinases that are regulated by direct binding to cyclins. CDK levels remain relatively constant throughout the cell cycle, and it is the selective activation of specific CDKs that allows for the proper ordering of the steps in cell cycle progression. Activation of CDKs requires heterodimerization with regulatory subunits known as cyclins. Cell cycle deregulation is a common feature of human cancer.

[0004] Cyclin-dependent kinase 2 (CDK2) participates in a range of biological activities and is a key cell cycle regulator. For example, CDK2 is active from the late Gl-phase and throughout the S-phase, is involved in DNA damage response (DDR) through the homologous recombination (HR) pathway, and also regulates aspects of apoptotic pathways. Cyclin El (CCNE1), cyclin E2 (CCNE2), cyclin Al (CCNA1), and cyclin A2 (CCNA2), along with p21Cipl / Wafl, p27Kipl and p57Kip2 (the cyclin dependent kinase inhibitors of the cyclin-CDK2 complex) are the main regulators of CDK2 activity. In cancer, persistent activation or hyper-activation of CDK2 can result from overexpression of the CDK2-binding cyclins El, E2, Al, or A2 or loss of activity of the cyclin-dependent kinase inhibitor proteins. (See S. Tadesse et al., Drug Discovery Today, Volume 25, Number 2 February 2020).

[0005] Amplification or overexpression of CCNE1 has been identified in ovarian and breast cancer (See Scaltriti, M. et al., Proc. Natl Acad. Sci. USA 108, 3761-3766 (2011) and Etemadmoghadam, D. et al. Proc. Natl Acad. Sci. USA 110, 19489-19494 (2013)). Poor outcomes in gastric, endometrial, and other cancers have been associated with overexpression or amplification of CCNE1 (See Ooi et al. Hum Pathol. (2017) 61 :58-67, and Noske et al, Oncotarget(2017) 8: 14794-14805). CCNE2 is frequently overexpressed in luminal breast cancers (Milioli et al. Endocrine Related Cancer (2020) 27: R93-R112).

[0006] Multiple pan-CDK inhibitors with activity against CDK2 and other CDKs have shown evidence of clinical activity, however they have also shown significant hematopoietic and gastrointestinal toxicities likely due to their inhibition of CDK1 and / or other CDK family members (Otto, T., and Sicinski, P., Nat. Review Cancer 2017; Kumar, K.S., et al. Blood 2015; Shapiro G.I., et al. Clin Cancer Research 2001).

[0007] While these findings indicate that CDK2 is a potential target for cancers with deregulated CDK2 activity, no agents selectively targeting CDK2 have been approved to date. Thus, there is a strong unmet need for developing new CDK2 inhibitors.SUMMARY OF THE DISCLOSURE

[0008] The present disclosure relates to compounds, pharmaceutical compositions, and methods for inhibiting the activity of CDK enzymes, in particular CDK2. An exemplary embodiment of the present disclosure provides a compound having a structure according to Formula (I).

[0009] In one aspect, the present disclosure provides a compound having a structure according toFormula (I):pharmaceutically acceptable salt thereof. In one embodiment, X is O or NH. In one embodiment, A is an optionally substituted heterocycle or bicyclic heterocycle selected from the group consisting. In one embodiment, Q1and Q2are ted from C and N, provided that at leastone of Q1, Q2and Q3is N. In one embodiment, R1is selected from the group consisting of a halogen, cyano, and C1-C6alkyl. In one embodiment, R2is selected from the group consisting of -NH2, -NHR3, -NR3R4, and C1-C6 alkyl. In one embodiment, R3 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, wherein the C1-C6alkyl, C3-C7cycloalkyl, and C3-C7heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2. In one embodiment, R4 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, wherein the C1-C6alkyl, C3-C7cycloalkyl, and C3-C7heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6 alkyl) -NH2, -NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2. In one embodiment, R5 is independently at each occurrence selected from the group consisting of C1-C6alkyl, or two R5groups are combined to form one or more of =O, a spiro and a bridged C3-C7cycloalkyl, which C1-C6 alkyl and C3-C7 cycloalkyl is optionally substituted with one or more of halogen, -OH, and -O(C1-C6 alkyl). In one embodiment, R6 is selected from the group consisting of hydrogen, C1-C6 alkyl, and -C(O)C1-C6alkyl.

[0010] In some embodiments, X is O. In other embodiments, X is NH. In some embodiments, R1 is selected from -F, -Cl, cyano and -CH3. In some particular embodiments, R1 is a halogen. In other embodiments, R1is cyano. In yet another embodiment, R1is C1-C6alkyl. In some embodiments, R2is C1-C6alkyl. In some particular embodiments, R2is -CH3. In other embodiments, R2is -NH2. In some other embodiments, R2 is -NHR3 and R3 is C1-C6 alkyl. In some embodiments, R2 is - NHR3and R3is -CH3. In some embodiments, R2is -NHR3and R3is -CD3. In some embodiments, R3is an optionally substituted -C2alkyl. In some embodiments, R3is selected from -CH2CH3, . In some embodiments, R3 is an optionallysu st tute 3- 4 a y . n anot er em o ment, R3 is selected from propyl, isopropyl, butyl,isobutyl, tert-butyl, and . In yet another embodiment, R3 is C3-C7 cycloalkyl. In certai l or cyclobutyl. In certain embodiments, R3is C3-C7heterocycloalkyl. In certain embodiments, R3is a combination of C1-C6alkyl and C3-C7heterocycloalkyl. In certain embodiments, R3 is a combination of C1-C3 alkyl and azetidinyl.

[0011] In some embodiment, R3 is selected from the group consisti ,. In one particular embodiment, R3is tetrahydrofuranyl.

[0012] In various embodiments is absent. In another embodiment, Ais selected from the group consistin , wherein R5 is independently at eac2, - CH2OH, and -CH2OCH3. In some embodiments, two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro- cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl. In various embodiments, A is selected from the group consisting ,,, .In a particular embodiment , wherein R5is absent, R5is independently at each occurrence selected from m -CHF2, -CH2OH, and -CH2OCH3, or two R5groupscombine to make a spiro-C3-C7 cycloalkyl selected from the group consisting of a spiro- cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl, and R6is selected from the group consisting of hydrogen, C1-C6alkyl, and -C(O)C1- C6 alkyl. In some embodiments wherein R5 is absent, R5 is independently at each occurrence selected fromF, -CHF2, -CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro- cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl. In some embodiments In certain embodiments,is and up, A , A thegroup consisting, wherein Q1is N or CH,wherein Q2 is N or CH, and wherein Q3 is N. In some embodiment orofa structure according to Formula (II): (II), or a pharmaceutically acceptable salt thereof.7

[0014] In some embodiments, the present disclosure provides a compound having a structure according to Formula a pharmaceutically acceptable salt thereof

[0015] In some embodiments, the present disclosure provides a compound having a structure according to Formula a pharmaceutically acceptable salt thereof.

[0016] In some embodiments, the present disclosure provides a compound having a structure according to Formula r a pharmaceutically acceptable salt thereof

[0017] In some embodiments, the present disclosure provides a compound having a structure according to Formula (III): I), or a pharmaceutically acceptable salt thereof.

[0018] In some embodiments, the present disclosure provides a compound having a structure according to Formula a pharmaceutically acceptable salt thereof.

[0019] In some embodiments, the present disclosure provides a compound having a structure according to Formula r a pharmaceutically acceptable salt thereof

[0020] In some embodiments, the compound has a structure selected from the group consisting of or a

[0021] In some embodiments, the present disclosure provides a compound having a structure A according to Formula lly acceptable salt thereof

[0022] In some embodiments, the present disclosure provides a compound having a structure A according to Formula a pharmaceutically acceptable salt thereof.

[0023] In some embodiments, the present disclosure provides a compound having the structure as shown in Table 1, or a pharmaceutically acceptable salt thereof.

[0024] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0025] In another aspect, the present disclosure provides a pharmaceutical dosage form comprising the compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of a compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0026] In yet another aspect, the present disclosure provides a method of targeting cyclin- dependent kinase 2 (CDK2) in a cell, the method comprising contacting the cell with an effective amount of a compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or the pharmaceutical dosage form comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0027] In some embodiments, the cell is a mammalian cell. In other embodiments, the cell is a tumor cell. In another embodiment, the tumor cell is a metastatic tumor cell.

[0028] In another aspect, the present disclosure provides a method of inhibiting CDK2 comprising contacting the CDK2 with an effective amount of the compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or the pharmaceutical dosage form comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0029] In some embodiments, the contacting is in a subject.

[0030] In yet another aspect, the present disclosure provides a method of treating a subject having, or at risk of developing, a disease or disorder associated with CDK2, comprising administering to the subject a therapeutically effective amount of a compound according to of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or the pharmaceutical dosage form comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0031] In yet another aspect, the present disclosure provides a method of treating a CDK2- mediated disorder or disease in a subject, the method comprising administering a therapeutically effective amount of a compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or the pharmaceutical dosage form comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0032] In some embodiments, the disorder is cancer. In some embodiments, the cancer treatable with a compound or composition of the present disclosure is a cancer of the lung, breast, gastrointestinal tract, esophagus, liver, biliary tract, bladder and other urinary tract tissues, pancreas, female and male genital organs, prostate, ovary, uterus, skin, lymphoid and blood cells, plasma cells (multiple myeloma) mesenchymal tissues (sarcomas), head and neck, visual system, brain and spinal cord, or melanoma. In some embodiments, the cancer can be selected from the group consisting of adrenal gland cancer, anal cancer, appendiceal cancer, ovarian cancer, uterine cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, cervical cancer, stomach cancer, sarcoma cancer, liver cancer, esophageal cancer, laryngeal cancer, multiple myeloma, colorectal cancer, rectal cancer, skin cancer, pancreatic cancer, brain and spinal cord cancer, leukemia or lymphoma. In some embodiments, the compound is at least two-fold more selective for CDK2 over CDK1, CDK5, CDK6, CDK7, and / or CDK9.

[0033] In yet another aspect, the present disclosure provides a method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1, or the pharmaceutical dosage form comprising the compound of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1.

[0034] In some embodiments, the cancer can be characterized by deregulation of CDK2 or cyclin E.

[0035] In one embodiment, the cancer can be characterized by overexpression of cyclin E1 and / or cyclin E2. In some embodiments, the overexpression of cyclin E1 and / or cyclin E2 can be theoverexpression of RNA and / or protein encoded by CCNE1 and / or CCNE2. In one embodiment, more than two copies of CCNE1 and / or CCNE2 can be present.

[0036] In some embodiments, the cancer can be characterized by a genomic alteration. In some embodiments, the genomic alteration can be characterized by one or more of the following: greater than the normal two copies (amplification) of the CCNE1 and / or CCNE2 genes, RB1 loss of function mutation, FBXW7 loss of function mutation, MYC amplification, and / or KRAS mutation. The RB1 loss of function can be attributed to function-disabling point mutation in the RB1 gene, RB1 gene deletion, and / or epigenetic repression of RB1 gene expression (transcription). The FBXW7 loss of function can be attributed to function-disabling point mutation, gene deletion, and / or epigenetic repression of FBXW7 gene expression (transcription). MYC gene amplification or protein stabilization can lead to MYC overexpression. The MYC overexpression can be attributed to one or more of the MYC family members, c-MYC, L-MYC and N-MYC.

[0037] In some embodiments, the cancer can be metastatic cancer. In one embodiment, the cancer can be characterized by its origination in or metastasis to the brain. In one embodiment, the cancer is a cancer of the lung, breast, esophagus, and melanoma that has metastasized to the brain.

[0038] In some embodiments, the cancer can be selected from the group consisting of adrenal gland cancer, anal cancer, appendiceal cancer, ovarian cancer, uterine cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, cervical cancer, stomach cancer, sarcoma cancer, liver cancer, esophageal cancer, laryngeal cancer, multiple myeloma, colorectal cancer, rectal cancer, skin cancer, pancreatic cancer, brain or spinal cord cancer, leukemia or lymphoma.

[0039] In some embodiments, the cancer is platinum-resistant and / or platinum-refractory. In some embodiments, the cancer has progressed despite platinum treatment.

[0040] In various embodiments, the adrenal gland cancer can be adrenocortical carcinoma or pheochromocytoma. The breast cancer can be hormone receptor (HR)-positive, HER2-negative breast cancer; HR-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer; triple negative breast cancer (TNBC), or inflammatory breast cancer. The breast cancer can be drug-naïve breast cancer, endocrine resistant breast cancer, trastuzumab resistant breast cancer, breast cancer demonstrating primary or acquired resistance to CDK4 / CDK6 inhibition, platinum-resistant breast cancer or platinum-refractory breast cancer. The breast cancer can be advanced or metastatic breast cancer. The liver cancer can be hepatocellular carcinoma. The lung cancer can be small cell lung cancer, non-small cell lung cancer, or large cell lung cancer. Thenon-small cell lung cancer can be squamous cell carcinoma or adenocarcinoma. The laryngeal cancer can be laryngeal squamous cell carcinoma. The skin cancer can be melanoma, basal cell carcinoma, squamous cell carcinoma, or Merkel cell cancer. The uterine cancer can be endometrial cancer or uterine sarcoma. In some embodiments, the uterine cancer (e.g., endometrial cancer) is platinum-resistant or platinum-refractory endometrial cancer. In some embodiments, the ovarian cancer is platinum-resistant or platinum-refractory endometrial cancer. The brain cancer can be selected from glioma, astrocytoma, meningioma, glioblastoma multiforme, medulloblastoma, ependymoma, oligodendroglioma, craniopharyngioma, pituitary adenoma, Schwannoma, anaplastic astrocytoma, germ cell tumor, primitive neuroectodermal tumor, chordoma, haemangioblastoma, optic nerve glioma, subependymoma, and germinoma .

[0041] In various embodiments, the subject can be a human. The subject can be an adult. The subject can be a pediatric subject 0 to 18 years of age.

[0042] In some embodiments, the compound, the pharmaceutical composition, or the pharmaceutical dosage form can be administered orally, intravenously or subcutaneously.

[0043] In some embodiments of any of the above methods, the method can further comprise administering an effective amount of a second therapeutic agent. The second therapeutic agent can be an anti-neoplastic agent. The anti-neoplastic agent can be selected from the group consisting of an antibody, an antibody-drug conjugate, a DNA synthesis inhibitor, a DNA-intercalating agent, a platinum-based agent, topoisomerase I inhibitor, topoisomerase II inhibitor, an alkylating agent, an anti-microtubule agent, an anti-mitotic agent, a taxane-related anti-neoplastic agent, an anti- metabolite, an anti-tumor plant alkaloid, an anti-estrogen agent, a protein or phosphatidylinositol 3-kinase inhibitor, an immunomodulator, a histone deacetylase inhibitor, a KRAS inhibitor, an immunotherapeutic agent, or an epigenetic modulator. The antibody-drug conjugate can comprise sacituzumab govitecan (Trodelvy), mirvetuximab soravtansine (Elahere), trastuzumab deruxtecan (Enhertu), enfortumab vedotin (Padcev), or tisotumab vedotin (Tivdak). The DNA synthesis inhibitor can comprise capecitabine, gemcitabine, nelarabine, or hydroxycarbamide. The platinum-based agent can comprise carboplatin, oxaliplatin or cisplatin. The topoisomerase I inhibitor can comprise camptothecin, irinotecan or topotecan. The DNA-intercalating agent can comprise doxorubicin or liposomal doxorubicin (Doxil). The topoisomerase II inhibitor can comprise etoposide or teniposide. The alkylating agent can comprise temozolomide, dactinomycin, melphalan, altretamine, carmustine, bendamustine, busulfan, lomustine, ,chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, or procarbazine. The anti- microtubule agent can comprise estramustine. The taxane anti-neoplastic agent can comprise paclitaxel, docetaxel, cabazitaxel larotaxel, or abraxane. The anti-metabolite can comprise 5- fluorouracil, 6-thioguanine, pemetrexed, cytarabine, hydroxyurea, fludarabine, floxuridine, cladribine, pentostatin, or methotrexate. The anti-tumor plant alkaloid can comprise vinblastine, vincristine, or vinorelbine. The anti-estrogen agent can comprise tamoxifen, toremifene, raloxifene, lasofoxifene, afimoxifene, arzoxifene, bazedoxifene, fispemifene, ormeloxifene, ospemifene, tesmilifene, trilostane, CHF 4227, fulvestrant, elacestrant, giredestrant, amcenestrant, camizestrant, ataraestane, formestane, exemestane, letrozole, anastrozole, fadrozole; gonadotropin-releasing hormone, leuprolide, leuprolide acetate, enzalutamide, abiraterone acetate, or bicalutamide. The protein kinase inhibitor can comprise a CDK4 / 6 inhibitor (e.g., palbociclib, ribociclib, trilaciclib, or abemaciclib), alvocidib, crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrectinib, lorlatinib, vemurafenib, dabrafenib, infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547, trametinib, cobimetinib, binimetinib, selumetinib, ulixertinib, MK-8353, LY-3214966, bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib, erlotinib, linifanib, sunitinib, pazopanib, gefitinib, osimertinib, cetuximab, panitumumab, trastuzumab, neratinib, lapatinib, or cabozantinib. The histone deacetylase inhibitor can comprise voninostat. The phosphatidylinositol 3-kinase inhibitor can comprise apelisib (Piqray), duvelisib (Copiktra), copanlisib (Aliqopa), or idelalisib (Zydelig). The KRAS inhibitor can comprise AMG510, MRTX849, JNJ-74699157 / ARS- 3248, Bl 1701963, Bl 1823911, BAY-293, GDC- 6036, MRTX1133, a RAS(ON) inhibitor, or combinations thereof. The immunotherapeutic agent can target at least one of PD1, PD-L1, PD-L2, CTLA-4, LAG3, TIM3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, 4-1BB, GITR, OX40, or TGF beta receptor. In some embodiments, the immunotherapeutic agent comprises a CTLA-4 inhibitor, a PD1 inhibitor, a PD-L1 inhibitor, a LAG3 inhibitor, or a 4-1BB agonist. The CTLA-4 inhibitor can comprise tremelimumab or ipilimumab. The PD1 inhibitor can comprise nivolumab or pembrolizumab. The PDL1 inhibitor can comprise atezolizumab, avelumab, or durvalumab. The LAG3 inhibitor can comprise BMS- 986016. In some embodiments, the immunotherapeutic agent comprises a chimeric antigen receptor (CAR) T-cell therapy. The epigenetic modulator may comprise EZH2a, ARID1A, ARID2, PRMT1-9, BRD4, IDH1 / 2, or BCL6.

[0044] These and other aspects of the present disclosure will become apparent to those skilled in the art after a reading of the following detailed description, including the appended claims. DETAILED DESCRIPTION

[0045] Detailed embodiments of the present disclosure are disclosed herein; however, it is to be understood that the disclosed embodiments are merely illustrative of the disclosure that may be embodied in various forms. In addition, each of the examples given in connection with the various embodiments of the disclosure is intended to be illustrative, and not restrictive. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously employ the present disclosure.

[0046] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. For purposes of interpreting this specification, the following description of terms will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that any description of terms set forth conflicts with any document incorporated herein by reference, the description of term set forth below shall control. Definitions

[0047] As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to “a method” includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure.

[0048] As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 10%. For example, as used herein, the expression "about 100" includes 90 and 110 and all values in between (e.g., 91, 92, 93, 94, 95, 96, 97, 98, 99, etc.).

[0049] Herein, the use of terms such as “having,” “has,” “including,” or “includes” are open- ended and are intended to have the same meaning as terms such as “comprising” or “comprises” and not preclude the presence of other structure, material, or acts. Similarly, though the use of terms such as “can” or “may” are intended to be open-ended and to reflect that structure, material,or acts are not necessary, the failure to use such terms is not intended to reflect that structure, material, or acts are essential. To the extent that structure, material, or acts are presently considered to be essential, they are identified as such.

[0050] By “comprising” or “containing” or “including” is meant that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if the other such compounds, material, particles, method steps have the same function as what is named.

[0051] It is also to be understood that the mention of one or more method steps does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified.

[0052] For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates.

[0053] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” or “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstitutedalkyl, alkenyl, alkynyl groups and hybrids thereof such as cycloalkyl, (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0054] The term “alkyl”, unless otherwise indicated, as used herein, refers to a monovalent aliphatic hydrocarbon radical having a straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof, wherein the radical is optionally substituted at one or more carbons of the straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof with one or more substituents at each carbon, wherein the one or more substituents are independently C1-C10 alkyl. In some embodiments, “cycloalkyl” (or “carbocycle”) refers to a monocyclic C3-C6hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. A carbocycle can be, under certain circumstances, a bridged bicyclic or a fused ring such as, e.g., an ortho-fused carbocycle, a spirofused carbocycle, etc. Examples of “alkyl” groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert- butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

[0055] The term “lower alkyl” refers to a C1-4straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0056] The term “lower haloalkyl” refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.

[0057] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).

[0058] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.

[0059] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., –(CH2)n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0060] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0061] The term “alkoxy” means an alkyl radical attached through an oxygen linking atom, represented by -O-alkyl. For example, “(C1-C4)alkoxy” includes methoxy, ethoxy, propoxy, and butoxy)

[0062] The term “halogen” means fluorine, chlorine, bromine, or iodine.

[0063] The term “aryl,” used alone or as part of a larger moiety, refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of compounds described herein, “aryl” refers to an aromatic ring system which includes, but is not limited to, phenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. It will be appreciated that an “aryl” group can comprise carbon and heteroatom ring members.

[0064] The terms “heteroaryl” or “heteroaromatic”, unless otherwise defined, as used herein refers to a monocyclic aromatic 5-6 membered ring containing one or more heteroatoms, for example one to four heteroatoms, such as nitrogen, oxygen, and sulfur, or an 8-10 membered polycyclic ring system containing one or more heteroatoms, wherein at least one ring in the polycyclic ring system is aromatic, and the point of attachment of the polycyclic ring system is through a ring atom on an aromatic ring. A heteroaryl ring may be linked to adjacent radicals though carbon or nitrogen. Examples of heteroaryl rings include but are not limited to furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, indole, tetrahydrofuranyl, etc.

[0065] The terms “heterocyclyl”, “heterocycle”, or “heterocyclic group”, unless otherwise defined, refer to a saturated or partially unsaturated 3-10 membered monocyclic or 7-14 membered polycyclic ring system, including bridged or fused rings (e.g., an ortho-fused bicyclic or a spirofused bicyclic ring), and whose ring system includes one to four heteroatoms, such as nitrogen, oxygen, and sulfur. Spirofused bicyclic rings can be spiro-C3-C7cycloalkyl, such as, for example, spiro-cyclopropyl, spiro-cyclobutyl, spiro-cyclopentyl, spiro-cyclohexyl, or bridge-C3- C7 cycloalkyl. A heterocyclyl ring may be linked to adjacent radicals through carbon or nitrogen.

[0066] The term “partially unsaturated” in the context of rings, unless otherwise defined, refers to a monocyclic ring, or a component ring within a polycyclic (e.g. bicyclic, tricyclic, etc.) ring system, wherein the component ring contains at least one degree of unsaturation in addition to those provided by the ring itself, but is not aromatic. Examples of partially unsaturated rings include, but are not limited to, 3,4-dihydro-2H-pyran, 3-pyrroline, 2-thiazoline, etc. Where a partially unsaturated ring is part of a polycyclic ring system, the other component rings in the polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on a partially unsaturated component ring.

[0067] The term “saturated” in the context of rings, unless otherwise defined, refers to a 3-10 membered monocyclic ring, or a 7-14 membered polycyclic (e.g. bicyclic, tricyclic, etc.) ring system, wherein the monocyclic ring or the component ring that is the point of attachment for the polycyclic ring system contains no additional degrees of unsaturation in addition to that provided by the ring itself. Examples of monocyclic saturated rings include, but are not limited to, azetidine, oxetane, cyclohexane, etc. Where a saturated ring is part of a polycyclic ring system, the other component rings in the polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on a saturated component ring.

[0068] The terms “alkylene”, “arylene”, “cycloalkylene”, “heteroarylene”, “heterocycloalkylene”, and the other similar terms with the suffix “-ylene” as used herein refers to a divalently bonded version of the group that the suffix modifies. For example, “alkylene” is a divalent alkyl group connecting the groups to which it is attached.

[0069] As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted.

[0070] As described herein, compounds described herein may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0071] The term “tautomer” as used herein refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. It is understood that tautomers encompass valence tautomers and proton tautomers (also known as prototropic tautomers). Valence tautomers include interconversions by reorganization of some of the bonding electrons. Proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Unless otherwise stated, all tautomers of the compounds described herein are within the scope of the disclosure.

[0072] The term “isotopic substitution” as used herein refers to the substitution of an atom with its isotope. The term “isotope” as used herein refers to an atom having the same atomic number as that of atoms dominant in nature but having a mass number (neutron number) different from the mass number of the atoms dominant in nature. It is understood that a compound with an isotopic substitution refers to a compound in which at least one atom contained therein is substituted with its isotope. Atoms that can be substituted with its isotope include, but are not limited to, hydrogen, carbon, and oxygen. Examples of the isotope of a hydrogen atom include2H (Deuterium, also represented as D) and3H (Tritium, also represented as T). Examples of the isotope of a carbon atom include13C and14C. Examples of the isotope of an oxygen atom include18O. Unless otherwise stated, all isotopic substitution of the compounds described herein are within the scope of the disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.

[0073] As used herein, "crystalline form" is meant to refer to a certain lattice configuration of a crystalline substance. Different crystalline forms (polymorphs) of the same substance typically have different crystalline lattices (e.g., unit cells) which are attributed to different physical properties that are characteristic of each of the crystalline forms. In some instances, different lattice configurations have different water or solvent content. Crystalline forms of a substance include both solvated (e.g., hydrated) and non-solvated (e.g., anhydrous) forms. A hydrated form is a crystalline form that includes water in the crystalline lattice. Hydrated forms can be stoichiometric hydrates, where the water is present in the lattice in a certain water / molecule ratio such as for hemihydrates, monohydrates, dihydrates, etc. Hydrated forms can also be non-stoichiometric, where the water content is variable and dependent on external conditions such as humidity.

[0074] The different crystalline lattices can be identified by solid state characterization methods such as by X-ray powder or thin film diffraction (XRD). Other characterization methods such as Raman spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), solid state NMR, and the like further help identify the crystalline form as well as help determine stability and solvent / water content. Typically, different crystalline forms of the same substance have different bulk properties relating to, for example, hygroscopicity, solubility, stability, and the like. Forms with high melting points often have good thermodynamic stability which is advantageous in prolonging shelf-life of formulations containing the solid form. Forms with lower melting points often are less thermodynamically stable, but are advantageous in that they have increased water solubility, translating to increased drug bioavailability. Forms that are weakly or non-hygroscopic are desirable for their stability to heat and humidity and are resistant to degradation during long storage. Anhydrous forms are often desirable because they can be consistently made without concern for variation in weight or composition due to varying solvent or water content. On the other hand, hydrated or solvated forms can be advantageous in that they are less likely to be hygroscopic and may show improved stability to humidity under storage conditions. With respect to XRD, the term "peak" refers to a reflection having a relative height / intensity of at least about 4% of the maximum peak height / intensity. Moreover, instrument variation and other factors can affect the 2-theta values. Thus, peak assignments, such as those reported herein, can vary by plus or minus about 0.2° (2-theta), and the term "substantially" as used in the context of XRD herein is meant to encompass the above-mentioned variations.

[0075] When a compound recrystallizes from a solution, slurry, within a porous media, or other means, the compound may crystallize with different spatial lattice arrangements, a property referred to as “polymorphism.” The different crystal forms are individually referred to as a “polymorph” or “form.” Different polymorphic forms of a compound may differ from each other with respect to one or more physical property, such as solubility, true density, crystal shape, compaction behavior, flow properties, lethality, solid state stability, and the like.

[0076] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Exemplary pharmaceutically acceptable salts are found, e.g., in Berge, et al. (J. Pharm. Sci.1977, 66(1), 1; and Gould, P.L., Int. J. Pharmaceutics 1986, 33, 201-217; (each hereby incorporated by reference in its entirety).

[0077] Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0078] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0079] Pharmaceutically acceptable salts are also intended to encompass hemi-salts, wherein the ratio of compound:acid is respectively 2:1. Exemplary hemi-salts are those salts derived from acids comprising two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid and citric acid. Other exemplary hemi- salts are those salts derived from diprotic mineral acids such as sulfuric acid. Exemplary hemi- salts include, but are not limited to, hemimaleate, hemifumarate, and hemisuccinate.

[0080] An “effective amount”, “sufficient amount” or “therapeutically effective amount” as used herein is an amount of a compound that is sufficient, when administered to a subject or population suffering from or susceptible to a disease, disorder, and / or condition in accordance with a therapeutic dosing regimen, to treat (e.g., effect beneficial or desired results, including clinical results) the disease, disorder, and / or condition. As such, the effective amount may be sufficient, e.g., to reduce or ameliorate the severity and / or duration of afflictions related to CDK2 signaling, or one or more symptoms thereof, prevent the advancement of conditions or symptoms related to afflictions related to CDK2 signaling, or enhance or otherwise improve the prophylactic or therapeutic effect(s) of another therapy. An effective amount also includes the amount of the compound that avoids or substantially attenuates undesirable side effects.

[0081] The terms “enhance” or “promote,” or “increase,” or “expand,” or “improve” refer generally to the ability of a composition contemplated herein to produce, elicit, or cause a greater physiological response (i.e., downstream effects) compared to the response caused by either vehicle or a control molecule / composition. A measurable physiological response may include an increase in immune cell expansion, activation, effector function, persistence, and / or an increase in tumor cell death killing ability, among others apparent from the understanding in the art and the description herein. In certain embodiments, an “increased” or “enhanced” amount can be a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7.1.8, etc.) the response produced by vehicle or a control composition.

[0082] The terms “decrease” or “lower,” or “lessen,” or “reduce,” or “abate”, or “attenuate”, or “suppress” refer generally to the ability of composition contemplated herein to produce, elicit, orcause a lesser physiological response (i.e., downstream effects) compared to the response caused by either vehicle or a control molecule / composition. In certain embodiments, a “decrease” or “reduced” amount can be a “statistically significant” amount, and may include a decrease that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7.1.8, etc.) the response (reference response) produced by vehicle or a control composition.

[0083] The terms “treat” or “treatment” of a state, disorder or condition include: (1) preventing, delaying, or reducing the incidence and / or likelihood of the appearance of at least one clinical or sub-clinical symptom of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition, but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; or (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof or at least one clinical or sub-clinical symptom thereof; or (3) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or sub-clinical symptoms. The benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician.

[0084] The terms “effective amount” or “therapeutically effective amount” refer to a quantity and / or concentration of a composition containing an active ingredient (e.g., CDK2 inhibitor compound) that when administered into a patient either alone (i.e., as a monotherapy) or in combination with additional therapeutic agents, yields a significant decrease in disease progression, for example, by ameliorating or eliminating symptoms and / or the cause of the disease. An effective amount may be an amount that relieves, lessens, or alleviates at least one symptom or biological response or effect associated with a disease or disorder, prevents progression of the disease or disorder, or improves physical functioning of the patient. A therapeutically effective amount of a composition containing an active agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the active agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the active agent are outweighed by the therapeutically beneficial effects. A therapeutically effective amount may be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic and / or prophylactic result.

[0085] The terms “individual”, “subject” and “patient” are used interchangeably herein to refer to an animal; for example a mammal. The terms include human and veterinary subjects. In some embodiments, methods of treating mammals, including, but not limited to, humans, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are provided. The subject can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. In some embodiments, a subject can be a subject in need of treatment for a disease or disorder. In particular embodiments, the subject is a human.

[0086] As used herein, the human subject can be an adult, older adult (e.g., geriatric), or a pediatric subject. “Adult” subjects mean 21 years to less than 65 years and “older adult” or "geriatric" subjects range from 65 years to less than 74 years; 75 years to less than 84 years; and greater than 85 years. “Pediatric” subjects include neonates (i.e., from birth through the first 28 days of life), infants (29 days to less than 2 years), children (2 years to less than 12 years), or adolescents (aged 12 years through 21 years).

[0087] The phrase “in need thereof” refers to the need for symptomatic or asymptomatic relief from conditions related to CDK2 signaling activity or that may otherwise be relieved by the compounds and / or compositions of the disclosure. Compounds of the Disclosure

[0088] In some embodiments, the compound can have a structure according to Formulas I, II, IIA, IIB, III, IIIA, IIIB, IIIC, or IV:or

[0089] In some embodiments of the compounds of Formulas (I), (II), (III) and (V), X is O or NH. In one embodiment, X is O. In another embodiment, X is NH.

[0090] In some embodiments of the compounds of Formulas (I), (III), (IIIA)-(IIIC) and (V), A is an optionally substituted heterocycle or bicyclic heterocycle selected from the group consisting of Q2 t atleast one of Q1, Q2and Q3is N.

[0092] In some embodiments is absent, or R5 is independently at each occurrence selected froalkyl.

[0093] In certain embodiments where A is selected fro ors absent, or R5is independently at each occurrence selected from the groupyl, or two R5 groups are combined to form one or more of =O, a spiro and a bridged C3-C7 cycloalkyl, which C1-C6 alkyl and C3-C7 cycloalkyl is optionally substituted with one or more of halogen, -OH, and -O(C1-C6alkyl). In some embodiments A is selected from the, , ,

[0094] In certain embodiment is absent, or R5 is independently at each occur-CH2OH, and - CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl, and R6 is selected from the group consisting of hydrogen, C1-C6 alkyl, and -C(O)C1-C6alkyl.

[0095] In certain embodiment is absent, or R5 is independently at each occurrence selected from CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro- cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl.

[0096] In certain embodiments .

[0097] In some embodiments is absent, or R5is independently at each occurrence selected f -CH2OH, and -CH2OCH3, or two R5 groups combine to make a spiro-C3-C7 cycloalkyl selected from the group consisting of a spiro- cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7cycloalkyl, and R6 is selected from the group consisting of hydrogen, C1-C6 alkyl, and -C(O)C1- C6 alkyl.

[0098] In some embodiments, A is selected from the group consistin ,.

[0099] In certain embodiment is absent, or R5is independently at each occurrence selected from CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7 cycloalkyl selected from the group consisting of a spiro- cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl.

[0100] In some embodiments, A is selected from the group consistin ,H,hyl, ethyl, -CH2F, -CHF2, -CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro- cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl.

[0102] In some embodiment R5 is absent, or R5is independently at e2, - CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7cycloalkyl.

[0103] In certain embodiments, A is selected from the group consisting of and H, l, -CH2F, -CHF2, -CH2OH, and -CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro- cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl.

[0105] In certain embodiments 5 is independently at each occurrence selecd - CH2OCH3, or two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7cycloalkyl.

[0106] In some embodiments, A is selected from the group consisti ,. bodiments described herein, R1 is selected from the groupconsisting of a halogen, cyano, and C1-C6alkyl. In one embodiment R1is a halogen. In one particular embodiment, R1 is F (Fluoro). In another embodiment, R1 is Cl (Chloro). In another embodiment, R1 is cyano. In yet another embodiment, R1 is C1-C6 alkyl. In one particular embodiment, R1is -CH3.

[0108] In any of the embodiments described herein, R2is selected from the group consisting of -NH2, -NHR3, -NR3R4, and C1-C6 alkyl. In one particular embodiment, R2 is -NH2. In another embodiment, R2 is -NHR3. In yet another embodiment, R2 is -NR3R4. In some embodiments, R2is C1-C6alkyl. In one particular embodiment, R2is -CH3.

[0109] In any of the embodiments described herein, R3 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, wherein the C1-C6alkyl, C3-C7cycloalkyl, and C3-C7heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2. In one particular embodiment, R3 is C1-C6 alkyl, optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6alkyl), -NH2, -NH(C1-C6alkyl), and -NH(C1-C6alkyl)2. In another embodiment, R3is C3-C7cycloalkyl, optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2. In yet another embodiment, R3 is heterocycloalkyl, optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6alkyl), -NH2, -NH(C1-C6alkyl), and -NH(C1-C6alkyl)2.

[0110] In some embodiments described herein, R3 is -CH3, -CD3, or is optionally substituted -C2 alkyl. In one particular embodiment, R3 is -CH3. In another embodiment, R3 is - CD3(deuterated methyl). In yet another embodiment, R3is substituted -C2alkyl.

[0111] In some embodiments, R3 is selected from -CH2CH3, ,. odiment, R3is an optionally substituted C3-C4alkyl. In certainembodiments, R3 is selected from propyl, isopropyl, butyl, isobutyl, tert-butyl andI i l i R i l I h i R is Inanother embodiment, R3is tert-butyl. In one particular embodiment, R3. In anotherembodiment, .

[0113] ments, R3 is C3-C7 cycolalkyl. In one embodiment, R3 is cyclopropyl or cyclobutyl. In yet another embodiment, R3is C3-C7heterocycolalkyl. In one particular embodiment, R3is a combination of C1-C6alkyl and C3-C7heterocycolalkyl. In another embodiment, R3 is a combination of C1-C3 alkyl and azetidinyl.

[0114] In any of the embodiments disclosed herein, R3is selected from the group ent, ent,, y y .

[0116] In any of the embodiments described herein, R4 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, whereinthe C1-C6 alkyl, C3-C7 cycloalkyl, and C3-C7 heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6 alkyl) -NH2, -NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2. In one particular embodiment, R4is C1-C6alkyl, optionally substituted with deuterium. In another embodiment, R4 is C1-C6 alkyl, optionally substituted with halogen. In another embodiment, R4 is C1-C6 alkyl, optionally substituted with -OH. In yet another embodiment, R4 is C1-C6alkyl, optionally substituted with -O(C1-C6alkyl)-NH2. In a certain embodiment, R4is C1- C6alkyl, optionally substituted with -NH(C1-C6alkyl). In another embodiment, R4is C1-C6alkyl, optionally substituted with -NH(C1-C6 alkyl)2.

[0117] In one particular embodiment, R4is C3-C7cycloalkyl, optionally substituted with one or more deuterium atoms. In another embodiment, R4is C3-C7cycloalkyl, optionally substituted with halogen. In another embodiment, R4 is C3-C7 cycloalkyl, optionally substituted with -OH. In yet another embodiment, R4 is C3-C7 cycloalkyl, optionally substituted with -O(C1- C6alkyl)-NH2. In a certain embodiment, R4is C3-C7cycloalkyl, optionally substituted with - NH(C1-C6 alkyl). In another embodiment, R4 is C3-C7 cycloalkyl, optionally substituted with - NH(C1-C6 alkyl)2.

[0118] In one particular embodiment, R4is heterocycolalkyl, optionally substituted with deuterium. In another embodiment, R4is heterocycolalkyl, optionally substituted with halogen. In another embodiment, R4 is heterocycolalkyl, optionally substituted with -OH. In yet another embodiment, R4is heterocycolalkyl, optionally substituted with -O(C1-C6alkyl)-NH2. In a certain embodiment, R4is heterocycolalkyl, optionally substituted with -NH(C1-C6alkyl). In another embodiment, R4 is heterocycolalkyl, optionally substituted with -NH(C1-C6 alkyl)2.

[0119] In any of the embodiments described herein, R5is independently at each occurrence selected from the group consisting of C1-C6alkyl, or two R5groups are combined to form one or more of =O, a spiro and a bridged C3-C7 cycloalkyl, which C1-C6 alkyl and C3-C7 cycloalkyl is optionally substituted with one or more of halogen, -OH, and -O(C1-C6 alkyl). In some embodiments, R5is independently at each occurrence selected from methyl, ethyl, -CH2F, -CHF2, -CH2OH, and -CH2OCH3. In one particular embodiment, R5 is C1-C6 alkyl, optionally substituted with one or more of halogen, -OH, and -O(C1-C6 alkyl). In another embodiment, two R5 groups are combined to form one or more of =O, a spiro and a bridged C3-C7cycloalkyl. In some embodiments, when two R5groups are combined to form a bridged C3-C7cycloalkyl, the C3-C7cycloalkyl is optionally substituted with one or more of halogen, -OH, and -O(C1-C6 alkyl).

[0120] In one particular embodiment, R5 is methyl. In another embodiment, R5 is ethyl. In yet another embodiment, R5 is -CH2F. In a certain embodiment, R5 is -CHF2. In one particular embodiment, R5is -CH2OH. In another embodiment, R5is -CH2OCH3.

[0121] In any of the embodiments described herein, R6 is selected from the group consisting of hydrogen, C1-C6 alkyl, and -C(O)C1-C6 alkyl. In one particular embodiment, R6 is hydrogen. In another embodiment, R6is C1-C6alkyl. In yet another embodiment, R6is -C(O)C1- C6alkyl.

[0122] In some embodiments, the compound according to Formulas I, II, IIA, IIB, III, IIIA, IIIB, IIIC, or IV is provided as a pharmaceutically acceptable salt thereof.

[0123] In some exemplary, non-limiting embodiments, the compound of the disclosure can be selected from a compound of Table 1.

[0124] Table 1: Exemplary compounds according to the disclosure and their IC50 values against CDK2 / E1 and CDK1 / E1 NB Compound NB CDK2 / E1 )O, . In some embodiments, the compounds of the disclosure are selective CDK2 inhibitors. As used herein, the term “selective CDK2 inhibitor” means a compound which selectively inhibits CDK2 over other CDKs and the kinome. Said another way, a selective CDK2 inhibitor has no activity or lower activity against other CDKs and the kinome. A selective CDK2 inhibitor’s inhibitory activity against CDK2 is more potent in terms of IC50value (i.e., the IC50value is lower) when compared with its inhibitory activity against other CDKs and many other kinases. Potency can be measured using known biochemical assays.

[0126] In some embodiments, the activity of a compound described herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) as an inhibitor of a CDK kinase, for example, CDK2, or a mutant thereof, may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine inhibition of either the phosphorylation activity and / or the subsequent functional consequences, or ATPase activity of activated CDK2, or a mutant thereof. Alternative in vitro assays quantitate the ability of the inhibitor to bind to CDK2. Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor / CDK2 complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with CDK2 bound to known radioligands. Representative in vitro and in vivo assays useful in assaying a CDK2 inhibitor include those described and disclosed in the patent and scientific publications described herein. Detailed conditions for assaying a compound described herein as an inhibitor of CDK2, or a mutant thereof, are set forth in the Examples below.

[0127] In some embodiments, the compounds of the disclosure are selective against CDK2 versus CDK1. In some embodiments, compounds show at least 2-fold selectivity for CDK2 versus CDK 1. In some embodiments, compounds show at least 5-fold selectivity for CDK2 versus CDK 1. In some such embodiments, compounds show at least 10-fold selectivity for CDK2 versus CDK1. In other embodiments, compounds show at least 20-fold selectivity for CDK2 versus CDK1. In some embodiments, compounds show at least 30-fold selectivity for CDK2 versus CDK1. in certain embodiments, compounds show at least 40-fold selectivity for CDK2 versus CDK1. In other embodiments, compounds show at least 50-fold selectivity for CDK2 versus CDK1. For example, compounds show at least 100-fold selectivity for CDK2 versus CDK1.

[0128] In some embodiments, the compounds of the disclosure are selective against CDK2 versus CDK5. In some embodiments, compounds show at least 2-fold selectivity for CDK2 versus CDK5. In some embodiments, compounds show at least 5-fold selectivity for CDK2 versus CDK5. In some such embodiments, compounds show at least 10-fold selectivity for CDK2 versus CDK5. In other embodiments, compounds show at least 20-fold selectivity for CDK2 versus CDK5. In some embodiments, compounds show at least 30-fold selectivity for CDK2 versus CDK5. in certain embodiments, compounds show at least 40-fold selectivity for CDK2 versus CDK5. In other embodiments, compounds show at least 50-fold selectivity for CDK2 versus CDK5. For example, compounds show at least 100-fold selectivity for CDK2 versus CDK5.

[0129] In some embodiments, the compounds of the disclosure are selective against CDK2 versus CDK6. In some embodiments, compounds show at least 2-fold selectivity for CDK2 versus CDK6. In some embodiments, compounds show at least 5-fold selectivity for CDK2 versus CDK6. In some such embodiments, compounds show at least 10-fold selectivity for CDK2 versus CDK6. In other embodiments, compounds show at least 20-fold selectivity for CDK2 versus CDK6. In some embodiments, compounds show at least 30-fold selectivity for CDK2 versus CDK6. in certain embodiments, compounds show at least 40-fold selectivity for CDK2 versus CDK6. In other embodiments, compounds show at least 50-fold selectivity for CDK2 versus CDK6. For example, compounds show at least 100-fold selectivity for CDK2 versus CDK6.

[0130] In some embodiments, the compounds of the disclosure are selective against CDK2 versus CDK7. In some embodiments, compounds show at least 2-fold selectivity for CDK2 versus CDK7. In some embodiments, compounds show at least 5-fold selectivity for CDK2 versus CDK7. In some such embodiments, compounds show at least 10-fold selectivity for CDK2 versus CDK7. In other embodiments, compounds show at least 20-fold selectivity for CDK2 versus CDK7. In some embodiments, compounds show at least 30-fold selectivity for CDK2 versus CDK7. in certain embodiments, compounds show at least 40-fold selectivity for CDK2 versus CDK7. In other embodiments, compounds show at least 50-fold selectivity for CDK2 versus CDK7. For example, compounds show at least 100-fold selectivity for CDK2 versus CDK7.

[0131] In some embodiments, the compounds of the disclosure are selective against CDK2 versus CDK9. In some embodiments, compounds show at least 2-fold selectivity for CDK2 versus CDK9. In some embodiments, compounds show at least 5-fold selectivity for CDK2 versus CDK9. In some such embodiments, compounds show at least 10-fold selectivity for CDK2 versus CDK9. In other embodiments, compounds show at least 20-fold selectivity for CDK2 versus CDK9. In some embodiments, compounds show at least 30-fold selectivity for CDK2 versus CDK9. in certain embodiments, compounds show at least 40-fold selectivity for CDK2 versus CDK9. In other embodiments, compounds show at least 50-fold selectivity for CDK2 versus CDK9. For example, compounds show at least 100-fold selectivity for CDK2 versus CDK9.Methods of use

[0132] In some embodiments, the CDK2 inhibitors of the present disclosure (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) are used in a method of targeting cyclin-dependent kinase 2 (CDK2) in a cell. The method can includecontacting the cell with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of a compound described herein, or the pharmaceutical dosage form of a compound described herein.

[0133] In certain embodiments, the CDK2 inhibitors of the present disclosure (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) are used in a method of inhibiting cyclin-dependent kinase 2 (CDK2) in a cell. The method can include contacting the cell with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of a compound described herein, or the pharmaceutical dosage form of a compound described herein.

[0134] In certain embodiments, the CDK2 inhibitors of the present disclosure (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) are used in a method of treating a subject having, or at risk of developing, a disease or disorder associated with CDK2. The method can include administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of a compound described herein, or the pharmaceutical dosage form of a compound described herein.

[0135] In certain embodiments, the CDK2 inhibitors of the present disclosure (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) are used in a method of treating a CDK2-mediated disorder or disease in a subject. The method can include administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of a compound described herein, or the pharmaceutical dosage form of a compound described herein.

[0136] As used herein, the term “CDK2-mediated” disorders, diseases, and / or conditions means any disease or other deleterious condition in which CDK2 or a mutant thereof is known to play a role. Accordingly, another embodiment of the present disclosure relates to treating or lessening the severity of one or more diseases in which CDK2, or a mutant thereof, is known to play a role. Such CDK2-mediated disorders include but are not limited to proliferative disorders (e.g. cancer).

[0137] In certain embodiments, the CDK2 inhibitors of the present disclosure (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) canbe useful in applications that benefit from inhibition of CDK2 enzymes. In addition, CDK2 inhibitors described herein can be useful for the treatment of proliferative diseases generally.

[0138] The term “cyclin E” comprises two separate gene products, termed cyclin El and cyclin E2. Cyclin El is a well-established oncogene. The CCNE1 gene encoding cyclin El is amplified in many cancers, including uterine, ovarian, triple-negative breast, and esophageal cancers. In addition, cyclin El can be overexpressed due to oncogenic growth factor signaling leading to upregulation of CCNE1 transcription, or loss of function of tumor suppressor genes such as RBI, which increases CCNE1 transcription, or FBXW7, which normally mediates cyclin El degradation. Loss of FBXW7 function increases cyclin El stability and causes cyclin El accumulation (Sailo et al. Cancers (2019) 11 :246-276). Cyclin E2 is also overexpressed in many cancer types, including luminal breast cancers, via mechanisms similar to those described for cyclin El, including increased transcription and decreased degradation (Milioli et al. Endocrine Related Cancer (2020) 27: R93-R112).

[0139] Overexpression of either cyclin El or E2 drives hyperactivation of CDK2, which leads to dysregulated cell proliferation, genetic instability, and tumor growth and metastasis. After the initiation of DNA replication, CDK2 can also associate with cyclin Al or cyclin A2, and triggers responses that prepare the cell for mitotic cell division (De Boer et al., Oncogene (2008) 27:4261-4268). A CDK2 inhibitor is expected to suppress CDK2 functions when it is associated with either the E-type or A-type cyclins.

[0140] CDK2 is known to be a factor in tumorigenesis and proliferation in many cancer types including, but not limited to, lung cancer, liver cancer, colon cancer, ovarian cancer, uterine (endometrial), and breast cancer (Opyrchal, Int J Oncol 2014; Shi, PLoS One 2015; Lim, Cancer Prev Res 2014). There is evidence showing that CDK2 is functionally linked with abnormal proliferation in multiple cancer types, and is therefore recognized as a potential therapeutic target for cancer therapy (Chohan, Curr Med Chem 2015). Persistent activation of CDK2 can drive the malignant transformation of breast epithelial cells. Suppression of CDK2 activity can effectively inhibit the proliferation of human breast cancer cells (Ali, Cancer Res 2009). Transgenic expression of constitutively-activated form of CDK2 in mouse mammary glands induces a highly invasive form of basal-like breast cancer (Corsino, Neoplasia 2008). Cyclin D1 / CDK2 complexes were detected in human breast cancer cell lines (Sweeney, Oncogene 1998), and the levels of these complexes correlated well with the degree of cyclin DI overexpression. The role of cyclin E andits associated kinase CDK2 in ovarian cancer has been investigated by screening primary, metastatic, recurrent and benign ovarian tumors. The CCNE1 gene encoding cyclin El was shown to be amplified in 21% and CDK2 in 6.4% of the cases analyzed. Additionally, cyclin El RNA was overexpressed in 29.5% and CDK2 in 6.5% of ovarian tumors tested. CDK2 expression has been found to be significantly elevated in glia-derived tumors especially in glioblastoma multiforme (GBM) and was functionally required for GBM cell proliferation and tumorigenesis (Wang, Transl Oncol 2016). CDK2 expression was significantly enriched in GBM tumors and functionally required for tumor proliferation both in vitro and in vivo. Additionally, high CDK2 expression was associated with poor prognosis in GBM patients. Radioresistance is a major predictor of poor clinical prognosis and tumor recurrence in GBM patients. CDK2 was found to be one of the most up-regulated kinase encoding genes in GBM after radiation treatment, and its expression level is correlated with the risk of disease recurrence. (Wang, Transl Oncol 2016). Elevated levels of CDK2 expression have been observed in human cholangiocarcinoma, and transcriptional repression of CDK2 induced cell cycle arrest and restrained tumor growth (Zheng, Oncol Rep 2016). CDK2 overexpression in oral squamous cell carcinoma (SCC) may elevate pRB phosphorylation and permit more rapid entry of the cancer cells into S phase. In a clinicopathological survey of oral SCC, incidence of CDK2 expression was high in the poorly differentiated lesions, and was associated with tumor invasion, lymph node involvement and survival, an indication that change in CDK2 expression is associated with oral cancer progression and aggressiveness (Mihara, Jpn J Cancer Res 2001). Thus, increased expression of CDK2 is a factor in oral cancer progression and a negative predictive marker of the patients' prognosis (Mihara, Jpn J Cancer Res 2001). CDK2 plays a role in cell proliferation of non-small cell lung cancer (NSCLC) (Kawana, Am J Pathol 1998) or small cell lung cancer (SCLC). CDK2 has also been found to play a role in cell proliferation of prostate cancer (Flores, Endocrinology 2010).

[0141] Provided compounds (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) are inhibitors of CDK2 and are therefore useful for treating one or more disorders associated with activity of CDK2 or mutants thereof. Thus, in certain embodiments, the present disclosure provides a method of treating a CDK2-mediated disorder in a subject comprising administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition of either of the foregoing, to a subject in need thereof. In certain embodiments, thepresent disclosure provides a method of treating a CDK2-mediated disorder in a subject comprising administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable composition thereof, to a subject in need thereof.

[0142] The compounds disclosed herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) inhibit CDK2 and therefore are useful for treating diseases for which CDK2 is dysregulated, such as cancer. The present disclosure provides a method of inhibiting CDK2 in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein.

[0143] In some embodiments, deregulated expression and activity of CDK2 binding partner cyclins A and E have been associated with a variety of cancer types including, without limitation, breast, lung, colorectal tumors, pancreatic and colon cancer. In some embodiments, the disease or disorder associated with CDK2 is N-myc amplified neuroblastoma ceils (see Molenaar, et al, Proc Natl Acad. Sci USA 106(31): 12968-12973); K-Ras mutant lung cancers (see Hu, S., et al., Mol Cancer Then, 2015 14(11): 2576-85; K-Ras-driven pancreatic and colon cancers (see Lukasik, P et al., Int J Mol Sci. 2021 Mar; 22(6): 2935); and cancers with FBXW7 loss of function mutation and CCNE1 overexpression (see Takada, et al., Cancer Res, 201777(18). 4881-4893), all of which are incorporated herein in their entirety for all purposes.

[0144] Subjects “in need of inhibiting CDK2” are those having a disease for which a beneficial therapeutic effect can be achieved by inhibiting CDK2, e.g., a slowing in disease progression, alleviation of one or more symptoms associated with the disease or increasing the longevity of the subject in view of the disease. In some embodiments, the disease or disorder associated with CDK2 is an adenocarcinoma, carcinoma, or cystadenocarcinoma.

[0145] In some embodiments, compounds disclosed herein can have a beneficial therapeutic effect for treating a patient having an amplified expression level of CCNE1 and suffering from, or at risk of developing, cancer, e.g., a solid tumor, a blood cancer. Disclosed herein is a method of treating a patient comprising administering to the patient a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein.

[0146] An amplification of the CCNE1 gene and / or an expression level of CCNE1 that is higher than a control expression level of CCNE1 is indicative / predictive that a human subjecthaving or at risk of developing a disease or disorder associated with CDK2 will respond to a CDK2 inhibitor. In some embodiments, the expression level of CCNE1 may be the level of CCNE1 mRNA. In other embodiments, the expression level of CCNE1 may be the level of CCNE1 protein.

[0147] Similar statements can be applied to the expression of cyclin E2. In normal cell cycles, E-type cyclins (cyclin El and cyclin E2 ) associate with CDK2 to promote Gl / S transition. Cyclin E / CDK2 complex mostly controls cell cycle progression and DNA replication through phosphorylation of specific substrates. Oncogenic activation of the Cyclin El or E2 / CDK2 complex impairs normal DNA replication, causing replication stress and DNA damage. As a consequence, Cyclin El or E2 / CDK2-induced replication stress leads to genomic instability and contributes to human carcinogenesis. For reasons that remain unclear, cyclin El overexpression appears to be more highly oncogenic than cyclin E2 overexpression. These and other indications suggest that cyclins El and E2 carry out both overlapping and distinct functions.

[0148] In some embodiments, the contemplated biomarker may be pl6 (also known as cyclin-dependent kinase inhibitor 2 A, multiple tumor suppressor 1, and pl6INK4A), which acts as a negative regulator of the proliferation of normal cells by interacting with CDK4 or CDK6. In other embodiments, the contemplated biomarker may be phosphorylation of Rb at the serine corresponding to amino acid position 780. Rb is a regulator of the cell cycle and acts as a tumor suppressor. Rb is activated upon phosphorylation by cyclin D-CDK4 / 6 at Ser780 and Ser795 and by cyclin E / CDK2 at Ser807 and Ser811.

[0149] The contemplated biomarker may also be selected from the group consisting of RBI, RBL1, RBL2, CDKN2A, CDKN1A, CDKN1B, FBXW7, CCNE1, CCNE2, CCNA1, CCNA2, CCND1, CCND2, CCND3, CDK2, CDK3, CDK4, CDK6, CDKN2A, CDNK1A, CDKN1B E2F1, E2F2, E2F3, C-MYC, MYCL, MYCN, EZH2, ER, HER2, HER3, HPV+, and EGFR.

[0150] The compounds disclosed herein inhibit CDK2 and therefore are useful for treating diseases for which CDK2 is dysregulated, such as cancer. The present disclosure provides a method of inhibiting CDK2 in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein.

[0151] In some embodiments, the disclosure provides a method of treating a disease or disorder associated with CDK2 in a patient, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I) or any of the formulas as described herein, or a pharmaceutically acceptable salt thereof.

[0152] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is cancer. In some embodiments, the proliferative disorder is cancer, a tumor, malignancy, polyp, cyst, outgrowth, proliferative neoplastic, metastatic cancer, or a treatment-resistant cancer.

[0153] In some embodiments, the proliferative disorder is breast cancer (e.g. ER- positive / HR-positive, HER2-negative breast cancer, HER2-positive breast cancer, ER- positive / HR-positive, HER2-positive breast cancer, triple negative breast cancer (TNBC), inflammatory breast cancer, ductal carcinoma in situ, inflammatory breast cancer, ductal carcinoma, Paget’s disease of the breast, invasive lobular carcinoma, lobular carcinoma in situ, metastatic breast cancer, phyllodes tumor, invasive tubular breast carcinoma, mucinous neoplasm, male breast cancer, angiosarcoma, metaplastic carcinoma, or medullary carcinoma), prostate cancer (e.g., acinar adenocarcinoma, prostatic ductal adenocarcinoma, or prostate sarcoma), lung cancer (e.g. lung nodules, non-small cell lung cancer, small cell lung cancer, mesothelioma, large cell lung cancer, salivary gland-type lung carcinoma, thymomas, or lung carcinoids), thyroid cancer (e.g. papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, Hurthle cell thyroid cancer, or anaplastic thyroid cancer), gastric cancer, ovarian cancer (e.g. epithelial ovarian carcinomas, germ cell tumor, or stromal cell tumors), rectal cancer, endometrial carcinoma (e g, endometrioid adenocarcinoma, uterine papillary serous carcinoma, uterine clear cell carcinoma,) and other uterine cancers (e.g., uterine carcinosarcoma or uterine sarcoma), anal cancer, bladder cancer (e.g. urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, sarcoma, or small cell bladder cancer), bone cancer (e.g. osteosarcoma, chondrosarcoma, Ewing sarcoma, fibrosarcoma, or malignant fibrous histiocytoma), brain cancer (e.g. glioma, meningioma, astrocytoma, glioblastoma multiforme, medulloblastoma, ependymoma, oligodendroglioma, craniopharyngioma, pituitary adenoma, Schwannoma, anaplastic astrocytoma, germ cell tumor, primitive neuroectodermal tumor, chordoma, haemangioblastoma, optic nerve glioma, subependymoma, or germinoma), cervical cancer (e.g. squamous cell carcinomas or cervical adenocarcinoma), colorectal cancer (e.g., adenocarcinoma, squamous cell carcinoma, and colon cancer), esophageal cancer (e.g. adenocarcinoma or squamous cell carcinoma, or small cell carcinoma), gastrointestinal stromal tumors, gestational trophoblasticdisease (e.g. hydatidiform mole (HM), also called molar pregnancy, and gestational trophoblastic neoplasia), appendiceal cancer (e.g. epithelial appendiceal cancer or neuroendocrine appendiceal cancer), head and neck cancer (e.g. laryngeal and hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, oral and oropharyngeal cancer, or salivary gland cancer), Hodgkin lymphoma (e.g. classical Hodgkin lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma), non-Hodgkin lymphoma (e.g. diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, double hit / triple hit lymphoma, or primary mediastinal large B-cell lymphoma), Kaposi sarcoma (e g. HIV-related Kaposi's sarcoma, classic Kaposi's sarcoma, transplant Kaposi's sarcoma, endemic, or African Kaposi's sarcoma), kidney cancer (e.g. renal cell carcinoma, urothelial carcinoma also called transitional cell carcinoma, sarcoma, Wilms tumor, or lymphoma), leukemia (e.g. acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, T-cell prolymphocytic leukemia, lymphoid leukemia, large granular lymphocytic leukemia, b-cell prolymphocytic leukemia, myeloproliferative neoplasm, or mastocytosis), liver cancer (e.g. hepatocellular carcinoma or cholangiocarcinoma (cancer of the bile ducts), laryngeal cancer (e.g. laryngeal squamous cell carcinoma), malignant mesothelioma (e.g. malignant pleural mesothelioma or malignant peritoneal mesothelioma), multicentric Castleman disease (e.g. POEMS-associated MCD, HHV- 8-associated MCD, or idiopathic MCD), myeloproliferative neoplasms (e g. chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis (also called chronic idiopathic myelofibrosis), essential thrombocythemia, chronic neutrophilic leukemia, or chronic eosinophilic leukemia), pancreatic cancer (e.g. adenocarcinoma or neuroendocrine tumors), retinoblastoma (e.g. unilateral retinoblastoma, bilateral retinoblastoma, intraocular retinoblastoma, or extraocular retinoblastoma), rhabdomyosarcoma (e.g. embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, botryoid rhabdomyosarcoma, or pleomorphic rhabdomyosarcoma), skin cancer (e.g. melanoma, basal cell carcinoma, squamous cell carcinoma, or Merkel cell cancer), soft tissue sarcoma (e.g. rhabdomyosarcoma, synovial sarcoma, liposarcoma, Ewing sarcoma, leiomyosarcoma, alveolar soft part sarcoma, fibrosarcoma, epithelioid sarcoma, undifferentiated pleomorphic sarcoma, dermatofibrosarcoma, Kaposi sarcoma, angiosarcoma, neurofibrosarcoma, gastrointestinal stromal tumor, clear cell sarcoma, desmoplastic small-round-cell tumor, low-grade fibromyxoid sarcoma, or solitary fibrous tumor), testicular cancer (e.g. seminoma andnonseminomatous germ cell tumors), vaginal cancer (e.g. squamous cell carcinoma, vaginal intraepithelial neoplasia, verrucous carcinoma, clear cell adenocarcinoma, papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma, embryonal rhabdomyosarcoma, melanoma, small cell cancer of the vagina, or vaginal lymphoma), vulvar cancer (e.g. squamous cell carcinoma, verrucous carcinoma, adenocarcinoma, melanoma, or sarcoma), or neuroblastoma. In some embodiments, the proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, lung squamous cell carcinoma, thyroid cancer, gastric cancer, or ovarian cancer. In some embodiments, the proliferative disorder is gastric cancer, hormone receptor-positive breast cancer, HER2-positive breast cancer, triple negative breast cancer, or rectal cancer. In some embodiments, the proliferative disorder is endometrial carcinoma, non-small cell lung cancer, lung squamous cell carcinoma, gastric cancer, breast cancer, or urothelial cancer.

[0154] In some embodiments, cancers treatable with compounds of the present disclosure include advanced / relapsed tumors, CCNE1 amplified platinum-resistant or platinum-refractory ovarian cancer or endometrial cancer (with prior platinum therapy) that has progressed following two or more lines of therapies; and gastric cancer (with prior platinum therapy) that has progressed following two or more lines of therapies; and ER+ HER2- breast cancer that has progressed despite treatment with a CDK4 / 6 inhibitor. In some embodiments, cancers treatable with compounds of the present disclosure include platinum-resistant or platinum-refractory CCNE1 amplified ovarian cancer, CCNE1 amplified endometrial cancer that has failed two or more lines of therapies, CCNE1 amplified advanced / relapsed tumors that do not belong to the other groups; ER+ HER2- breast cancer that has progressed despite treatment with a CDK4 / 6 inhibitor; platinum-resistant or platinum- refractory CCNE1 amplified ovarian cancer; and ER+ HER2- breast cancer that has progressed despite treatment with a CDK4 / 6 inhibitor.Pharmaceutical Compositions

[0155] In some embodiments, the compounds of the present disclosure are administered as a pharmaceutical composition. When employed as pharmaceuticals, the compounds of the disclosure can be administered in the form of pharmaceutical compositions which is a combination of the compounds of the disclosure and a pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes. Such pharmaceutical compositions can be administered systemically. The term“systemic” as used herein includes parenteral, topical, transdermal, oral, by inhalation / pulmonary, rectal, nasal, buccal, and sublingual administration. The term “parenteral” as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intracranial, and intraperitoneal administration. Preferably, the compounds are administered intramuscularly, subcutaneously, orally, or intranasally in therapeutically effective amounts to treat diseases Any composition described herein can also be formulated for “non-systemic” or local oral, sublingual, cutaneous, percutaneous, subcutaneous, transdermal, intramuscular, intravenous, intravascular, or nasal, delivery. In some embodiments, oral delivery may include liquid drug products (e.g., elixirs, suspensions, solutions, syrups) that are packaged with dosage delivery devices (e.g., calibrated cups, droppers, syringes, spoons).

[0156] Provided herein, in certain embodiments, is a pharmaceutical composition comprising a therapeutically effective amount of any compound described herein. In certain instances, the pharmaceutical composition comprises a CDK2 inhibitor (e.g., any CDK2 inhibitor described herein).

[0157] In certain embodiments, pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers including, e.g., excipients and auxiliaries which facilitate processing of the active compounds into preparations which are suitable for pharmaceutical use. In certain embodiments, proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Mareel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), all of which are incorporated herein in their entirety for all purposes.

[0158] A pharmaceutical composition, as used herein, refers to a mixture of a compound described herein, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and / or excipients. In certain instances, the pharmaceutical composition facilitates administration of the compound to an individual or cell. In certain embodiments of practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceuticalcomposition to an individual having a disease, disorder, or condition to be treated. Tn specific embodiments, the individual is a human. As discussed herein, the compounds described herein are either utilized singly or in combination with one or more additional therapeutic agents.

[0159] In certain embodiments, the pharmaceutical formulations described herein are administered to an individual in any manner, including one or more of multiple administration routes, such as, by way of non-limiting example, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.

[0160] In certain embodiments, a pharmaceutical composition described herein includes one or more compound described herein as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In some embodiments, the compounds described herein are utilized as an N-oxide or in a crystalline or amorphous form (i.e., a polymorph). In some situations, a compound described herein exists as tautomers. All tautomers are included within the scope of the compounds presented herein. In certain embodiments, a compound described herein exists in an unsolvated or solvated form, wherein solvated forms comprise any pharmaceutically acceptable solvent, e.g., water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be described herein.

[0161] A “carrier” includes, in some embodiments, a pharmaceutically acceptable excipient and is selected on the basis of compatibility with compounds described herein, such as, compounds of any of Formula I- VI, and the release profile properties of the desired dosage form. Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. See, e.g., Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Mareel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), all of which are incorporated herein in their entirety for all purposes.

[0162] The pharmaceutical composition described herein optionally include an additional therapeutic compound described herein and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, filling agent, suspending agent, flavoring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer,moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof. In some aspects, using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000), a film coating is provided around the formulation of the compound of Formula I. In one embodiment, a compound described herein is in the form of a particle and some or all of the particles of the compound are coated. In certain embodiments, some or all of the particles of a compound described herein are microencapsulated. In some embodiments, the particles of the compound described herein are not microencapsulated and are uncoated.

[0163] Solid dosage forms for administration of the compounds according to the present disclosure can be manufactured by standard manufacturing techniques. Non-limiting examples of oral solid dosage forms for administration of the compounds of the disclosure are described below. Tablet and Capsule Compositions

[0164] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; (c) humectants such as glycerol; (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin; (f) absorption accelerators such as quaternary ammonium compounds; (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate; (h) absorbents such as kaolin and bentonite clay; and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0165] Solid compositions of a similar type may also be employed as fillers in soft- and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only,or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[0166] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0167] The tablet or capsule compositions of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0168] Tablets and capsule formulations may further contain one or more adjuvants, binders, diluents, disintegrants, excipients, fillers, or lubricants, each of which are known in the art. Examples of such include carbohydrates such as lactose or sucrose, dibasic calcium phosphate anhydrous, corn starch, mannitol, xylitol, cellulose or derivatives thereof, microcrystalline cellulose, gelatin, stearates, silicon dioxide, talc, sodium starch glycolate, acacia, flavoring agents, preservatives, buffering agents, disintegrants, and colorants. Orally administered compositions may contain one or more optional agents such as, e.g., sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preservative agents, to provide a pharmaceutically palatable preparation.Effervescent Compositions

[0169] The effervescent compositions of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0170] Effervescent formulations contain and effervescent couple of a base component and an acid component, which components reach in the presence of water to generate a gas. In some embodiments, the base component may comprise, for example, an alkali metal or alkaline earth metal carbonate, or bicarbonate. The acid component may comprise, for example, an aliphatic carboxylic acid or a salt thereof, such as citric acid. The base and acid components may each independently constitute, for example, 25% to 55% (w / w) of the effervescent composition. The ratio of acid component to base component may be within the range of 1 :2 to 2: 1.

[0171] The effervescent compositions of the disclosure may be formulated using additional pharmaceutically acceptable carriers or excipients as appropriate. For example, one or more taste masking agents may be used. Dyes may also be used, as pediatric patients often prefer colorful pharmaceutical combinations. The compositions may take the form of, for example, tablets, granules or powders, granules or powders presented in a sachet.Chewable Tablets

[0172] The chewable tablets of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0173] Chewable tablets are tablets that are intended to disintegrate in the mouth under the action of chewing or sucking and where, in consequence, the active ingredient has greater opportunity to come into contact with the bitter-taste receptors on the tongue.

[0174] One method of overcoming this issue is to absorb the active ingredient onto a suitable substrate. This approach is known in the art and described for example in U.S. Pat. No. 4,647,459, which is incorporated herein by reference in its entirety for all purposes.

[0175] Another approach involves forming the active ingredient into an aggregate along with a pre-swelled substantially anhydrous hydrocolloid. The hydrocolloid absorbs saliva and acquires a slippery texture which enables it to lubricate the particles of aggregate and mask the taste of the active ingredient. This approach is known in the art and described for example in European patent application 0190826, which is incorporated herein by reference in its entirety for all purposes.

[0176] Another approach involves employing a water-insoluble hygroscopic excipient such as microcrystalline cellulose. This approach is known in the art and described for example in U.S. Pat. No. 5,275,823, which is incorporated herein by reference in its entirety for all purposes.

[0177] In addition to the above approaches, the chewable tablets of the present disclosure can also contain other standard tableting excipients such as a disintegrant and a taste-masking agent.Orodispersible Tablets

[0178] The orodispersible tablets of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0179] In orodispersible tablets of the disclosure, the excipient mixtures are such as to provide it with a disintegration rate so that its disintegration in the buccal cavity occurs in an extremely short time and especially shorter than sixty seconds. In some embodiments, the excipient mixture is characterized by the fact that the active substance is in the form of coated or non-coated microcrystals of microgranules. In some embodiments, the orodispersible tablet comprises one or several disintegrating agents of the carboxymethylcellulose type or insoluble reticulated PVP type, one or several swelling agents which may comprise a carboxymethylcellulose, a starch, a modified starch, or a microcrystalline cellulose or optionally a direct compression sugar.Powders for Reconstitution

[0180] The powder for reconstitution pharmaceutical compositions of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0181] In some embodiments, the powder for reconstitution compositions of the disclosure comprise an effective amount of at least one internal dehydrating agent. The internal dehydrating agent can enhance the stability of the powder. In some embodiments, the internal dehydrating agent is magnesium citrate or disodium carbonate. In some embodiments, the powder composition comprises a pharmaceutically acceptable diluents, such as sucrose, dextrose, mannitol, xylitol, or lactose.

[0182] Powder compositions of the disclosures may be placed in sachets or bottles for contemporaneous dissolution or for short term storage in liquid form (e.g. 7 days).Gummy Candies

[0183] The gummy candies of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0184] Traditional gummy candy is made from a gelatin base. Gelatin gives the candy its elasticity, the desired chewy consistency, and a longer shelflife. In some embodiments, the gummycandy pharmaceutical composition of the disclosure includes a binding agent, a sweetener, and an active ingredient.

[0185] In some embodiments, the binding agent is a pectin gel, gelatin, food starch, or any combination thereof.

[0186] In some embodiments, the gummy candy comprises sweeteners, a binding agent, natural and / or artificial flavors and colors and preservatives. In some embodiments, the gummy candy comprises glucose syrup, natural cane juice, gelatin, citric acid, lactic acid, natural colors, natural flavors, fractionated coconut oil, and carnauba wax.Liquid Dosage Forms

[0187] The pharmaceutical liquid dosage forms of the disclosure may be prepared according to techniques well-known in the art of pharmacy.

[0188] A solution refers to a liquid pharmaceutical formulation wherein the active ingredient is dissolved in the liquid. Pharmaceutical solutions of the disclosure include syrups and elixirs. A suspension refers to a liquid pharmaceutical formulation wherein the active ingredient is in a precipitate in the liquid.

[0189] In a liquid dosage form, it is desirable to have a particular pH and / or to be maintained within a specific pH range. In order to control the pH, a suitable buffer system can be used. In addition, the buffer system should have sufficient capacity to maintain the desired pH range. Examples of the buffer system useful in the present disclosure include but are not limited to, citrate buffers, phosphate buffers, or any other suitable buffer known in the art. Preferably the buffer system include sodium citrate, potassium citrate, sodium bicarbonate, potassium bicarbonate, sodium dihydrogen phosphate and potassium dihydrogen phosphate, etc. The concentration of the buffer system in the final suspension varies according to factors such as the strength of the buffer system and the pH / pH ranges required for the liquid dosage form. In one embodiment, the concentration is within the range of 0.005 to 0.5 w / v % in the final liquid dosage form.

[0190] The pharmaceutical composition comprising the liquid dosage form of the present disclosure can also include a suspending / stabilizing agent to prevent settling of the active material. Over time the settling could lead to caking of the active to the inside walls of the product pack, leading to difficulties with redispersion and accurate dispensing. Suitable stabilizing agents include but are not limited to, the polysaccharide stabilizers such as xanthan, guar and tragacanthgums as well as the cellulose derivatives HPMC (hydroxypropyl methylcellulose), methyl cellulose and Avicel RC-591 (microcrystalline cellulose / sodium carboxymethyl cellulose). In another embodiment, polyvinylpyrrolidone (PVP) can also be used as a stabilizing agent.

[0191] In addition to the aforementioned components, an oral liquid dosage form can also optionally contain other excipients commonly found in pharmaceutical compositions such as alternative solvents, taste-masking agents, antioxidants, fillers, acidifiers, enzyme inhibitors and other components as described in Handbook of Pharmaceutical Excipients, Rowe et al., Eds., 4thEdition, Pharmaceutical Press (2003), which is hereby incorporated by reference in its entirety for all purposes.

[0192] Addition of an alternative solvent may help increase solubility of an active ingredient in the liquid dosage form, and consequently the absorption and bioavailability inside the body of a subject. Preferably the alternative solvents include methanol, ethanol or propylene glycol and the like.

[0193] In another aspect, the present disclosure provides a process for preparing the liquid dosage form. The process comprises steps of bringing the CDK2 inhibitor or its pharmaceutically acceptable salts thereof into mixture with the components including glycerol or syrup or the mixture thereof, a preservative, a buffer system and a suspending / stabilizing agent, etc., in a liquid medium. In general, the liquid dosage form is prepared by uniformly and intimately mixing these various components in the liquid medium. For example, the components such as glycerol or syrup or the mixture thereof, a preservative, a buffer system and a suspending / stabilizing agent, etc., can be dissolved in water to form the aqueous solution, then the active ingredient can be then dispersed in the aqueous solution to form a suspension.

[0194] In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.001 ml to about 100 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 90 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 80 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 70 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 60 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 50 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 40ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 30 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 20 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 0.1 ml to about 10 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of between about 10 ml to about 30 ml. In some embodiments, the liquid dosage form provided herein can be in a volume of about 20 ml. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 0.001% to about 90% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 0.01% to about 80% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 0.1% to about 70% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 60% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 50% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 40% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 30% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 20% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 1% to about 10% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 70% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 60% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 50% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 40% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 30% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 20% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 5% to about 10% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 10% to about 50% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 10% to about 40% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 10% to about 30% of the total volume. In some embodiments, the CDK2 inhibitor can be in an amount ranging from about 10% to about20% of the total volume. In one embodiment, the resulted liquid dosage form can be in a liquid volume of 10 ml to 30 ml, preferably 20 ml, and the active ingredient can be in an amount ranging from about 0.001 mg / ml to about 16 mg / ml, or from about 0.025 mg / ml to about 8 mg / ml, or from about 0.1 mg / ml to about 4 mg / ml, or about 0.25 mg / ml, or about 0.5 mg / ml, or about 1 mg / ml, or about 2 mg / ml, or about 4 mg / ml, or about 5 mg / ml, or about 8 mg / ml, or about 10 mg / ml, or about 12 mg / ml, or about 14 mg / ml or about 16 mg / ml. In certain embodiments, tablets prepared for oral administration contain various excipients, including, by way of non-limiting example, binders, diluents, lubricants, disintegrants, fillers, stabilizers, surfactants, preservatives, coloring agents, flavoring agents and the like. In some embodiments, binders are used to impart cohesive qualities to a tablet, ensuring that the tablet remains intact after compression. Suitable binder materials include, by way of non-limiting example, starch (including corn starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose and lactose), polyethylene glycol, propylene glycol, waxes, and natural and synthetic gums, e.g., acacia sodium alginate, polyvinylpyrrolidone, cellulosic polymers (including hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, and the like), Veegum, and combinations thereof. In certain embodiments, diluents are utilized to increase the bulk of the tablet so that a practical size tablet is provided. Suitable diluents include, by way of non-limiting example, dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, powdered sugar and combinations thereof. In certain embodiments, lubricants are used to facilitate tablet manufacture; examples of suitable lubricants include, by way of non-limiting example, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma, glycerin, magnesium stearate, calcium stearate, stearic acid and combinations thereof. In some embodiments, disintegrants are used to facilitate disintegration of the tablet, and include, by way of non-limiting example, starches, clays, celluloses, algins, gums, crosslinked polymers and combinations thereof. Fillers include, by way of non-limiting example, materials such as silicon dioxide, titanium dioxide, alumina, talc, kaolin, powdered cellulose and microcrystalline cellulose, as well as soluble materials such as mannitol, urea, sucrose, lactose, dextrose, sodium chloride and sorbitol. In certain embodiments, stabilizers are used to inhibit or retard drug decomposition reactions that include, by way of example, oxidative reactions. In certain embodiments, surfactants are anionic, cationic, amphoteric or nonionic surface active agents.Dosage Forms

[0195] Moreover, in certain embodiments, the pharmaceutical compositions described herein are formulated as a dosage form. As such, in some embodiments, provided herein is a dosage form comprising a compound described herein, suitable for administration to an individual. In certain embodiments, suitable dosage forms include, by way of non-limiting example, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.

[0196] In certain aspects, the composition or formulation containing one or more compounds described herein is orally administered for local delivery of a CDK2 inhibitor, or a compound described herein. Unit dosage forms of such compositions include a pill, tablet or capsules formulated. In certain embodiments, such pills, tablets or capsule contain the compositions described herein entrapped or embedded in microspheres. In some embodiments, microspheres include, by way of non-limiting example, chitosan microcores HPMC capsules and cellulose acetate butyrate (CAB) microspheres. In certain embodiments, oral dosage forms are prepared using conventional methods known to those in the field of pharmaceutical formulation. For example, in certain embodiments, tablets are manufactured using standard tablet processing procedures and equipment. An exemplary method for forming tablets is by direct compression of a powdered, crystalline or granular composition containing the active agent(s), alone or in combination with one or more carriers, additives, or the like. In alternative embodiments, tablets are prepared using wet-granulation or dry-granulation processes. In some embodiments, tablets are molded rather than compressed, starting with a moist or otherwise tractable material.

[0197] In other embodiments, the compositions described herein are administered orally for non-systemic delivery of the CDK2 inhibitor. In specific embodiments, compositions formulated for oral administration are, by way of non-limiting example, enterically coated or formulated oral dosage forms, such as, tablets and / or capsules.

[0198] In prophylactic applications, compounds or compositions containing compounds described herein may be administered to an individual susceptible to or otherwise at risk of a particular disease, disorder or condition. In certain embodiments of this use, the precise amountsof compound administered depend on the individual's state of health, weight, age, gender, and the like. Furthermore, in some instances, when a compound or composition described herein is administered to an individual, effective amounts for this use depend on the severity and course of the disease, disorder or condition, previous therapy, the individual's health status and response to the drugs, and the judgment of the treating physician.

[0199] In certain embodiments of the methods of the present disclosure, wherein following administration of a selected dose of a compound or composition described herein, an individual's condition does not improve, upon the doctor's discretion the administration of a compound or composition described herein is optionally administered chronically, that is, for an extended period of time, including throughout the duration of the individual's life in order to ameliorate or otherwise control or limit the symptoms of the individual's disorder, disease or condition.

[0200] In certain embodiments of the methods of the present disclosure, an effective amount of a given agent varies depending upon one or more of a number of factors such as the particular compound, disease or condition and its severity, the identity (e.g., weight) of the subject or host in need of treatment, and is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. In some embodiments, doses administered include those up to the maximum tolerable dose. In some embodiments, doses administered include those up to the maximum tolerable dose by a newborn or an infant.

[0201] In various embodiments of the methods of the present disclosure, a desired dose is conveniently presented in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub- doses per day. In various embodiments, a single dose of a CDK2 inhibitor is administered every 6 hours, every 12 hours, every 24 hours, every 48 hours, every 72 hours, every 96 hours, every 5 days, every 6 days, or once a week. In some embodiments the total single dose of a CDK2 inhibitor is in a range described below.

[0202] In various embodiments of methods of the present disclosure, in the case wherein the patient's status does improve, upon the doctor's discretion a CDK2 inhibitor is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”). The length of the drugholiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100% of the original dose, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the original dose. In some embodiments the total single dose of a CDK2 inhibitor is in a range described below.

[0203] Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In some embodiments, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms.

[0204] In certain instances, there are a large number of variables in regard to an individual treatment regime, and considerable excursions from these recommended values are considered within the scope described herein. Dosages described herein are optionally altered depending on a number of variables such as, by way of non-limiting example, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.

[0205] Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined by pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LDso (the dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50. Compounds exhibiting high therapeutic indices are preferred. In certain embodiments, data obtained from cell culture assays and animal studies are used in formulating a range of dosage for use in human. In specific embodiments, the dosage of compounds described herein lies within a range of circulating concentrations that include the EDsowith minimal toxicity. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.

[0206] The therapeutic dosage of the compounds of the disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds of the disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0207] In some embodiments, the compound of the disclosure is present in a composition or a unit dose of a composition described herein in an amount of from about 0.0001 mg to about 10,000 mg (e.g., about 0.001-1000 mg, about 0.01-100 mg, about 0.1-10 mg, about 1-5 mg or about 2-3 mg).

[0208] In certain aspects, about 0.05 mg to about 50 mg, about 0.25 mg to about 20 mg, about 0.25 mg to about 15 mg, about 0.25 mg to about 10 mg, or about 0.25 mg to about 5 mg (e.g., about 0.1 to about 5 mg, about 0.25 to about 2.5 mg, about 0.3 mg to about 2 mg, about 0.5 mg to about 1 mg, about 0.7 mg to about 1.5 mg, about 0.375 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg or about 2 mg) of the compound per day or per dose is administered to a patient.

[0209] In some embodiments, the compound is present in a unit dose in an amount of between about 5 mg and about 500 mg. In some embodiments, the amount of the compound administered daily or in a unit dose is between about 5 mg and about 300 mg. In other embodiments, the amount of the compound present in a unit dose or administered daily is between about 5 and about 250 mg, or between about 5 and about 200 mg, between about 5 mg and about 150 mg, between about 5 mg and about 100 mg, or between about 5 and about 50 mg.

[0210] In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh. Some examples ofsuitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the disclosure can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

[0211] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound according to the disclosure. When referring to these pre- formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.000001 to about 2000 mg of the active ingredient of the present application.

[0212] The tablets or pills containing a compound according to the disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0213] In some embodiments, the CDK2 inhibitor is administered at a dose of about or at least about 0.5 µg / kg, 1 µg / kg, 2 µg / kg, 3 µg / kg, 4 µg / kg, 5 µg / kg, 6 µg / kg, 7 µg / kg, 8 µg / kg, 9 µg / kg, 10 µg / kg, 15 µg / kg, 20 µg / kg, 25 µg / kg, 30 µg / kg, 35 µg / kg, 40 µg / kg, 45 µg / kg, 50 µg / kg, 55 µg / kg, 60 µg / kg, 65 µg / kg, 70 µg / kg, 75 µg / kg, 80 µg / kg, 85 µg / kg, 90 µg / kg, 100 µg / kg, 140 µg / kg, 150 µg / kg, 200 µg / kg, 240 µg / kg, 280 µg / kg, 300 µg / kg, 250 µg / kg, 280 µg / kg, 300 µg / kg, 400 µg / kg, 500 µg / kg, 560 µg / kg, 600 µg / kg, 700 µg / kg, 800 µg / kg, 900 µg / kg, 1,000 µg / kg, 1,100µg / kg, 1,200 µg / kg, 1,300 µg / kg, 1,400 µg / kg, 1500 µg / kg, 1,600 µg / kg, 1,700 µg / kg, 1,800 µg / kg, 1,900 µg / kg, or 2,000 µg / kg.

[0214] In various embodiments, the CDK2 inhibitor is administered at a dose not exceeding about 1 µg / kg, 2 µg / kg, 3 µg / kg, 4 µg / kg, 5 µg / kg, 6 µg / kg, 7 µg / kg, 8 µg / kg, 9 µg / kg, 10 µg / kg, 15 µg / kg, 20 µg / kg, 25 µg / kg, 30 µg / kg, 35 µg / kg, 40 µg / kg, 45 µg / kg, 50 µg / kg, 55 µg / kg, 60 µg / kg, 65 µg / kg, 70 µg / kg, 75 µg / kg, 80 µg / kg, 85 µg / kg, 90 µg / kg, 100 µg / kg, 140 µg / kg, 150 µg / kg, 200 µg / kg, 240 µg / kg, 280 µg / kg, 300 µg / kg, 250 µg / kg, 280 µg / kg, 300 µg / kg, 400 µg / kg, 500 µg / kg, 560 µg / kg, 600 µg / kg, 700 µg / kg, 800 µg / kg, 900 µg / kg, 1,000 µg / kg, 1,100 µg / kg, 1,200 µg / kg, 1,300 µg / kg, 1,400 µg / kg, 1,500 µg / kg, 1,600 µg / kg, 1,700 µg / kg, 1,800 µg / kg, 1,900 µg / kg, 2,000, or 2,100 µg / kg.

[0215] In various embodiments, the CDK2 inhibitor is administered at a dose of about or of at least about 0.5 mg / day, 1 mg / day, 2 mg / day, 3 mg / day, 4 mg / day, 5 mg / day, 6 mg / day, 7 mg / day, 8 mg / day, 9 mg / day, 10 mg / day, 11 mg / day, 12 mg / day, 13 mg / day, 14 mg / day, 15 mg / day, 16 mg / day, 17 mg / day, 18 mg / day, 19 mg / day, 20 mg / day, 30 mg / day, 40 mg / day, 50 mg / day, 60 mg / day, 70 mg / day, 80 mg / day, 90 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 300 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, 800 mg / day, 900 mg / day, 1000 mg / day.

[0216] In various embodiments, the CDK2 inhibitor is administered at a dose of not more than about 1 mg / day, 2 mg / day, 3 mg / day, 4 mg / day, 5 mg / day, 6 mg / day, 7 mg / day, 8 mg / day, 9 mg / day, 10 mg / day, 11 mg / day, 12 mg / day, 13 mg / day, 14 mg / day, 15 mg / day, 16 mg / day, 17 mg / day, 18 mg / day, 19 mg / day, 20 mg / day, 30 mg / day, 40 mg / day, 50 mg / day, 60 mg / day, 70 mg / day, 80 mg / day, 90 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 300 mg / day, 500 mg / day, 600 mg / day, 700 mg / day, 800 mg / day, 900 mg / day, 1,000 mg / day, 1,100 mg / day.

[0217] In some embodiments, the CDK2 inhibitor is administered at a dose of from about 140 µg / kg / day to about 1400 µg / kg / day. In various embodiments, the CDK2 inhibitor is administered at a dose of about or at least about 0.5 µg / kg / day, 1 µg / kg / day, 2 µg / kg / day, 3 µg / kg / day, 4 µg / kg / day, 5 µg / kg / day, 6 µg / kg / day, 7 µg / kg / day, 8 µg / kg / day, 9 µg / kg / day 10 µg / kg / day, 15 µg / kg / day, 20 µg / kg / day, 25 µg / kg / day, 30 µg / kg / day, 35 µg / kg / day, 40 µg / kg / day, 45 µg / kg / day, 50 µg / kg / day, 100 µg / kg / day, 140 µg / kg / day, 150 µg / kg / day, 200 µg / kg / day, 240 µg / kg / day, 280 µg / kg / day, 300 µg / kg / day, 250 µg / kg / day, 280 µg / kg / day, 300 µg / kg / day, 400 µg / kg / day, 500 µg / kg / day, 560 µg / kg / day, 600 µg / kg / day, 700 µg / kg / day, 800 µg / kg / day, 900 µg / kg / day, 1,000 µg / kg / day, 1,100 µg / kg / day, 1,200 µg / kg / day, or 1,300 µg / kg / day.

[0218] In various embodiments, the CDK2 inhibitor is administered at a dose not exceeding about 1 µg / kg / day, 2 µg / kg / day, 3 µg / kg / day, 4 µg / kg / day, 5 µg / kg / day, 6 µg / kg / day, 7 µg / kg / day, 8 µg / kg / day, 9 µg / kg / day 10 µg / kg / day, 15 µg / kg / day, 20 µg / kg / day, 25 µg / kg / day, 30 µg / kg / day, 35 µg / kg / day, 40 µg / kg / day, 45 µg / kg / day, 50 µg / kg / day, 100 µg / kg / day, 140 µg / kg / day, 150 µg / kg / day, 200 µg / kg / day, 240 µg / kg / day, 280 µg / kg / day, 300 µg / kg / day, 250 µg / kg / day, 280 µg / kg / day, 300 µg / kg / day, 400 µg / kg / day, 500 µg / kg / day, 560 µg / kg / day, 600 µg / kg / day, 700 µg / kg / day, 800 µg / kg / day, 900 µg / kg / day, 1,000 µg / kg / day, 1,100 µg / kg / day, 1,200 µg / kg / day, 1,300 µg / kg / day, or 1,400 µg / kg / day.

[0219] In various embodiments, the CDK2 inhibitor is administered at a dose of from about 0.5 µg / kg / day to about 500 µg / kg / day, from about 0.5 µg / kg / day to about 250 µg / kg / day, from about 1 µg / kg / day to about 100 µg / kg / day, from about 10 µg / kg / day to about 50 µg / kg / day, from about 10 µg / kg / day to about 100 µg / kg / day, from about 0.5 µg / kg / day to about 2000 µg / kg / day, from about 280 µg / kg / day to about 1400 µg / kg / day, from about 420 µg / kg / day to about 1400 µg / kg / day, from about 250 to about 550 µg / kg / day, from about 560 µg / kg / day to about 1400 µg / kg / day, from 700 µg / kg / day to about 1400 µg / kg / day, from about 560 µg / kg / day to about 1200 µg / kg / day, from about 700 µg / kg / day to about 1200 µg / kg / day, from about 560 µg / kg / day to about 1000 µg / kg / day, from about 700 µg / kg / day to about 1000 µg / kg / day, from about 800 µg / kg / day to about 1000 µg / kg / day, from about 200 µg / kg / day to about 600 µg / kg / day, from about 300 µg / kg / day to about 600 µg / kg / day, from about 400 µg / kg / day to about 500 µg / kg / day, from about 400 µg / kg / day to about 600 µg / kg / day, from about 400 µg / kg / day to about 700 µg / kg / day, from about 400 µg / kg / day to about 800 µg / kg / day, from about 500 µg / kg / day to about 800 µg / kg / day, from about 500 µg / kg / day to about 900 µg / kg / day, from about 600 µg / kg / day to about 900 µg / kg / day, from about 700 µg / kg / day to about 900 µg / kg / day, from about 200 µg / kg / day to about 600 µg / kg / day, from about 800 µg / kg / day to about 900 µg / kg / day, from about 100 µg / kg / day to about 1500 µg / kg / day, from about 300 µg / kg / day to about 2,000 µg / kg / day, or from about 400 µg / kg / day to about 2000 µg / kg / day.

[0220] In some embodiments, the CDK2 inhibitor is administered at a dose of from about 30 µg / kg to about 1400 µg / kg per dose. In some embodiments, the CDK2 inhibitor is administered at a dose of from about 0.5 µg / kg to about 2000 µg / kg per dose, from about 0.5 µg / kg to about 1500 µg / kg per dose, from about 100 µg / kg to about 700 µg / kg per dose, from about 5 µg / kg to about 100 µg / kg per dose, from about 10 µg / kg to about 500 µg / kg per dose, from about 50 µg / kgto about 1400 µg / kg per dose, from about 300 µg / kg to about 2,000 µg / kg per dose, from about 60 µg / kg to about 1200 µg / kg per dose, from about 70 µg / kg to about 1000 µg / kg per dose, from about 70 µg / kg to about 700 µg / kg per dose, from 80 µg / kg to about 1000 µg / kg per dose, from 80 µg / kg to about 800 µg / kg per dose, from 100 µg / kg to about 800 µg / kg per dose, from 100 µg / kg to about 600 µg / kg per dose, from 150 µg / kg to about 700 µg / kg per dose, from 150 µg / kg to about 500 µg / kg per dose, from 200 µg / kg to about 400 µg / kg per dose, from 200 µg / kg to about 300 µg / kg per dose, or from 300 µg / kg to about 400 µg / kg per dose.

[0221] In some embodiments, the CDK2 inhibitor is administered at a dose of from about 0.5 mg / day to about 550 mg / day. In various embodiments, the CDK2 inhibitor is administered at a dose of from about 1 mg / day to about 500 mg / day, from about 1 mg / day to about 300 mg / day, from about 1 mg / day to about 200 mg / day, from about 2 mg / day to about 300 mg / day, from about 2 mg / day to about 200 mg / day, from about 4 mg / day to about 300 mg / day, from about 4 mg / day to about 200 mg / day, from about 4 mg / day to about 150 mg / day, from about 5 mg / day to about 150 mg / day, from about 5 mg / day to about 100 mg / day, from about 5 mg / day to about 80 mg / day, from about 5 mg / day to about 50 mg / day, from about 5 mg / day to about 40 mg / day, from about 5 mg / day to about 30 mg / day, from about 5 mg / day to about 20 mg / day, from about 5 mg / day to about 15 mg / day, from about 10 mg / day to about 100 mg / day, from about 10 mg / day to about 80 mg / day, from about 10 mg / day to about 50 mg / day, from about 10 mg / day to about 40 mg / day, from about 10 mg / day to about 20 mg / day, from about 20 mg / day to about 100 mg / day, from about 20 mg / day to about 80 mg / day, from about 20 mg / day to about 50 mg / day, or from about 20 mg / day to about 40 mg / day, or from about 20 mg / day to about 30 mg / day.

[0222] In various embodiments, the dose of the CDK2 inhibitor is a first dose level. In various embodiments, the dose of the CDK2 inhibitor is a second dose level. In some embodiments, the second dose level is greater than the first dose level. In some embodiments, the second dose level is about or at least about 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 times or fold greater than the first dose level. In some embodiments, the second dose level is not in excess of about 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 150 times or fold greater than the first dose level.

[0223] In various embodiments, the CDK2 inhibitor is administered once daily (QD) at one of the above doses or within one of the above dose ranges. In various embodiments, the CDK2 inhibitor is administered twice daily (BID) at one of the above doses or within one of the abovedose ranges. In various embodiments, a CDK2 inhibitor dose is administered daily, every other day, twice a week, or once a week.

[0224] In various embodiments, the CDK2 inhibitor is administered regularly for a period of about or of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 48, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, or 800 weeks. In various embodiments, the CDK2 inhibitor is administered for not more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 48, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, or 1000 weeks. In various embodiments, the CDK2 inhibitor is administered regularly for a period of about or of at least about 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years. In various embodiments, the CDK2 inhibitor is administered regularly for a period not in excess of about 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 15 years.Kits

[0225] In another aspect, provided herein are kits containing a device for administration of a pre-filled a pharmaceutical composition comprising a CDK2 inhibitor, as described herein. In certain embodiments, kits contain a device for oral administration and a pharmaceutical composition as described herein. In certain embodiments the kits include prefilled sachet or bottle for oral administration.

[0226] In certain embodiments, the present disclosure provides one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of the compounds of the disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and / or guidelines for mixing the components, can also be included in the kit.

[0227] Delivery devices are important not only for delivering the compounds of the disclosure, but also for providing an appropriate environment for storage. This would include protection from microbial contamination and chemical degradation. The device and formulation should be compatible so as to avoid potential leaching or adsorption. The delivery device (or its packaging) can be optionally provided with a label and / or with instructions for use indicating how the composition should be administered, e.g., orally or subcutaneously.Combinations

[0228] In certain embodiments, a pharmaceutical composition comprising a CDK2 inhibitor, as described herein, can further include one or more additional therapeutic agents. In certain embodiments, a CDK2 inhibitor or a pharmaceutical composition thereof, as described herein, can be administered in combination with one or more additional therapeutic agents. The CDK2 inhibitor or a pharmaceutical composition thereof, and the one or more additional therapeutic agents, as described herein, may be administered simultaneously or sequentially in any order and / or at any interval appropriate to achieve a desirable therapeutic outcome.

[0229] In some embodiments, the one or more additional therapeutic agents is selected from antibodies, antibody-drug conjugates, kinase inhibitors, immunomodulators, histone deacetylase inhibitors, and anti-neoplastic agents. In some embodiments, the one or more additional therapeutic agent is selected from the following agents, or a pharmaceutically acceptable salt thereof BCR-ABL inhibitors (e.g. imatinib, inilotinib, nilotinib, dasatinib, bosutinib, ponatinib, bafetinib, danusertib, saracatinib, PF03814735); ALK inhibitors (see Dardaei et al, 2018, Nat Med.; 24(4):512-517) (e.g. crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrecinib, lorlatinib); BRAF inhibitors (see Prahallad et al, 2015, Cell Rep. 12, 1978-1985) (e.g. vemurafenib, dabrafenib); FGFR inhibitors (e.g. infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547); FLT3 inhibitors (e.g. sunitinib, midostaurin, tanutinib, sorafenib, lestaurtinib, quizartinib, and crenolanib); MEK Inhibitors (see Fedele et al, 2018, BioRxiv 307876; Torres- Ayuso et al, 2018, Cancer Discov.8, 1210-1212; and Wong et al, 2016, Oncotarget.2016 Oct 4; 7(40): 65676-65695) (e.g. trametinib, cobimetinib, binimetinib, selumetinib); ERK inhibitors (e.g. ulixertinib, MK-8353, LY-3214996); VEGF receptor inhibitors (e.g. bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib); Tyrosine kinase inhibitors (e.g. erlotinib, linifanib, sunitinib, pazopanib); Epidermal growth factor receptor (EGFR) inhibitors: gefitinib, osimertinib, cetuximab, panitumumab); HER2 receptor inhibitors (e.g. trastuzumab, neratinib, lapatinib, lapatinib); MET inhibitors (e.g. crizotinib, cabozantinib); CD20 antibodies (e.g. rituximab, tositumomab, ofatumumab); DNA Synthesis inhibitors (e.g. capecitabine, gemcitabine, nelarabine, hydroxycarbamide); Antineoplastic agents (e.g. oxaliplatin, cisplatin); HER dimerization inhibitors (e.g. pertuzumab); Human Granulocyte colony-stimulating factor (G-CSF) modulators (e.g. filgrastim); Immunomodulators (e.g. afutuzumab, lenalidomide, thalidomide, pomalidomide); CD40 inhibitors (e.g. dacetuzumab); Pro-apoptotic receptor agonists (PARAs) (e.g. dulanermin); Heat Shock Protein (HSP) inhibitors (e.g. tanespimycin (17-allylamino-17-desmethoxygeldanamycin); Hedgehog antagonists (e.g. vismodegib); Proteasome inhibitors (e g. bortezomib); PI3K inhibitors (e.g. pictilisib, dactolisib, buparlisib, taselisib, idelalisib, duvelisib, umbralisib); Phospholipase A2 inhibitors (e.g. anagrelide); BCL-2 inhibitors (e.g. venetoclax); Aromatase inhibitors (e.g. exemestane, letrozole, anastrozole, faslodex, tamoxifen); Topoisomerase I inhibitors (e.g. irinotecan, topotecan); Topoisomerase II inhibitors (e.g. etoposide, teniposide); mTOR inhibitors (e.g. temsirolimus, ridaforolimus, everolimus, sirolimus); Osteoclastic bone resorption inhibitors (e.g. zoledronic acid); CD33 Antibody Drug Conjugates (e g. gemtuzumab ozogamicin); CD22 Antibody Drug Conjugates (e.g. inotuzumab ozogamicin); CD20 Antibody Drug Conjugates (e.g. ibritumomab tiuxetan); Somatostain analogs (e.g. octreotide); Interleukin- 11 (IL-11) (e.g. oprelvekin); Synthetic erythropoietin (e.g. darbepoetin alfa); Receptor Activator for Nuclear Factor K B (RANK) inhibitors (e g. denosumab); Thrombopoietin mimetic peptides (e.g. romiplostim); Cell growth stimulators (e.g. palifermin); Anti-Insulin-like Growth Factor-1 receptor (IGF-1R) antibodies (e g. figitumumab); Anti-CSl antibodies (e.g. elotuzumab); CD52 antibodies (e.g. alemtuzumab); CTLA-4 inhibitors (e.g. tremelimumab, ipilimumab); PD1 inhibitors (e.g. nivolumab, pembrolizumab); an immunoadhesin fusion protein (e.g. pidilizumab, AMP-224); PDL1 inhibitors (e.g. MSB0010718C, YW243.55.S70, atezolizumab, MEDI-4736, Avelumab, BMS-936559); LAG-3 inhibitors (e.g. relatlimab); GITR agonists; GITR fusion proteins and anti-GITR antibodies; Histone deacetylase inhibitors (HDI) (e.g. voninostat); Anti-CTLA4 antibodies (e.g. tremelimumab, ipilimumab); Alkylating agents (e.g. temozolomide, dactinomycin, melphalan, altretamine carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, procarbazine, mechlorethamine, mustine and mechloroethamine, streptozocin, thiotepa); Biologic response modifiers (e.g. bacillus calmette- guerin, denileukin diftitox); Anti-tumor antibiotics (e.g. doxorubicin, bleomycin, daunomycin, daunorubicin, liposomal mitoxantrone epirubicin, idarubicin, mitomycin C); Anti -microtubule agents (e.g. estramustine); Cathepsin K inhibitors (e.g. odanacatib); Epothilone analogs (e.g. ixabepilone); TpoR agonists (e.g. eltrombopag); Anti-mitotic agents (e.g. docetaxel); Adrenal steroid inhibitors (e.g. aminoglutethimide); Anti-androgens (e.g. nilutamide); Androgen Receptor inhibitors (e.g. enzalutamide, abiraterone acetate, orteronel, galeterone, and seviteronel, bicalutamide, flutamide); Androgens (e.g. fluoxymesterone); CDK inhibitors (e.g. alvocidib, palbociclib, ribociclib, trilaciclib, abemaciclib); Gonadotropin-releasing hormone (GnRH)receptor agonists (e.g. leuprolide or leuprolide acetate); Taxane anti-neoplastic agents (e g. cabazitaxel, larotaxel); 5-HTla receptor agonists (e.g. xaliproden); HPV vaccines (e.g. Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck); Iron Chelating agents (e.g. deferasirox); Anti-metabolites (e.g. cladribine, 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, cytarabine liposomal, decitabine, hydroxyurea, fludarabine, floxuridine, cladribine, methotrexate, pentostatin); Bisphosphonates (e.g. pamidronate); Demethylating agents (e.g. 5-azacitidine, decitabine); Anti-tumor Plant Alkaloids (e.g. paclitaxel protein-bound, vinblastine, vincristine, vinorelbine, paclitaxel); Retinoids (e.g. alitretinoin, tretinoin, isotretinoin, bexarotene); Glucocorticosteroids (e.g. hydrocortisone, dexamethasone, prednisolone, prednisone, methylprednisolone); Cytokines (e.g. interleukin-2, interleukin- 11 (oprevelkin), alpha interferon alfa (IFN-alpha)); estrogen receptor downregulators (e.g. fulvestrant); Anti-estrogens (e.g. tamoxifen, toremifene); Selective estrogen receptor modulators (SERMs) (e.g. raloxifene); Luteinizing hormone releasing hormone (LHRH) agonists (e.g. goserelin); Progesterones (e g. megestrol); cytotoxic agents (e.g. arsenic trioxide, asparaginase (also known as L-asparaginase, Erwinia L- asparaginase); Anti-nausea drugs (e.g. NK-1 receptor antagonists (e.g. casopitant)); Cytoprotective agents (e.g. amifostine, leucovorin); and Immune checkpoint inhibitors.

[0230] The term "immune checkpoints" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. Immune checkpoint molecules include, but are not limited to, Programmed Death 1 (PD- 1), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), B7H1, B7H4, 0X40, CD 137 (4-1BB), CD40, and LAG3. Immunotherapeutic agents which can act as immune checkpoint inhibitors useful in the methods of the present disclosure, include, but are not limited to, inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD 160, 2B4 and / or TGF beta receptor.

[0231] As used herein, anti-neoplastic agents are drugs or active agents that are used to treat cancer (e.g., anticancer drugs, chemotherapy, cytotoxic drugs, and the like). The anti- neoplastic agent can include, without limitation, an antibody, an antibody-drug conjugate (e.g., sacituzumab govitecan, mirvetuximab soravtansine, trastuzumab deruxtecan, enfortumab vedotin, or tisotumab vedotin), a DNA synthesis inhibitor (e.g., capecitabine, gemcitabine, nelarabine, or hydroxycarbamide), a platinum-based agent (e.g., carboplatin, oxaliplatin or cisplatin), topoisomerase I inhibitor (e g., irinotecan or topotecan), topoisomerase II inhibitor (e.g., etoposide or teniposide), an DNA-intercalating agent (e g., doxorubicin or liposomal doxorubicin), analkylating agent (e.g., temozolomide, dactinomycin, melphalan, altretamine, carmustine, bendamustine, busulfan, lomustine, chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, or procarbazine), an anti-microtubule agent (e.g., estramustine), a taxane-related anti- mitotic agent (e.g., docetaxel, paclitaxel, cabazitaxel, abraxane, or larotaxel), an anti-metabolite (e g., cladribine, 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, hydroxyurea, fludarabine, floxuridine, pentostatin, or methotrexate), an anti-tumor plant alkaloid (e.g., vinblastine, vincristine, or vinorelbine), an anti-estrogen agent (e.g., tamoxifen, toremifene, raloxifene, lasofoxifene, afimoxifene, arzoxifene, bazedoxifene, fispemifene, ormeloxifene, ospemifene, tesmilifene, trilostane, CHF 4227, fulvestrant, elacestrant, giredestrant, amcenestrant, camizestrant, ataraestane, formestane, exemestane, letrozole, anastrozole, fadrozole; gonadotropin-releasing hormone, leuprolide, leuprolide acetate, enzalutamide, abiraterone acetate, or bicalutamide), a protein kinase inhibitor (e.g., a CDK4 / 6 inhibitor (e.g., palbociclib, ribociclib, trilaciclib, or abemaciclib), alvocidib, crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrectinib, lorlatinib, vemurafenib, dabrafenib, infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547, trametinib, cobimetinib, binimetinib, selumetinib, ulixertinib, MK-8353, LY-3214966, bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib, erlotinib, linifanib, sunitinib, pazopanib, gefitinib, osimertinib, cetuximab, panitumumab, trastuzumab, neratinib, lapatinib, or cabozantinib), a phosphatidylinositol 3-kinase inhibitor (e.g., apelisib, duvelisib, copanlisib, or idelalisib), an immunomodulator, a histone deacetylase inhibitor (e.g., voninostat), a KRAS inhibitor (e.g., AMG510, MRTX849, JNJ-74699157 / ARS- 3248, Bl 1701963, Bl 1823911, BAY-293, GDC-6036, MRTX1133, a RAS(ON) inhibitor), or an immunotherapeutic agent (e g., PD1, PD-L1, PD-L2, CTLA-4, LAG3, TIM3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, 4-1BB, GITR, 0X40, or TGF beta receptor), an epigenetic modulator (e.g., EZH2a, ARID1A, ARID2, PRMT1-9, BRD4, IDH1 / 2, or BCL6), and combinations thereof. In some embodiments, the immunotherapeutic agent is a CTLA-4 inhibitor (e.g., tremelimumab or ipilimumab), a PD1 inhibitor (e.g., nivolumab or pembrolizumab), a PD-L1 inhibitor (e.g., atezolizumab, avelumab, or durvalumab), a LAG3 inhibitor (e.g., comprises BMS-986016). In some embodiments, the immunotherapeutic agent comprises a CAR T-cell therapy.

[0232] In some embodiments, the one or more additional therapeutic agent is selected from the following agents: anti-CDK2 agents; cytotoxic agents; Estrogen Receptor-targeted or other endocrine therapies, immune-checkpoint inhibitors, other CDK inhibitors, Receptor TyrosineKinase inhibitors, BRAF inhibitors, MEK inhibitors, PI3K inhibitors, SHP2 inhibitors, and SRC inhibitors. (See M. Katoh, Nat. Rev. Clin. Oncol.2019, 16: 105-122; Y.K. Chae, et al. Oncotarget 2017, 8: 16052-16074; L. Formisano et al., Nat. Comm. 2019, 10: 1373-1386; and references cited therein, all of which are incorporated herein in their entirety for all purposes.)

[0233] In some embodiments, the additional and -neoplastic agent may be selected from purine antagonists (such as 6-mercaptopurine riboside, mercaptopurine, 6-thioguanine, cladribine, clofarabine (Clolar). fludarabine, nelarabine, and raltitrexed), pyrimidine antagonists (such as 5- fluorouracil (5-FU), Alimta (pemetrexed disodium, LY231514, MFA), capeci tabine (Xeloda™), cytosine arabinoside, gemcitabine (Gernzar™), Tegafur (UFT Orzei orUforal and including TS-I combination of tegafur, gimestat and otostat), doxifl uridine, carmofur, cytarabine (including ocfosfate, phosphate stearate, sustained release and liposomal forms), enocitabine, 5-azacitidine (Vidaza), deci tabine, and etbynyl cytidine), dihydrofolate reductase inhibitors (such as methotrexate and NeuTrexin (trimetresate glucuronate)), and other anti metabolites such as AG- 014699, ABT-472, INO-1001, KU-0687, GPI 18180, efl ornithine, hydroxyurea, leucovorin, nolatrexed (Thymitaq), triapine, trimetrexate, and N-(5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyi)-N-methylamino]-2-tlienoyl)-L-glutamic acid, and combinations thereof.

[0234] Further examples of anti-neoplastic agents include, but are not limited to, Abraxane, Advexin (ING 201 ), Batabulin, bexarotene (Targretirt™), EPO 906, Virifhmine, actinomycin D, bleomycin, mitomycin C, neocarzinostatin (Zinostatin), vinblastine, vincristine, vindesine, vinorelbine (Navelbine), docetaxel (Taxotere), Oriataxel, paclitaxel (including Taxoprexin a DHA / paclitaxel conjugate), Nedaplatin, oxaliplatin (Eloxatin), Satraplatin, Camptosar, capec-itabine (Xeloda), oxaliplatin (Eloxatin), Taxotere alitretinoin, Canfosfamide (Telcyta™), DMXAA (Antisoma), ibandronic acid, L-asparaginase, pegaspargase (Oncaspar™), Efaproxiral (Efaproxyn™ - radiation therapy), Tesmilifene (DPPE- enhances efficacy of cytotoxics), Theratope™ (Biomira), Tretinoin (Vesanoid™), tirapazamine (Trizaone™), motexafm gadolinium (Xcytrin™) Cotara™ (mAb), and NBI-3001, polyglutamate- paclitaxel (Xyotax™), TNFerade (GeneVec, a compound which express TNFalpha in response to radiotherapy), RB94, Genasense (Obiimersen), Combretastatin A4P (CA4P), Oxi -4503, AVE- 8062, TZT-1027, Ator.'asiatin (Lipitor), Provastatin (Pravachol). Lovastatin (Mevacor),Simvastatin (Zocor), Fluvastatin (Lescol), Cerivastatin (Baycot), Rosuvastatin (Crestor), Lovostatin, Niacin (Advicor), Caduet, torcetrapib, ZD-6126, and combinations thereof.

[0235] A compound described herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB),(III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) may also be used in combination with known therapeutic processes, for example, the administration of hormones or radiation. In certain embodiments, a provided compound is used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[0236] A compound described herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB),(III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound described herein and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound described herein can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.

[0237] In one embodiment, the compound described herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) may be used in combination with a CDK4 / CDK6 inhibitor. The CDK4 / CDK6 may be selected from palbociclib, ribociclib, trilaciclib, or abemaciclib.

[0238] In one embodiment, the compound described herein (e.g., the compounds of Formula (I), (II), (IIA), (IIB), (III), (IIIA), (IIIB), (IIIC), (IV) and / or Table 1) may be used in combination with a chemotherapeutic agent. The chemotherapeutic agent may be selected from a DNA synthesis inhibitor (e.g., capecitabine, gemcitabine, nelarabine, or hydroxycarbamide), a platinum-based agent (e.g., carboplatin, oxaliplatin or cisplatin), topoisomerase I inhibitor (e.g., irinotecan or topotecan), topoisomerase II inhibitor (e.g., etoposide or teniposide), an DNA- intercalating agent (e.g., doxorubicin or liposomal doxorubicin), an alkylating agent (e.g., temozolomide, dactinomycin, melphalan, altretamine, carmustine, bendamustine, busulfan,lomustine, chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, or procarbazine), an anti -microtubule agent (e.g., estramustine), a taxane-related anti-mitotic agent (e.g., docetaxel, paclitaxel, cabazitaxel, abraxane, or larotaxel), an anti-metabolite (e.g., cladribine, 5 -fluorouracil, 6-thioguanine, pemetrexed, cytarabine, hydroxyurea, fludarabine, floxuridine, pentostatin, or methotrexate), or an anti-tumor plant alkaloid (e.g., vinblastine, vincristine, or vinorelbine).Examples

[0239] The following examples are provided by way of illustration. The examples should not be construed as limiting, as the examples merely provide specific understanding and practice of the embodiments and their various aspects.General Methods

[0240] The chemical shifts (8) for H-NMR spectra are reported in ppm with respect to the NMR solvents used for analysis and are reported as s - singlet, d - doublet, t - triplet, q - quartet, dd - doublet of doublet, dt - doublet of triplet, dq - doublet of quartet, and m - multiplet. Coupling constants (J) are reported in hertz (Hz).

[0241] Example 1

[0242] Compound 1: Synthesis of (S)-(4-([4-(2,2-dimethylmorpholin-4-yl)-5- fluoropyrimidin-2-yl] aminophenyl)(imino)methyl-X6-sulfanone according to Scheme 1.

[0243] Scheme 1 :Compound 1

[0244] Step 1 : To a 20 ml vial was added a solution of 2,2-dimethylmorpholine (500 mg, 4.341 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (869.8 mg, 5.209 mmol, 1.2 equiv)in EtOH (10 mL). TEA (1757.2 mg, 17.364 mmol, 4.0 equiv) was added at room temperature. The reaction was stirred for 8 h at 25°C under nitrogen then concentrated under reduced pressure to afford 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2-dimethylmorpholine (1 g, 82% yield) as a white oil.

[0245] Step 2: To a stirred solution of 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2- dimethylmorpholine (200 mg, 0.814 mmol, 1.0 equiv) and (4-aminophenyl)(imino)methyl- λ6- sulfanone (166.3 mg, 0.977 mmol, 1.2 equiv) in 1,4-dioxane (10 mL) was added Cs2CO3(530.5 mg, 1.628 mmol, 2.0 equiv), X-Phos (77.6 mg, 0.163 mmol, 0.2 equiv) and Pd(OAc)2(18.3 mg, 0.081 mmol, 0.1 equiv) at room temperature. The reaction mixture was stirred for 16 h at 100°C under nitrogen then cooled to room temperature, diluted with MeCN (10 mL), filtered and concentrated under reduced pressure. The residue was purified via prep-HPLC under the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L HCOOH), 5% to 40% gradient in 40 min; detector, UV 210 nm) to afford (4-([4-(2,2-dimethylmorpholin-4-yl)-5- fluoropyrimidin-2-yl]aminophenyl)(imino)methyl-λ6-sulfanone (150 mg, 44% yield) as a light yellow oil.

[0246] Step 3: (4-([4-(2,2-dimethylmorpholin-4-yl)-5-fluoropyrimidin-2- yl]aminophenyl)(imino) methyl-16-sulfanone was purified via SFC under the following conditions (Column: CHIRALPAK IE 2*25 cm, 5 μm; Mobile Phase A: Hexane (0.5% 2M NH3-MeOH)-- HPLC, Mobile Phase B: EtOH-HPLC; Flow rate: 20 mL / min; Gradient: isocratic 40; Wavelength: 220 / 254 nm; RT1(min): 24; RT2 (min): 29.302; Sample Solvent: EtOH--HPLC; Injection Volume: 1 mL; Number Of Runs: 6) to afford (S)-(4-([4-(2,2-dimethylmorpholin-4-yl)-5-fluoropyrimidin- 2-yl]aminophenyl)(imino)methyl-λ6-sulfanone (Compound 1, 38 mg, 12% yield) as a white solid.

[0247] LC-MS (ES, m / z): 380 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.67 (s, 1H), 8.08 (d, J = 6.7 Hz, 1H), 7.86 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 3.96 (s, 1H), 3.78 – 3.66 (m, 4H), 3.56 (s, 2H), 3.01 (s, 3H), 1.20 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ - 156.3.

[0248] Example 2

[0249] Compound 2: Synthesis of 4-{[5-chloro-4-(2,2-dimethylmorpholin-4- yl)pyrimidin-2-yl]amino}benzenesulfonamide according to Scheme 2.

[0250] Scheme 2:300 mg,2.61 mmol, 1.0 equiv) in EtOH (6 mL), 2,4,5-trichloropyrimidine (478 mg, 2.61 mmol, 1.0 equiv) and TEA (527 mg, 5.21 mmol, 2.0 equiv). The reaction was stirred for 2 h at 25°C then partitioned between ethyl acetate (20 mL) and water (40 mL). The aqueous layer was extracted with EA (100 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. This afforded 4-(2,5-dichloropyrimidin-4-yl)-2,2-dimethylmorpholine (500 mg, 68% yield) as a white solid.

[0252] Step 2: To a vial was added a solution of 4-(2,5-dichloropyrimidin-4-yl)-2,2- dimethylmorpholine (100 mg, 0.355 mmol, 1.0 equiv,) in 1,4-dioxane (5 mL), sulfanilamide (183 mg, 1.07 mmol, 3.0 eq) and TsOH (305 mg, 1.78 mmol, 5.0 eq). The reaction was stirred for 5 h at 100°C then cooled to room temperature and purified via prep-HPLC under the following conditions: Column, C18 silica gel; mobile phase, Mobile Phase A: Water (0.1% NH4HCO3), Mobile Phase B: ACN; Flow rate: 100 mL / min; Gradient: 0% B to 30% B in 30 min; Detector, UV 254 nm, 210 nm. This afforded 4-{[5-chloro-4-(2,2-dimethylmorpholin-4-yl)pyrimidin-2- yl]amino}benzenesulfonamide (Compound 2, 29.2 mg, 20% yield).

[0253] LC-MS (ES, m / z): 398.10 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.85 (s, 1H), 8.17 (s, 1H), 7.88 – 7.80 (m, 2H), 7.73 – 7.70 (m, 2H), 7.17 (s, 2H), 3.79 (dd, J = 6.0, 4.0 Hz, 2H), 3.59 (t, J = 4.9 Hz, 2H), 3.34 (s, 2H), 1.22 (s, 6H).

[0254] Example 3

[0255] Compound 3: Synthesis of 4-([4-(2,2-dimethylmorpholin-4-yl)-5-fluoropyrimidin- 2-yl]amino benzenesulfonamide according to Scheme 3.

[0256] Scheme 3:

[0257] Step 1: To a stirred solution of 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2- dimethylmorpholine (200 mg, 0.814 mmol, 1.0 equiv) and sulfanilamide (168.2 mg, 0.977 mmol, 1.2 equiv) in 1,4-dioxane (4 mL) and H2O (400 uL) was added Cs2CO3 (530.5 mg, 1.628 mmol, 2.0 equiv), DavePhos (64.1 mg, 0.163 mmol, 0.2 equiv) and Pd2(dba)3 (74.6 mg, 0.081 mmol, 0.1 equiv) at room temperature. The reaction mixture was stirred for 16 h at 100°C under nitrogen then cooled, diluted with MeCN (5 mL), filtered; and concentrated under reduced pressure. The residue was purified via prep-HPLC under the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L HCOOH), 5% to 40% gradient in 40 min; detector, UV 210 nm.) to afford 4-([4-(2,2-dimethylmorpholin-4-yl)-5-fluoropyrimidin-2- yl]aminobenzenesulfonamide (Compound 3, 100 mg, 30% yield) as a brown solid.

[0258] LC-MS (ES, m / z): 382 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.61 (s, 1H), 8.07 (d, J = 6.7 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.74 – 7.65 (m, 2H), 7.14 (s, 2H), 3.72 (dd, J = 15.0, 5.5 Hz, 4H), 3.55 (s, 2H), 1.20 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.4.

[0259] Example 4

[0260] Compound 4: Synthesis of (S)-{4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]phenyl}(imino)methyl-λ6-sulfanone according to Scheme 4.

[0261] Scheme 4:

[0262] Step 1: To a vial was added a solution of 7-(2,5-dichloropyrimidin-4-yl)-4-oxa-7- azaspiro[2.5]octane (200 mg, 0.769 mmol, 1.0 equiv) and (4-aminophenyl)(imino)methyl-λ6- sulfanone (157.1 mg, 0.923 mmol, 1.2 equiv) in dioxane (4 mL), Pd(OAc)2 (17.3 mg, 0.077 mmol, 0.1 equiv), X-Phos (73.3 mg, 0.154 mmol, 0.2 equiv) and Cs2CO3 (501 mg, 1.538 mmol, 2.0 equiv) at room temperature. The reaction was stirred for 12 h at 100°C under nitrogen, cooled, concentrated then purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 20% to 50% gradient in 30 min; detector, UV 210 nm. This resulted in {4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]phenyl}(imino) methylsulfanone (50 mg, 16% yield) as a yellow solid.

[0263] Step 2: ({4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7-yl}pyrimidin-2- yl)amino]phenyl} (imino)methylsulfanone (50 mg, 0.127 mmol, 1.0 equiv) was separated by prep- SFC under the following conditions (Column: CHIRALPAKIC3; Mobile Phase: (Hex: DCM=3: 1)(0.1%DEA): EtOH=80: 20; Flow rate: 1.0 mL / min; Gradient: isocratic; Injection Volume: 3L mL) to afford (S)-{4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7-yl}pyrimidin-2- yl)amino]phenyl}(imino)methyl-λ6-sulfanone (Compound 4, 11.3 mg, 22% yield) as a white solid.

[0264] LCMS (ES, m / z): 394.05 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.90 (s, 1H), 8.18 (s, 1H), 7.94 – 7.69 (m, 4H), 4.00 (s, 1H), 3.89 – 3.71 (m, 4H), 3.67 (s, 2H), 3.02 (s, 3H), 0.84 – 0.53 (m, 4H).

[0265] Example 5

[0266] Compound 5: Synthesis of 4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 5.

[0267] Scheme 5:octane (700 mg, 4.68 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (944 mg, 5.15 mmol, 1.1 equiv) in EtOH (35 mL), then, TEA (1.42 g, 14.0 mmol, 3.0 equiv) was added dropwise at room temperature under nitrogen atmosphere. The reaction was stirred for 15 h at 80°C then cooled and concentrated under reduced pressure. This provided 7-(2,5-dichloropyrimidin-4-yl)-4-oxa-7- azaspiro[2.5]octane (1 g, 76% yield) as a white solid.

[0269] Step 2: To a 100 mL flask was added a solution of 7-(2,5-dichloropyrimidin-4-yl)- 4-oxa-7-azaspiro[2.5] octane (200 mg, 0.769 mmol, 1.0 equiv) and sulfanilamide (265 mg, 1.54 mmol, 2.0 equiv) in dioxane (40 mL). Then, p-toluenesulfonic acid (794 mg, 4.61 mmol, 6.0 equiv) was added in portions at room temperature under nitrogen. The reaction was stirred for 2 days at 100°C. The reaction solution was cooled, concentrated and purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 30% to 60% gradient in 30 min; detector, UV 210 nm. This resulted in 4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino] benzenesulfonamide (Compound 5, 33 mg, 10% yield) as a yellow solid.

[0270] LC-MS (ES, m / z): 396.05 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.85 (s, 1H), 8.18 (s, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.75 – 7.63 (m, 2H), 6.34 (s, 2H), 3.87 – 3.70 (m, 4H), 3.67 (s, 2H), 0.86 – 0.60 (m, 4H).

[0271] Example 6

[0272] Compound 6: Synthesis of 4-[(5-fluoro-4-{1-methyl-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl}pyrimidin-2-yl)amino] benzenesulfonamide according to Scheme 6.

[0273] Scheme 6:

[0274] Step 1: To a 20 mL vial was added a solution of 1-methyl-2-oxa-5- azabicyclo[2.2.1]heptane (150 mg, 0.710 mmol, 1.0 equiv) in EtOH (3 mL), 2,4-dichloro-5- fluoropyrimidine (130.5 mg, 0.781 mmol, 1.1 equiv) and Et3N (143.8 mg, 1.420 mmol, 2.0 equiv) at room temperature under nitrogen. The reaction was stirred for 2 h at 25°C then concentrated under reduced pressure. The residue was used in the next step directly without further purification.

[0275] Step 2: To a 20 mL vial was added a solution of 5-(2-chloropyrimidin-4-yl)-1- methyl-2-oxa-5-azabicyclo [2.2.1]heptane (100 mg, 0.443 mmol, 1.0 equiv) in 1,4-dioxane (5 mL), sulfanilamide (77.7 mg, 0.487 mmol, 1.1 equiv) and K2CO3(170.2 mg, 1.230 mmol, 3.0 equiv), X-Phos (39.1 mg, 0.082 mmol, 0.2 equiv) and Pd(OAc)2 (9.2 mg, 0.041 mmol, 0.1 equiv). The reaction was stirred for 16 h at 100°C under nitrogen, cooled, concentrated and purified via reverse-phase flash chromatography under the following conditions: Column: Xselect CSH OBD Column, 30*150mm, 5 um; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 30% B in 10 min; Wavelength: 254 nm / 220 nm. The reaction was concentrated under reduced pressure. This resulted in 4-[(5-fluoro-4-{1-methyl-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl}pyrimidin-2-yl)amino] benzenesulfonamide (Compound 6, 13.8 mg, 8% yield) as a white solid.

[0276] LC-MS (ES, m / z):380.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.58 (s, 1H), 8.03 (d, J = 5.5 Hz, 1H), 7.93 – 7.80 (m, 2H), 7.75 – 7.64 (m, 2H), 7.12 (s, 2H), 4.96 (s, 1H), 3.97 – 3.86 (m, 1H), 3.81 (d, J = 7.4 Hz, 1H), 3.67 (d, J = 10.2 Hz, 1H), 3.56 – 3.43 (m, 1H), 1.97 (d, J = 9.8 Hz, 1H), 1.78 (d, J = 9.9 Hz, 1H), 1.48 (s, 3H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -163.91.

[0277] Example 7

[0278] Compound 7: Synthesis of 4-[(5-fluoro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 7.

[0279] Scheme 7:n of 4-oxa-7-azaspiro[2.5]octane (27 g, 239 mmol, 1.0 equiv) in EtOH (540 mL) at 20°C. To the above was added 2,4-dichloro-5-fluoropyrimidine (39.8 g, 239 mmol, 1.0 equiv) and TEA (48.29 g, 477 mmol, 2.0 equiv) dropwise at 20°C. The reaction mixture was stirred for 2 h at 20°C under nitrogen then concentrated under reduced pressure to remove EtOH. The residue was dissolved in water (300 mL) and stirred for 30 min. The precipitated solids were collected by filtration and washed with water (3 x 270 mL). This resulted in 7-(2-chloro-5-fluoropyrimidin-4-yl)-4-oxa-7- azaspiro[2.5]octane (42 g, 65% yield) as a white solid.

[0281] Step 2: To a 100 mL 3-necked flask was added 7-(2-chloro-5-fluoropyrimidin-4- yl)-4-oxa-7-azaspiro[2.5] octane (4 g, 16.4 mmol, 1.0 equiv) in 1,4-dioxane (40 mL) at room temperature. To the above mixture was added sulfanilamide (8.48 g, 49.2 mmol, 3.0 equiv) and 4- methylbenzene-1-sulfonic acid (14.1 g, 82.1 mmol, 5.0 equiv) at room temperature under N2. The reaction was stirred for 24 h at 100°C under N2then cooled and filtered and the filter cake was washed with 1,4-dioxane (3 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10 µm; mobile phase, MeCN in water (0.1% FA), 10% to 40% gradient in 30 min; detector, UV 210 / 254 nm to afford 4-[(5-fluoro-4-{4-oxa-7- azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino]benzenesulfonamide (Compound 7, 2.8 g, 44% yield) as a grey solid.

[0282] LC-MS (ES, m / z): 380 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.63 (s, 1H), 8.09 (d, J = 6 Hz, 1H), 7.81 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 7.14 (s, 2H), 3.78 (s, 4H), 3.69 (s, 2H), 0.82 – 0.70 (m, 2H), 0.70 – 0.58 (m, 2H);19F-NMR (300 MHz, DMSO-d6, ppm): δ-156.24.

[0283] Example 8

[0284] Compound 8: Synthesis of 4-((5-methyl-4-(4-oxa-7-azaspiro[2.5]octan-7- yl)pyrimidin-2-yl)amino)benzenesulfonamide according to Scheme 8.

[0285] Scheme 8:

[0286] Step 1: To a 40 mL vial under nitrogen was added a solution of 4-oxa-7- azaspiro[2.5]octane (1 g, 8.837 mmol, 1.0 equiv) in EtOH (20 mL), 2,4-dichloro-5- methylpyrimidine (1.58 g, 9.721 mmol, 1.1 equiv) and TEA (1.79 g, 17.689 mmol, 2.0 equiv) at room temperature. The mixture was stirred for 2 h at room temperature then concentrated and purified via reverse-phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10µm; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 40% to 70% gradient in 30 min; detector, UV 210 / 254 nm, The eluent of product was concentrated and freeze dried to afford 7-(2-chloro-5-methylpyrimidin-4-yl)-4-oxa-7- azaspiro[2.5]octane (236 mg, 15% yield) as a white solid.

[0287] Step 2: To a 40 mL vial under nitrogen was added a solution of 7-(2-chloro-5- fluoropyrimidin-4-yl)-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.41 mmol, 1.0 equiv) in 1,4-dioxane (10 mL), N1-methylsulfanilamide (76.4 mg, 0.41 mmol, 1.0 equiv), Pd(OAc)2(9.2 mg, 0.041 mmol, 0.1 equiv), X-Phos (39.1 mg, 0.082 mmol, 0.2 equiv) and Cs2CO3(267.4 mg, 0.820 mmol, 2.0 equiv) at room temperature. The mixture was stirred for 12 h at 110°C, cooled, concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10µm; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 40% to 70% gradient in 30 min; detector, UV 210 / 254 nm,The eluent of product was concentrated and freeze dried to afford 4-((5-methyl-4-(4-oxa-7-azaspiro[2.5]octan- 7-yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 8, 7.5 mg, 4% yield) as a white solid.

[0288] LC-MS: (ES, m / z):376 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.52 (s, 1H), 8.03 – 7.79 (m, 3H), 7.69 (d, J = 8.4 Hz, 2H), 7.11 (s, 2H), 3.80 (s, 2H), 3.54 (s, 2H), 3.43 (s, 2H), 2.12 (s, 3H), 0.69 (d, J = 25.4 Hz, 4H).

[0289] Example 9

[0290] Compound 9: Synthesis of (S)-(4-((5-chloro-4-(5-oxa-8-azaspiro[3.5]nonan-8- yl)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone according to Scheme 9.

[0291] Scheme 9: zaspiro[3.5]nonan-8-yl}pyrimidin-2-yl)amino]phenyl}(imino)methyl-λ6-sulfanone (70 mg, 0.172 mmol, 1.0 equiv) was purified via prep-HPLC under the following conditions (Column: CHIRALPAKIC3; Mobile Phase A: (Hex: DCM=3: 1)(0.1%DEA): EtOH=70: 30; Flow rate: 1.0 mL / min mL / min; Gradient: isocratic; Injection Volume: 3 uL) to afford (S)-(4-((5-chloro-4-(5-oxa-8-azaspiro[3.5]nonan-8- yl)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone (Compound 9, 11.7 mg, 16% yield) as a white solid.

[0293] LC-MS (ES,m / z): 408 [M+H]+;1H-NMR: (400 MHz, DMSO-d6, ppm) δ 9.92 (s, 1 H), 8.20 (s, 1H), 8.02–7.67 (m, 4H), 4.02 (s, 1H), 3.62 (d, J = 41.5 Hz, 4H), 3.57 (s, 2H),3.02 (s , 3H), 2.17–1.87 (m, 4H), 1.87–1.53 (m, 2H).

[0294] Example 10

[0295] Compound 10: Synthesis of {4-[(5-fluoro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl}py rimidin-2-yl)amino]phenyl}(imino)methyl-16-sulfanone according to Scheme 10.

[0296] Scheme 10:

[0297] Step 1: 4-[(5-fluoro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl}pyrimidin-2- yl)amino]phenyl}(imino)methyl-λ6-sulfanone (36 mg, 0.092 mmol, 1.0 equiv) was separated by Prep-CHIRAL-HPLC with the following conditions Column: CHIRALCellulose B; Mobile Phase: MtBE (0.1%DEA): EtOH=90: 10; Flow rate: 1.0 mL / min; Gradient: isocratic; Injection Volume: 3 μL to afford {4-[(5-fluoro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl}pyrimidin-2- yl)amino]phenyl}(imino)methyl-λ6-sulfanone (Compound 10, 14.6 mg, 40% yield) as a white solid.

[0298] LC-MS (ES, m / z): 392.05 [M+H]+;1H NMR (400 MHz, DMSO-d6, ppm) δ 9.69 (s, 1H), 8.10 (d, J = 6.7 Hz, 1H), 7.89 – 7.75 (m, 4H), 3.97 (s, 1H), 3.72 (s, 2H), 3.66 (p, J = 5.3, 4.5 Hz, 4H), 3.02 (s, 3H), 1.98 (t, J = 9.4 Hz, 4H), 1.87 – 1.77 (m, 1H), 1.71 – 1.59 (m, 1H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.4.

[0299] Example 11

[0300] Compound 11: Synthesis of 4-[(5-chloro-4-(5-oxa-8-azaspiro[3.5]nonan-8- ylpyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 11.

[0301] Scheme 11:e (2 g, 15.725 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (3.17 g, 17.297 mmol, 1.1 equiv) in THF (40 mL) at 25°C. To the above mixture was added TEA (3.18 g, 31.450 mmol, 2.0 equiv) dropwise over 5 min at 0°C. The reaction was stirred for 3 h at 25°C then concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1N NH4HCO3, 40% to 70% yield) gradient in 30 min; detector, UV 254 / 210 nm to afford 8-(2,5-dichloropyrimidin-4-yl)-5-oxa-8-azaspiro[3.5]nonane (Compound 11, 2.1 g, 48% yield) as an off white solid.

[0303] Step 2: To an 8 ml vial was added 8-(2,5-dichloropyrimidin-4-yl)-5-oxa-8- azaspiro[3.5]nonane (100 mg, 0.365 mmol, 1.0 equiv), sulfanilamide (75.4 mg, 0.438 mmol, 1.2equiv) and pTsOH (376.9 mg, 2.190 mmol, 6.0 equiv) in1,4-dioxane (2 mL) at 25 °C. The reaction was stirred for 12 h at 100°C under a nitrogen atmospherethen cooled, concentrated and purified via reverse-phase flash chromatography under the following conditions: column, XB-C18 silica gel; mobile phase, MeCN in Water (0.1% NH4HCO3, 30% to 60% yield) gradient in 30 min; detector, UV 254 / 210nm to afford 4-[(5-chloro-4-(5-oxa-8-azaspiro[3.5]nonan-8-ylpyrimidin-2- yl)amino]benzenesulfonamide (Compound 11, 26.7 mg, 17% yield) as a white solid.

[0304] LC-MS (ES,m / z): 410.05[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.87 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 7.91 – 7.65 (m, 4H), 7.17 (s, 2H), 3.76 – 3.48 (m, 6H), 2.11 – 1.89 (m, 4H), 1.72 (dq, J = 54.4, 10.3, 9.6 Hz, 2H).

[0305] Example 12

[0306] Compound 12: Synthesis of (S)-4-((5-chloro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)benzenesulfonamide according to Scheme 12.

[0307] Scheme 12:

[0308] Step 1: To a 1000 mL three-necked flask was added (2S)-2-aminopropan-1-ol (25 g, 332.8 mmol, 1 equiv) and TEA (101.45 g, 998.5 mmol, 3 equiv) in DCM (250 mL) at room temperature. TsCl (63.455 g, 332.840 mmol, 1 equiv) was added at 0°C. The mixture was stirred for 2 h at room temperature then quenched with H2O (300 mL) and extracted with DCM (600 mL).The organic layer was dried with Na2SC>4, fdtered and concentrated. This resulted in 60 g of (S)- N-(l-hydroxypropan-2-yl)-4-methylbenzenesulfonamide as a yellow oil.

[0309] Step 2: To a 100 mL three-necked flask was added N-[(2S)-l-hydroxypropan- 2-yl]-4-methylbenzenesulfonamide (60g, 261.67 mmol, 1 equiv) and 3 -bromoprop- 1-yne (38.8g, 261.67 mmol, 1 equiv) in acetonitrile (900 mL) at room temperature. K2CO3 (108.47 g, 784.87 mmol, 3 equiv) and KI (8.68 g, 52.32 mmol, 0.2 equiv) were added. The mixture was stirred overnight at 80°C then fdtered and concentrated under vacuum. This resulted in 65 g of (S)-N-(l-hydroxypropan-2-yl)-4-methyl-N-(prop-2-yn-l-yl)benzenesulfonamide as a colorless oil.

[0310] Step 3: Into a 2 L three-necked flask was placed a solution of (S)-N-(l- hydroxypropan-2-yl)-4-methyl-N-(prop-2-yn-l-yl)benzenesulfonamide (55 g, 205.73 mmol, 1 equiv) in toluene (825 mL). Ag2CO3 (56 g, 205.731 mmol, 1 equiv) was added and the mixture was stirred for 3 h at 80°C. The reaction mixture was fdtered and concentrated under vacuum. The mixture was purified by column chromatography (PE / EA=0~10% yield). This resulted in 22.7 g (25% yield for 3 steps) of (S)-5-methyl-2-methylene-4-tosylmorpholine as a yellow oil

[0311] Step 4: Into a 1 L three-necked flask containing ZnEt2 (75.56 mL, 75.560 mmol, 2.02 equiv) was added dry DCM (300 mL) at -78°C, followed by CH2I2 (20.04 g, 74.812 mmol, 2 equiv) in DCM (80 mL) over 10 min under an atmosphere of nitrogen. The reaction was stirred for 30 min at -78°C and then at for 30 min at -10°C. The mixture was then re-cooled to -78°C and a solution of TFA (2.13 g, 18.703 mmol, 0.5 equiv) in DCM (20 mL) added dropwise. After stirring for 30 min at -78°C, the mixture was added dropwise to a solution of (S)-5-methyl-2-methylene- 4-tosylmorpholine (10 g, 37.45 mmol, 1 equiv) in DCM (100 mL) at -78°C. The reaction was stirred at -78°C for 10 min, 0°C for 1 h and 25 °C for 3 h. Saturated aq. NH4CI solution (200 mL) was added, and the mixture extracted with DCM (300 mL x 2). The organic layers were washed with H2O (300 mL) and dried over anhydrous Na2SO4. The solvent was removed, and the residue was purified by column chromatography (PE / EA = 0 ~ 10% yield). This resulted in 9.69 g (88% yield) of (S)-6-methyl-7-tosyl-4-oxa-7-azaspiro[2.5]octane as a yellow oil.

[0312] Step 5: Into a 250 mL three-necked flask was added a solution of (S)-6-methyl-7- tosyl-4-oxa-7-azaspiro[2.5]octane (4.5 g, 15.993 mmol, 1 equiv) in THF (66 mL) at 0°C. Potassium diphenylphosphide (IM in THF, 4.66 g, 20.791 mmol, 1.3 equiv) was added dropwise over 5 min at 0°C. The reaction was stirred for 6 h at room temperature then HC1 (95.96 mL,95.958 mmol, 6 equiv) was added and the reaction stirred another 3 h at room temperature. The mixture was washed with EA (250 mL) and the water layer used in the next step.

[0313] Step 6: To a 500 mL three-necked flask containing a solution of (S)-6-methyl-4- oxa-7-azaspiro[2.5]octane (2.04 g, 16.039 mmol, 1 equiv) in water (100 mL) at 0°C was added DIEA (16.58 g, 128.312 mmol, 8 equiv) and DCM (60 mL) followed by a solution of 2,4,5- trichloropyrimidine (2.33 g, 12.831 mmol, 0.8 equiv) in DCM. The reaction was stirred overnight at 25°C then extracted with DCM (50 mL), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under vacuum. The mixture was purified by column chromatography (PE / EA = 0~5% yield). This resulted in 1.8 g (Yield 41% for 2 steps) of (S)-7-(2,5-dichloropyrimidin-4-yl)- 6-methyl-4-oxa-7-azaspiro[2.5]octane as a yellow oil.

[0314] Step 7: To an 8 ml vial was added a solution of (S)-7-(2,5-dichloropyrimidin-4-yl)- 6-methyl-4-oxa-7-azaspiro[2.5]octane (110 mg, 0.4 mmol, 1 equiv) and 4- aminobenzenesulfonamide (113.75 mg, 0.481 mmol, 1.2 equiv) in dioxane (3.3 mL) at room temperature. p-TsOH (345.47 mg, 2 mmol, 5 equiv) was added and the mixture was stirred overnight at 100°C. The reaction was filtered and purified via Column: Cl 8; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 28% B to 68% B in 20 min; Wavelength: 220 nm; RTl(min): 12.00. This afforded (S)-4-((5-chloro-4-(6- methyl-4-oxa-7-azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 12, 77 mg, 40% yield) as a white solid.

[0315] LC-MS (ES, m / z): 410.10 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm) 5 9.79 (s, 1H), 8.15 (s, 1H), 7.81 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.16 (s, 2H), 4.64 - 4.57 (m, 1H), 3.82 (d, J = 12.9 Hz, 2H), 3.66 (d, J = 10.8 Hz, 1H), 3.57 (d, J = 13.7 Hz, 1H), 1.35 (d, J = 6.8 Hz, 3H), 0.91 - 0.80 (m, 1H), 0.77 - 0.56 (m, 3H).

[0316] Example 13

[0317] Compound 13: Synthesis of 4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide according to Scheme 13.

[0318] Scheme 13:f 7-(2,5-dichloropyrimidin-4-yl)-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.384 mmol, 1.0 equiv) and 1,4-dioxane (5 mL). Then N1- methylsulfanilamide (78.8 mg, 0.422 mmol, 1.1 equiv), Cs2CO3 (251 mg, 0.768 mmol, 2.0 equiv), X-Phos (36.7 mg, 0.077 mmol, 0.2 equiv) and Pd(OAc)2(17.3 mg, 0.077 mmol, 0.1 equiv) were added at room temperature. The reaction was stirred for 12 h at 100°C under a nitrogen atmosphere then cooled to room temperature and concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in 0.1% NH4HCO3Water, 30% to 60% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under reduced pressure. This resulted in 4-[(5-chloro- 4-{4-oxa-7-azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide (Compound 13, 16.5 mg, 9% yield) as a white solid.

[0320] LC-MS (ES, m / z): 410.15 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.90 (s, 1H), 8.19 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.22 (s, 1H), 3.88 – 3.59 (m, 7H), 2.39 (s, 3H), 0.79 – 0.60 (m, 4H).

[0321] Example 14

[0322] Compound 14: Synthesis of 4-({5-fluoro-4-[(6S)-6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl]pyrimidin-2-yl}amino)benzenesulfonamide according to Scheme 14.

[0323] Scheme 14:

[0324] Step 1: To a 500 mL three-necked flask containing a solution of (S)-6-methyl-4- oxa-7-azaspiro[2.5]octane (2.04 g, 16.039 mmol, 1 equiv) in water (100 mL) was added DIEA (16.58 g, 128.312 mmol, 8 equiv) and DCM (96 mL) at 0°C. To the above mixture was added a solution of 2,4-dichloro-5-fluoropyrimidine (2.14 g, 12.831 mmol, 0.8 equiv) in DCM and the reaction was stirred overnight at room temperature. The mixture was extracted with DCM (50 mL), dried over anhydrous Na2SO4, filtered and the filtrate concentrated under vacuum. The residue was purified via column chromatography (PE / EA =20: 1). This resulted in 1.6 g of (S)-7-(2-chloro-5- fluoropyrimidin-4-yl)-6-methyl-4-oxa-7-azaspiro[2.5]octane as a yellow oil.

[0325] Step 2: To an 8 ml vial under nitrogen was added a solution of (6S)-7-(2-chloro-5- fluoropyrimidin-4-yl)-6-methyl-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.388 mmol, 1 equiv) in dioxane (2 mL) and H2O (0.2 mL). Sulfanilamide (133.65 mg, 0.776 mmol, 2 equiv), Cs2CO3 (505.75 mg, 1.552 mmol, 4 equiv), DavePhos (30.54 mg, 0.078 mmol, 0.2 equiv) and Pd2(dba)3 (35.54 mg, 0.039 mmol, 0.1 equiv) were added and the reaction was stirred for 2 h at 100°C. The mixture was cooled to room temperature and concentrated. The residue was purified via prep- HPLC with the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 35% B in 2.5 min, 35% B to 40% B in 10 min; Wavelength: 254 nm / 220 nm; RT1(min): 10.3. This afforded 4-({5-fluoro-4-[(6S)-6-methyl- 4-oxa-7-azaspiro[2.5]octan-7-yl]pyrimidin-2-yl}amino)benzenesulfonamide (Compound 14, 45 mg, 29% yield) as a white solid.

[0326] LC-MS (ES, m / z): 394.10 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.60 (s, 1H), 8.08 (d, J = 6.8 Hz, 1H), 7.86 – 7.74 (m, 2H), 7.74 – 7.62 (m, 2H), 7.13 (s, 2H), 4.62 – 4.47 (m, 1H), 3.91 – 3.79 (m, 2H), 3.68 (dd, J = 11.4, 1.2 Hz, 1H), 3.56 (d, J = 13.7 Hz, 1H), 1.36 (d, J = 6.8 Hz, 3H), 0.94 – 0.80 (m, 1H), 0.80 – 0.64 (m, 2H), 0.64 – 0.46 (m, 1H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -157.04.

[0327] Example 15

[0328] Compound 15: Synthesis of 4-[(5-fluoro-4-{5-oxa-8-azaspiro[2.6] nonan-8- yl}pyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 15.

[0329] Scheme 15:5-oxa-8-azaspiro[2.6] nonane (200 mg, 1.572 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (262.5 mg, 1.572 mmol, 1.0 equiv) in DCM (2 mL). The mixture was cooled to 0°C and DIEA (528.4 mg, 4.087 mmol, 2.6 equiv) was added. The mixture was stirred for 1 h at room temperature. The resulting solution was diluted with water (10 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine (10 mL), dried with sodium sulfate, filtered and the filtrate was concentrated in vacuum. This resulted in 280 mg of 8-(2-chloro-5-fluoropyrimidin- 4-yl)-5-oxa-8-azaspiro [2.6]nonane as a yellow oil.

[0331] Step 2: To an 8 ml vial under nitrogen was added a solution of 8-(2-chloro-5- fluoropyrimidin-4-yl)-5-oxa-8-azaspiro [2.6] nonane (130 mg, 0.504 mmol, 1.0 equiv) and sulfanilamide (112.9 mg, 0.655 mmol, 1.3 equiv) in a 10: 1 dioxane: H2O solution (2.6 mL). Then DavePhos (79.4 mg, 0.202 mmol, 0.4 equiv), Cs2CO3 (657.5 mg, 2.016 mmol, 4.0 equiv) and Pd2(dba)3(92.4 mg, 0.101 mmol, 0.2 equiv) were added and the reaction was stirred for 2 h at 100°C then cooled and concentrated. The residue was purified via prep-HPLC under the following conditions: Column: XSelect Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: 5% B to 5% B in 1 min, 5% B to 23% B in 1.5 min, 23% B to 28% B in 10 min; Wavelength: 220 nm; RT1(min): 10. This afforded 4-[(5-fluoro-4-{5-oxa-8-azaspiro[2.6] nonan-8-yl}pyrimidin-2- yl)amino]benzenesulfonamide (Compound 15, 105 mg, 52% yield for 2 steps) as a white solid.

[0332] LC-MS (ES, m / z): 394.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.56 (s, 1H), 8.04 (d, J = 6.8 Hz, 1H), 7.85 – 7.77 (m, 2H), 7.73 – 7.65 (m, 2H), 7.14 (s, 2H), 4.00 – 3.92 (m, 2H), 3.90 – 3.90 (m, 2H), 3.71 (d, J = 1.3 Hz, 2H), 3.46 (s, 2H), 0.65 – 0.59 (m, 2H), 0.59 – 0.53 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -157.47.

[0333] Example 16

[0334] Compound 16: Synthesis of 4-[(5-fluoro-4-(5-oxa-8-azaspiro[3.5] nonan-8- ylpyrimi- din-2-yl)amino]benzenesulfonamide according to Scheme 16.

[0335] Scheme 16: O O NH O S2(1 eq) O (4 eq) O NH2

[0336] Step 1: To a 100 mL vial under nitrogen was added 2,4-dichloro-5- fluoropyrimidine (1.25 g, 7.46 mmol, 1.0 equiv), 5-oxa-8-azaspiro[3.5]nonane (0.95 g, 7.46 mmol, 1.0 equiv) in EtOH (25 mL), and Et3N (1.5 g, 14.9 mmol, 2.0 equiv) at 0°C. The reaction was stirred for 2 h at 25°C then concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 30% to 70% gradient in 40 min; detector, UV 210 nm). The reaction was extracted with EA (3 x 200 mL). The combined organic layers were washed with H2O (100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford 8-(2-chloro-5-fluoropyrimidin-4-yl)-5-oxa-8-azaspiro[3.5]nonane (1.55 g, 79% yield) as a white solid.

[0337] Step 2: To a 1 L 3-necked round bottom flask was added 8-(2-chloro-5- fluoropyrimidin-4-yl)- 5-oxa-8-azaspiro[3.5]nonane (5 g, 19.4 mmol, 1.0 equiv), sulfanilamide (13.4 g, 77.6 mmol, 4.0 equiv) in 1,4-dioxane (500 mL) and p-toluenesulfonic acid (26.7 g, 155 mmol, 8.0 equiv) at room temperature. The reaction was stirred for 48 h at 100°C under nitrogen then cooled and diluted with water (500 mL). The mixture was basified to pH 8 with Na2CO3and extracted with EtOAc (3 x 500 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC with the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 30% to 65% gradient in 35 min; detector, UV 210 nm) to afford 4-[(5-fluoro-4-(5-oxa-8-azaspiro[3.5] nonan-8-ylpyrimidin-2-yl)amino]benzene sulfonamide (Compound 16, 2.5 g, 32% yield) as a light brown solid.

[0338] LC-MS (ES, m / z): 394 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.63 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.82 (d, J = 8.9 Hz, 2H), 7.74 – 7.65 (m, 2H), 6.9 – 7.2 (m, 2H), 3.7 – 3.3 (m, 6H), 2.09 – 1.74 (m, 5H), 1.64 (m, 1H);19F-NMR (300 MHz, DMSO-d6, ppm) δ -156.63.

[0339] Example 17

[0340] Compound 17: Synthesis of 4-[(5-fluoro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide according to Scheme 17.

[0341] Scheme 17:

[0342] Step 1: To a 40 mL vial under nitrogen was added a solution of 7-(2-chloro-5- fluoropyrimidin-4-yl)-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.410 mmol, 1.0 equiv) in 1,4- dioxane (10 mL) at room temperature. To the above mixture was added N1-methylsulfanilamide (76.4 mg, 0.410 mmol, 1.0 equiv), Pd(OAc)2(9.2 mg, 0.041 mmol, 0.1 equiv), X-Phos (39.1 mg, 0.082 mmol, 0.2 equiv) and Cs2CO3(267.4 mg, 0.820 mmol, 2.0 equiv). The mixture was stirred for 12 h at 110°C then concentrated and purified via reverse-phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10 µm; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 40% to 70% gradient in 30 min; detector, UV 210 / 254 nm, The eluent of product was concentrated and freeze dried to afford 4-[(5-fluoro-4-{4-oxa-7- azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide (Compound 17, 7.5 mg, 4% yield) as a white solid.

[0343] LC-MS (ES, m / z):394.15 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.89 – 9.61 (m, 1H), 8.26 – 8.01 (m, 1H), 8.01 – 7.77 (m, 2H), 7.75 – 7.60 (m, 1H), 7.20 (s, 1H), 5.08 (s, 2H), 4.48 (s, 2H), 4.28 – 4.05 (m, 2H), 3.85 (d, J = 20.6 Hz, 3H), 3.52 – 3.35 (m, 3H), 2.39 (t, J = 5.3 Hz, 2H);19F-NMR (282 MHz, DMSO, ppm): δ -157.621, -157.653, -158.688.

[0344] Example 18

[0345] Compound 18: Synthesis of 4-{[5-cyano-4-(2,2-dimethylmorpholin-4- yl)pyrimidin-2-yl]amino}benzenesulfonamide according to Scheme 18.

[0346] Scheme 18: (300 mg,2.61 mmol, 1.0 equiv) in EtOH (6 mL), 2,4-dichloropyrimidine-5-carbonitrile (544 mg, 3.13 mmol, 1.2 equiv) and TEA (527 mg, 5.21 mmol, 2.0 equiv) at 0oC under a nitrogen atmosphere. The reaction was stirred for 2 h at room temperature then filtered and purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in H2O (0.1 % NH4HCO3), 30% to 70% gradient in 20 min; detector, UV 210 nm. The reaction was concentrated under vacuum. This resulted in 2-chloro-4-(2,2-dimethylmorpholin-4-yl)pyrimidine- 5-carbonitrile (300 mg, 45% yield) as a white solid.

[0348] Step 2: Into a 40 mL 3-necked flask was added 2-chloro-4-(2,2-dimethylmorpholin- 4-yl)pyrimidine-5-carbonitrile (200 mg, 0.791 mmol, 1.0 equiv) in 1,4-dioxane (10 mL) at room temperature. To the above mixture was added sulfanilamide (409 mg, 2.37 mmol, 3.0 equiv), Pd(OAc)2(17.8 mg, 0.079 mmol, 0.1 equiv), X-Phos (75.5 mg, 0.158 mmol, 0.2 equiv) and Cs2CO3(516 mg, 1.58 mmol, 2.0 equiv) under a N2atmosphere. The reaction was stirred for 16 h at 100°C then cooled filtered and concentrated. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in H2O (0.1 % NH4HCO3), 30% to 70% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under vacuum. The remaining aqueous mixture was lyophilized. This afforded 4-{[5- cyano-4-(2,2-dimethylmorpholin-4-yl)pyrimidin-2-yl]amino}benzenesulfonamide (Compound 18, 33.3 mg, 10% yield) as a white solid.

[0349] LC-MS (ES, m / z): 389 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 8.51 (s, 1H), 7.82 (d, J = 8.9 Hz, 2H), 7.76 (d, J = 8.6 Hz, 2H), 6.02 (s, 1H), 3.85 (t, J = 4.8 Hz, 2H), 3.78 (s, 4H), 1.21 (s, 6H).

[0350] Example 19

[0351] Compound 19: Synthesis of (S)-(4-((5-chloro-4-((S)-2,2,5- trimethylmorpholino)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone according to Scheme 19.

[0352] Scheme 19:

[0353] Step 1: To a 2 L 3-necked round-bottom flask was added 4- (methylthio)benzenamine (78 g, 560 mmol, 1 equiv), (Boc)2O (134 g, 614 mmol, 1.10 equiv) and THF (780 mL). The mixture was stirred at 60°C at 4 h then cooled and concentrated under vacuum. This resulted in 152 g of tert-butyl N-[4-(methylsulfanyl)phenyl]carbamate as a white solid.

[0354] Step 2: To a 5 L 3-necked round-bottom flask was added tert-butyl 4- (methylthio)phenylcarbamate (150 g, 627 mmol, 1 equiv) and MeOH (2.25 L). Ammonium carbamate (196 g, 2.51 mol, 4 equiv) and PhI(OAc)2(606 g, 1.88 mol, 3 equiv) were added and the reaction was stirred for 16 h at room temperature then filtered, and the filter cake washed withMeOH (3 x 1 L). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EA:PE=0%-40%. This resulted in tert-butyl (4- (S-methylsulfonimidoyl) phenyl)carbamate (70 g, 51% for 2 steps) as a yellow solid.

[0355] Step 3: tert-butyl (4-(S-methylsulfonimidoyl)phenyl)carbamate (30 g) was purified by Prep-SFC. (Column: CHIRALPAK AD-H 2*25 cm, 5 μm; Mobile Phase A: CO2, Mobile Phase B: MEOH-ACN-DCM = 331 (0.1%DEA); Gradient: isocratic 50% B; Column Temperature (℃): 35; Back Pressure (bar): 100; Wavelength: 220 nm; RT1 (min): 3.6; RT2 (min): 5; Sample Solvent: MEOH; Injection Volume: 4 mL.) This resulted in 11 g (36% yield) of tert-butyl (S)-(4-(S- methylsulfonimidoyl)phenyl)carbamate as a white solid.

[0356] Step 4: To a 500 ml 3-neck flask under nitrogen was added a solution of tert-butyl (S)-(4-(S-methylsulfonimidoyl)phenyl)carbamate (11 g, 40.7 mmol, 1 equiv) in dioxane (110 mL). HCl (gas) in 1,4-dioxane (110 mL) was added at 0°C. The reaction was stirred overnight at room temperature then concentrated under vacuum. This resulted in 10.5 g (crude) (S)-(4- aminophenyl)(imino)(methyl)-λ6-sulfanone hydrochloride as a yellow solid.

[0357] Step 5: To a 20 mL vial was added a solution of (5S)-2,2,5-trimethylmorpholine (380 mg, 2.94 mmol, 1 equiv) and 2,4,5-trichloropyrimidine (539 mg, 2.94 mmol, 1 equiv) in EtOH (7.6 mL). TEA (893 mg, 8.82 mmol, 3 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 24 h then diluted with DCM (30 mL). The organic layer was washed with brine (2 x 20 mL), dried over anhydrous Na2SO4 and concentrated. This resulted in 800 mg (5S)-4-(2,5-dichloropyrimidin-4-yl)-2,2,5-trimethylmorpholine as a white solid.

[0358] Step 6: To an 8 ml vial was added a solution of (5S)-4-(2,5-dichloropyrimidin-4- yl)-2,2,5-trimethylmorpholine (150 mg, 0.543 mmol, 1 equiv) and (S)-(4- aminophenyl)(imino)(methyl)-λ6-sulfanone hydrochloride (225 mg, 1.09 mmol, 2 equiv) in dioxane (2.25 mL). p-TsOH (468 mg, 2.72 mmol, 5 equiv) was added and the mixture heated to 80°C and stirred overnight. The reaction was cooled, filtered and the filtrate purified by prep- HPLC under the following conditions: Column: Xselect CSH Prep Fluoro-phenyl Column, 30*150 nm, 5 μm; Mobile Phase A: Water (0.1%FA), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 25% B in 2.5 min, 25% B to 30% B in 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 8.9. This afforded (S)-(4-((5-chloro-4-((S)-2,2,5- trimethylmorpholino)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone (Compound 19, 20 mg, 8% yield for two steps) as a white solid.

[0359] LC-MS (ES, m / z): 410.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.84 (s, 1H), 8.15 (s, 1H), 7.95 – 7.84 (m, 2H), 7.84 – 7.73 (m, 2H), 4.55 – 4.42 (m, 1H), 4.05 – 3.88 (m, 3H), 3.47 (dd, J = 11.9, 2.1 Hz, 1H), 3.17 (d, J = 13.4 Hz, 1H), 3.02 (s, 3H), 1.29 (d, J = 6.7 Hz, 3H), 1.23 (s, 6H).

[0360] Example 20

[0361] Compound 20: Synthesis of (R)-(4-((5-chloro-4-((S)-2,2,5- trimethylmorpholino)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone according to Scheme 20.

[0362] Scheme 20:

[0363] Step 1: Tert-butyl (4-(S-methylsulfonimidoyl)phenyl)carbamate (30 g) was purified by Prep-SFC. (Column: CHIRALPAK AD-H 2*25 cm, 5 μm; Mobile Phase A: CO2, Mobile Phase B: MEOH-ACN-DCM = 331 (0.1%DEA); Gradient: isocratic 50% B; Column Temperature (℃): 35; Back Pressure (bar): 100; Wavelength: 220 nm; RT1 (min): 3.6; RT2 (min): 5; Sample Solvent: MEOH; Injection Volume: 4 mL.) This resulted in 7.5 g (25% yield) of tert-butyl (R)-(4-(S-methylsulfonimidoyl)phenyl)carbamate as a white solid.

[0364] Step 2: To a 500 mL 3-neck round bottom flask under nitrogen was added a solution of tert-butyl (R)-(4-(S-methylsulfonimidoyl)phenyl)carbamate (7.5 g, 27.8 mmol, 1.0 equiv) in dioxane (75 mL). HCl (gas) in 1,4-dioxane (75 mL) was added at 0°C. The reaction was stirred overnight at room temperature then concentrated under vacuum. This resulted in 6.8 g of (R)-(4-aminophenyl)(imino)(methyl)-λ6-sulfanone hydrochloride as a yellow solid.

[0365] Step 3: To a 20 mL vial was added a solution of (5S)-2,2,5-trimethylmorpholine (380 mg, 2.94 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (539 mg, 2.941 mmol, 1.0 equiv) in EtOH (7.6 mL). TEA (893 mg, 8.82 mmol, 3.0 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 24 h then diluted with DCM (30 mL). The organic layer was washed with brine (2 x 20 mL), dried over anhydrous Na2SO4 and concentrated. This resulted in 800 mg of (5S)-4-(2,5-dichloropyrimidin-4-yl)-2,2,5-trimethylmorpholine as a white solid.

[0366] Step 4: To an 8 ml vial was added a solution of (5S)-4-(2,5-dichloropyrimidin-4- yl)-2,2,5-trimethyl-morpholine (150 mg, 0.543 mmol, 1.0 equiv) and (R)-(4- aminophenyl)(imino)(methyl)-λ6-sulfanone hydrochloride (225 mg, 1.09 mmol, 2.0 equiv) in dioxane (2.25 mL). p-TsOH (468 mg, 2.72 mmol, 5.0 equiv) was added. The mixture was heated to 80°C and stirred overnight. The mixture was cooled, filtered and the filtrate was purified by prep-HPLC with the following conditions: Column: Xselect CSH Prep Fluoro-phenyl Column, 30*150 nm, 5 μm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 25% B in 0.2 min, 25% B to 30% B in 10 min; Wavelength: 220 nm; RT1 (min): 10. This afforded (R)-(4-((5-chloro-4-((S)-2,2,5- trimethylmorpholino)pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone (Compound 20, 30 mg, 13% yield for 2 steps) as a white solid.

[0367] LC-MS (ES, m / z): 410.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.86 (s, 1H), 8.15 (s, 1H), 7.94 – 7.85 (m, 2H), 7.85 – 7.70 (m, 2H), 4.56 – 4.41 (m, 1H), 4.22 (s, 1H), 4.06 – 3.86 (m, 2H), 3.47 (d, J = 11.8 Hz, 1H), 3.17 (d, J = 13.5 Hz, 1H), 3.03 (s, 3H), 1.29 (d, J = 6.6 Hz, 3H), 1.23 (s, 6H).

[0368] Example 21

[0369] Compound 21 / 22 / 23: Synthesis of (4-((5-fluoro-4-((S)-2,2,5- trimethylmorpholino)pyrimidin-2-yl)amino)phenyl)(imino) (methyl)-λ6-sulfanone, (R)-(4-((5- fluoro-4-((S)-2,2,5-trimethylmorpholino) pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6- sulfanone and (R)-(4-((5-fluoro-4-((S)-2,2,5-trimethylmorpholino) pyrimidin-2- yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone according to Scheme 21.

[0370] Scheme 21:HN(517 mg, 3.10 mmol, 1.0 equiv) and (5S)-2,2,5-trimethylmorpholine (400 mg, 3.10 mmol, 1.0 equiv) in DCM (3.2 mL). Then, DIEA (1.04 g, 8.05 mmol, 2.6 equiv) was added at 0°C. The reaction was stirred for 24 h at room temperature then diluted with DCM (8 mL). The organic layer was washed with brine (2 x 8 mL), dried over anhydrous Na2SO4and concentrated. This resulted in 750 mg (crude) (5S)-4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2,5-trimethylmorpholine as a white solid.

[0372] Step 2: To a 20 ml vial under nitrogen was added a solution of (5S)-4-(2-chloro-5- fluoropyrimidin-4-yl)-2,2,5-trimethylmorpholine (300 mg, 1.15 mmol, 1.0 equiv), (4- aminophenyl)(imino)methyl-λ6-sulfanone (236 mg, 1.38 mmol, 1.2 equiv) and Cs2CO3 (1.13 g, 3.46 mmol, 3.0 equiv) in dioxane (6 mL) and H2O (0.6 mL). DavePhos (90.9 mg, 0.231 mmol, 0.2 equiv) and Pd2(dba)3 (106 mg, 0.116 mmol, 0.1 equiv) was added and the reaction mixture was stirred for 2 h at 100°C then cooled, filtered and purified via prep-HPLC under the following conditions: Column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 29% B in 0.2 min, 29% B to 31% B in 10 min; Wavelength: 220 nm; RT1 (min): 10. This afforded (4-((5-fluoro-4-((S)-2,2,5-trimethylmorpholino)pyrimidin-2- yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone (Compound 21, 185 mg , 37% yield for 2 steps) as an off-white solid.

[0373] LC-MS (ES, m / z): 394.00 [M+H]+;1H-NMR-: (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.94 – 7.83 (m, 2H), 7.83 – 7.72 (m, 2H), 4.54 – 4.38 (m, 1H), 4.06 – 3.85 (m, 3H), 3.47 (dd, J = 12.0, 2.1 Hz, 1H), 3.18 (d, J = 13.6 Hz, 1H), 3.01 (s, 3H), 1.29 (d, J = 6.7 Hz, 3H), 1.21 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.79.

[0374] Step 3: (4-((5-fluoro-4-((S)-2,2,5-trimethylmorpholino)pyrimidin-2-yl)amino) phenyl)(imino)(methyl)-λ6-sulfanone (100 mg, 0.254 mmol) was purified by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IC 2*25 cm, 5 μm; Mobile Phase A: (HEX: DCM=1: 1)(0.05% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL / min; Gradient: isocratic 10; Wavelength: 220 / 254 nm; RT1 (min): 8.148. This resulted in 35 mg (Compound 22, 34% yield) of (R)-(4-((5-fluoro-4-((S)-2,2,5-trimethylmorpholino) pyrimidin-2- yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone as a white solid.

[0375] LC-MS (ES, m / z): 394.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.94 – 7.83 (m, 2H), 7.83 – 7.72 (m, 2H), 4.54 – 4.38 (m, 1H), 4.06 – 3.85 (m, 3H), 3.47 (dd, J = 12.0, 2.1 Hz, 1H), 3.18 (d, J = 13.6 Hz, 1H), 3.01 (s, 3H), 1.29 (d, J = 6.7 Hz, 3H), 1.21 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.79

[0376] And 38 mg (Compound 23, 37% yield) of (S)-(4-((5-fluoro-4-((S)-2,2,5- trimethylmorpholino) pyrimidin-2-yl)amino)phenyl)(imino)(methyl)-λ6-sulfanone as a white solid.

[0377] LC-MS (ES, m / z): 394.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.94 – 7.83 (m, 2H), 7.83 – 7.72 (m, 2H), 4.54 – 4.38 (m, 1H), 4.06 – 3.85 (m, 3H), 3.47 (dd, J = 12.0, 2.1 Hz, 1H), 3.18 (d, J = 13.6 Hz, 1H), 3.01 (s, 3H), 1.29 (d, J = 6.7 Hz, 3H), 1.21 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.79.

[0378] Example 22

[0379] Compound 24: Synthesis of 4-({5-chloro-4-[(5S)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2-yl} amino)benzenesulfonamide according to Scheme 22.

[0380] Scheme 22:

[0038] Step : o a 0 m v a was added a so ut on o (5S)- , ,5-tr met y morpholine (380 mg, 2.941 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (539.5 mg, 2.941 mmol, 1.0 equiv) in EtOH (7.6 mL). TEA (892.9 mg, 8.823 mmol, 3.0 equiv) was added to the mixture at 0°C. The mixture was warmed to room temperature and stirred for 24 h. The reaction was diluted with DCM (8 mL). The combined organic layers were washed with brine (2 x 8 mL), dried over anhydrous Na2SO4 and concentrated. This resulted in 800 mg (crude) (5S)-4-(2,5-dichloropyrimidin-4-yl)- 2,2,5-trimethylmorpholine as a white solid.

[0382] Step 2: To an 8 mL vial was added a solution of (5S)-4-(2,5-dichloropyrimidin-4- yl)-2,2,5-trimethylmorpholine (150 mg, 0.543 mmol, 1.0 equiv) in dioxane (3 mL) and H2O (0.3 mL). Sulfanilamide (187.1 mg, 1.086 mmol, 2.0 equiv), Cs2CO3(530.9 mg, 1.629 mmol, 3.0 equiv), DavePhos (42.8 mg, 0.109 mmol, 0.2 equiv) and Pd2(dba)3(49.7 mg, 0.054 mmol, 0.1 equiv) was added to the mixture at room temperature. The reaction was stirred for 2 h at 100°C then cooled to room temperature and purified by prep-HPLC under the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 40% B in 2.5 min, 40% B to 40% B in 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 11. This afforded 4-({5-chloro-4-[(5S)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2-yl} amino) benzenesulfonamide (Compound 24, 42 mg, 27% yield for 2 steps) as a white solid.

[0383] LC-MS (ES, m / z): 411.95 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.79 (s, 1H), 8.14 (s, 1H), 7.88 – 7.76 (m, 2H), 7.75 – 7.64 (m, 2H), 7.15 (s, 2H), 4.54 – 4.42 (m, 1H), 4.04 – 3.87 (m, 2H), 3.47 (dd, J = 11.9, 2.1 Hz, 1H), 3.17 (d, J = 13.5 Hz, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.22 (s, 6H).

[0384] Example 23

[0385] Compound 25: Synthesis of 4-({5-fluoro-4-[(5S)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2-yl} amino)benzenesulfonamide according to Scheme 23.

[0386] Scheme 23:(516.9 mg, 3.096 mmol, 1.0 equiv) and (5S)-2,2,5-trimethylmorpholine (400 mg, 3.096 mmol, 1.0 equiv) in DCM (3.2 mL). DIEA (1040.4 mg, 8.050 mmol, 2.6 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 24 h then diluted with DCM (8 mL). The organic layer was washed with brine (2 x 8 mL), dried over anhydrous Na2SO4and concentrated. This resulted in 750 mg (crude) of (5S)-4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2,5- trimethylmorpholine as a white solid.

[0388] Step 2: To a 20 mL vial under nitrogen was placed a solution of (5S)-4-(2-chloro- 5-fluoropyrimidin-4-yl)-2,2,5-trimethylmorpholine (200 mg, 0.770 mmol, 1.0 equiv), sulfanilamide (265.2 mg, 1.540 mmol, 2.0 equiv) and K2CO3 (319.3 mg, 2.310 mmol, 3.0 equiv) in dioxane (4 mL). X-Phos (73.4 mg, 0.154 mmol, 0.2 equiv) and Pd(OAc)2(17.3 mg, 0.077 mmol, 0.1 equiv) were added. The mixture was warmed to 100°C and stirred for 1 h. The mixture was cooled, filtered, and the filtrate was purified by Column chromatography with the following conditions: Column: C18; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 100 mL / min; Gradient: 20% B to 80% B in 30 min; Wavelength: 210 / 254 nm; RT1 (min): 20. This afforded 4-({5-fluoro-4-[(5S)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2-yl} amino)benzenesulfonamide (Compound 25, 145 mg, 44% yield for 2 steps) of as an off-white solid.

[0389] LC-MS (ES, m / z): 396.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.59 (s, 1H), 8.06 (d, J = 6.9 Hz, 1H), 7.88 – 7.76 (m, 2H), 7.75 – 7.61 (m, 2H), 7.12 (s, 2H), 4.53 – 4.40 (m, 1H), 4.05 – 3.86 (m, 2H), 3.47 (dd, J = 12.0, 2.2 Hz, 1H), 3.17 (d, J = 13.6 Hz, 1H), 1.29 (d, J = 6.7 Hz, 3H), 1.21 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.95.

[0390] Example 24

[0391] Compound 26: Synthesis of 4-({5-fluoro-4-[(5R)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2-yl} amino)benzenesulfonamide according to Scheme 24.

[0392] Scheme 24:

[0393] Step 1: To an 8 mL vial was added a solution of (5, , y rpholine (350 mg, 2.709 mmol, 1.0 equiv) in DCM (3.5 mL). Then, 2,4-dichloro-5-fluoropyrimidine (452.3 mg, 2.709 mmol, 1.0 equiv) and DIEA (910.3 mg, 7.043 mmol, 2.6 equiv) were added to the mixture at 0oC. The mixture was stirred for 24 h at room temperature. The resulting solution was diluted with DCM (10 mL), and washed with H2O (3 x 3 mL), dried with anhydrous Na2SO4, filtered and concentrated. This resulted in 700 mg (crude) (5R)-4-(2-chloro-5-fluoropyrimidin-4- yl)-2,2,5-trimethylmorpholine as a yellow oil.

[0394] Step 2: To an 8 mL vial was added a solution of (5R)-4-(2-chloro-5- fluoropyrimidin-4-yl)-2,2,5-trimethyl-morpholine (100 mg, 0.385 mmol, 1.0 equiv) in dioxane (2 mL) and H2O (0.2 mL). Then, sulfanilamide (132.6 mg, 0.770 mmol, 2.0 equiv), DavePhos (30.3 mg, 0.077 mmol, 0.2 equiv), Cs2CO3(376.4 mg, 1.155 mmol, 3.0 equiv) and Pd2(dba)3(35.3 mg, 0.039 mmol, 0.1 equiv) was added to the reaction. The mixture was stirred for 2 h at 100°C then cooled and concentrated under vacuum. The residue was purified by prep-HPLC with the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 35% B in 2.5 min, 35% B to 38% B in 10 min; Wavelength: 254nm / 220nm. This afforded 4-({5-fluoro-4-[(5R)-2,2,5-trimethylmorpholin-4-yl] pyrimidin-2- yl} amino)benzenesulfonamide (Compound 26, 21.3 mg, 13% yield) as a white solid.

[0395] LC-MS (ES, m / z): 396.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.60 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.86 – 7.78 (d, 2H), 7.72 – 7.65 (d,2H), 7.13 (s, 2H), 4.47 (s, 1H), 4.05 – 3.89 (m, 2H), 3.47 (dd, J = 12.1, 2.1 Hz, 1H), 3.18 (d, J = 13.6 Hz, 1H), 1.29 (d, J = 6.7 Hz, 3H), 1.22 (s, 6H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.95.

[0396] Example 25

[0397] Compound 27 / 28 / 29: Synthesis of 4-{[5-fluoro-4-(2,2,6-trimethylmorpholin-4- yl)pyrimidin-2-yl]amino}benzenesulfonamide, 4-({5-fluoro-4-[(6R)-2,2,6-trimethylmorpholin-4-yl]pyrimidin-2-yl}amino)benzenesulfonamide and 4-({5-fluoro-4-[(6S)-2,2,6-trimethylmorpholin -4-yl]pyrimidin-2-yl}amino)benzenesulfonamide according to Scheme 25.

[0398] Scheme 25: 00mg, 4.644 mmol, 1.0 equiv), 2,4-dichloro-5-fluoropyrimidine (775.3 mg, 4.644 mmol, 1.0 equiv) in DCM (6 mL) followed by DIEA (1800.6 mg, 13.932 mmol, 3.0 equiv. The mixture was stirred at room temperature for 1 h then diluted with DCM (10 mL) and washed with H2O (3 x 10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (0~20% yield). This resulted in 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2,6-trimethylmorpholine (860 mg, 71% yield) as a yellow oil.

[0400] Step 2: To an 8 mL vial under nitrogen was added a solution of 6-(2-chloro-5- fluoropyrimidin-4-yl)-6-azaspiro[3.4]octan-8-one (200 mg, 0.77 mmol, 1.0 equiv) and (S)-(4- aminophenyl)(imino)methyl-λ6-sulfanone (199.9 mg, 1.587 mmol, 1.5 equiv) in dioxane (6 mL). K2CO3(319.2 mg, 1.425 mmol, 3.0 equiv), Pd(OAc)2(36 mg, 0.154 mmol, 0.2 equiv) and X-Phos (147.8 mg, 0.308 mmol, 0.4 equiv) were added. The mixture was stirred at 100°C for 1 h then cooled to room temperature. The reaction was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography under the following conditions (ACN: H2O with 0.1% NH4HCO3 20%~70%, 30 min, RT=16min). This resulted in 4-{[5-fluoro-4-(2,2,6- trimethylmorpholin-4-yl)pyrimidin-2-yl]amino}benzenesulfonamide (Compound 27, 125 mg, 21% yield) as a white solid.

[0401] LCMS (ES, m / z): 396.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.61 (s, 1H), 8.08 (m, 1H), 7.92 – 7.74 (m, 2H), 7.73 – 7.61 (m, 2H), 7.14 (s, 2H), 4.38 – 4.25 (m, 1H),4.11– 4.13 (m, 1H), 3.92 (m, 1H), 2.95– 2.85 (m, 1H), 2.71– 2.64 (m, 1H), 1.19 (m, 6H), 1.10 (m, 3H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.42.

[0402] Step 3: 4-{[5-fluoro-4-(2,2,6-trimethylmorpholin-4-yl)pyrimidin-2-yl]amino} benzenesulfonamide (70 mg) was separated by Prep-Chiral-HPLC with the following conditions: [Column: Lux 5um Celluloes-3, 3*25 cm, 5um; Mobile Phase A: CO2, Mobile Phase B: IPA; Flow rate: 100 mL / min; Gradient: isocratic 30% B; Column Temperature(℃): 35; Back Pressure(bar): 100; Wavelength: 220 nm; RT1(min): 3.7 (P1); Sample Solvent: ACN-MEOH = 3: 1; Injection Volume: 4.9 mL]. This resulted in 4-({5-fluoro-4-[(6R)-2,2,6-trimethylmorpholin-4-yl]pyrimidin- 2-yl}amino)benzenesulfonamide (Compound 28, 19 mg, 27% yield) as a white solid.

[0403] LC-MS (ES, m / z): 396.00 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.63 (s, 1H), 8.12 – 8.06 (m, 1H), 7.83– 7.80 (m, 2H), 7.70 – 7.68 (m, 2H), 7.15 (s, 2H), 4.35 – 4.25 (m, 1H), 4.14 – 4.11 (m, 1H), 3.94 – 3.92 (m, 1H), 2.95– 2.85 (m, 1H), 2.71– 2.64 (m, 1H), 1.22 – 1.16 (m, 6H), 1.13 – 1.07 (m, 3H); 19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.12.

[0404] And in 4-({5-fluoro-4-[(6S)-2,2,6-trimethylmorpholin-4-yl]pyrimidin-2-yl}amino) benzenesulfonamide (Compound 29, 18 mg, 25% yield) as a white solid.

[0405] LC-MS (ES, m / z): 396.00 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.63 (s, 1H), 8.12 – 8.06 (m, 1H), 7.83– 7.80 (m, 2H), 7.70 – 7.68 (m, 2H), 7.15 (s, 2H), 4.35 – 4.25 (m, 1H), 4.14 – 4.11 (m, 1H), 3.94 – 3.92 (m, 1H), 2.95 – 2.85 (m, 1H), 2.71– 2.64 (m, 1H), 1.22 – 1.16 (m, 6H), 1.13 – 1.07 (m, 3H); 19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.39.

[0406] Example 26

[0407] Compound 30 / 31: Synthesis of 4-({5-fluoro-4-[2-(methoxymethyl)-2- methylmorpholin-4-yl]pyrimidin-2-yl}amino)benzenesulfonamide and 4-({5-fluoro-4-[(2R)-2- (methoxymethyl)-2-methylmorpholin-4-yl]pyrimidin-2-yl}amino)benzenesulfonamide according to Scheme 26.

[0408] Scheme 26:

[0409] Step 1: To a 20 mL vial under nitrogen was placed a solution of 2- (methoxymethyl)-2-methylmorpholine (500 mg, 3.443 mmol, 1.0 equiv) and 2,4-dichloro-5- fluoropyrimidine (574.9 mg, 3.443 mmol, 1.0 equiv) in DCM (5 mL) at 0°C. Then, DIEA (1157.2 mg, 8.952 mmol, 2.6 equiv) was added and the mixture was stirred for 1 h at room temperature. The resulting solution was diluted with 20 mL of water, then extracted with DCM (2 x 10 mL) and the combined extract was washed with brine, and then dried over sodium sulfate, and then concentrated in vacuum. This resulted in 0.8 g (crude) 4-(2-chloro-5-fluoropyrimidin-4-yl)-2- (methoxymethyl)-2-methylmorpholine as a brown oil.

[0410] Step 2: To a 20 mL vial was added a solution of 4-(2-chloro-5-fluoropyrimidin-4- yl)-2-(methoxymethyl)-2-methylmorpholine (200 mg, 0.725 mmol, 1.0 equiv) in dioxane (4 mL) and H2O (0.4 mL). Sulfanilamide (249.8 mg, 1.450 mmol, 2.0 equiv), DavePhos (57.1 mg, 0.145 mmol, 0.2 equiv), Cs2CO3 (709.1 mg, 2.175 mmol, 3.0 equiv) and Pd2(dba)3 (66.4 mg, 0.072 mmol, 0.1 equiv) was added. The mixture was stirred for 2 h at 100oC then cooled to room temperature, filtered and concentrated under vacuum. The residue was purified by column chromatography (ACN: H2O with 0.1% NH4HCO320%~60%, 30 min). This resulted in 4-({5- fluoro-4-[2-(methoxymethyl)-2-methylmorpholin-4-yl] pyrimidin-2-yl} amino)benzenesulfonamide (Compound 30, 150 mg, 50% yield) as a white solid.

[0411] Step 3: 4-({5-fluoro-4-[2-(methoxymethyl)-2-methylmorpholin-4-yl]pyrimidin-2- yl}amino)benzenesulfon amide (150 mg, 0.365 mmol, 1 equiv) was purified via prep-Chiral- HPLC with the following conditions: Column: Lux 3 μ Cellulose-3, 4.6*100 mm, 3 μm; MobilePhase A: Hex (0.1% 2M NH3-MeOH)--HPLC, Mobile Phase B: EtOH; Gradient: isocratic 95; Wavelength: 220 / 254 nm; RT1 (min): 11.145; Sample Solvent: EtOH; Injection Volume: 1.5 mL. This resulted in 63.6 mg (Compound 31, 42% yield) of 4-({5-fluoro-4-[(2R)-2-(methoxymethyl)- 2-methylmorpholin-4-yl]pyrimidin-2-yl}amino)benzenesulfonamide as a white solid.

[0412] LC-MS (ES, m / z): 412.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.62 (s, 1H), 8.08 (d, J = 6.6 Hz, 1H), 7.88 – 7.79 (m, 2H), 7.73 – 7.66 (m, 2H), 7.14 (s, 2H), 3.85 – 3.76 (m, 3H), 3.73 – 3.58 (m, 3H), 3.37 (d, J = 9.4 Hz, 1H), 3.30 (s, 1H), 3.28 (s, 3H), 1.18 (s, 3H);19F- NMR (376 MHz, DMSO-d6, ppm)δ -156.71.

[0413] Example 27

[0414] Compound 32: Synthesis of (4-{[4-(2,2-diethylmorpholin-4-yl)-5-fluoropyrimidin- 2-yl] amino} phenyl)(imino)methyl-λ6-sulfanone according to Scheme 27.

[0415] Scheme 27:

[0416] Step 1: To a 20 mL vial was added a solution of 2,2-diethylmorpholine (500 mg, 3.491 mmol, 1.0 equiv) in DCM (5 mL). Then, 2,4-dichloro-5-fluoropyrimidine (582.8 mg, 3.491 mmol, 1.0 equiv) and DIEA (1128 mg, 8.728 mmol, 2.5 equiv) were added at 0°C. The mixture was stirred for 1 h at room temperature. The resulting solution was diluted with DCM (6 mL), and washed with H2O (3 x 3 mL), dried with anhydrous Na2SO4. The reaction was concentrated under vacuum. This resulted in 850 mg (crude) 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2- diethylmorpholine as a yellow oil.

[0417] Step 2: To an 8 mL vial was added a solution of 4-(2-chloro-5-fluoropyrimidin-4- yl)-2,2-diethylmorpholine (300 mg, 1.096 mmol, 1.0 equip) in dioxane (3 mL). Then, (4- aminophenyl) (imino)methyl-λ6-sulfanone (223.9 mg, 1.315 mmol, 1.2 equiv), X-Phos (209 mg, 0.438 mmol, 0.4 equiv), K2CO3(605.8 mg, 4.384 mmol, 4.0 equiv) and Pd(OAc)2(49.2 mg, 0.219 mmol, 0.2 equiv) was added. The mixture was stirred for 2 h at 100oC then cooled, filtered and concentrated under vacuum. The residue was purified by column chromatography (ACN: H2Owith 0.1% NH4HCO315%~45%, 30 min). This resulted in 32 mg (Compound 32, 7% yield) (4- {[4-(2,2-diethylmorpholin-4-yl)-5-fluoropyrimidin-2-yl] amino}phenyl) (imino)methyl-λ6- sulfanone as a white solid.

[0418] LC-MS (ES, m / z): 408.05 [M+H]+;1H-NMR (376 MHz, DMSO-d6, ppm): δ 9.67 (s, 1H), 8.08 (d, J = 6.8 Hz, 1H), 7.85 (d, J = 9.0 Hz, 2H), 7.77 (d, J = 9.0 Hz, 2H), 3.97 (s, 1H), 3.71 (s, 4H), 3.61 (s, 2H), 3.05 – 2.98 (m, 3H), 1.64 (dq, J = 14.9, 7.5 Hz, 2H), 1.45 (dq, J = 14.7, 7.4 Hz, 2H), 0.82 (t, J = 7.5 Hz, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.56.

[0419] Example 28

[0420] Compound 33: Synthesis of 4-({5-chloro-4-[(5S)-2,2,5-trimethylmorpholin-4- yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide according to Scheme 28.

[0421] Scheme 28:

[0422] Step 1: To a 20 mL vial was added a solution of (5S)-2,2,5-trimethylmorpholine (380 mg, 2.941 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (539.5 mg, 2.941 mmol, 1.0 equiv) in EtOH (7.6 mL). TEA (892.9 mg, 8.823 mmol, 3.0 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 24 h. The reaction was diluted with DCM (8 mL). The combined organic layers were washed with brine (2 x 8 mL), dried over anhydrous Na2SO4and concentrated. This resulted in 800 mg (crude) (5S)-4-(2,5-dichloropyrimidin-4-yl)-2,2,5- trimethylmorpholine as a white solid.

[0423] Step 2: To an 8 mL vial was added a solution of (5S)-4-(2,5-dichloropyrimidin-4- yl)-2,2,5-trimethylmorpholine (100 mg, 0.362 mmol, 1.0 equiv) and N1-methylsulfanilamide (80.9 mg, 0.434 mmol, 1.2 equiv) in dioxane (1.5 mL). p-TsOH (311.8 mg, 1.810 mmol, 5.0 equiv) was added and the mixture was warmed to 80°C and stirred overnight. After filtration the filtrate was purified by prep-HPLC with the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN;Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 46% B in 2.5 min, 46% B to 46% B in 10 min; Wavelength: 254nm / 220nm; RT1(min): 10.7. This resulted in 50 mg (31% yield for 2 steps) 4-({5-chloro-4-[(5S)-2,2,5-trimethylmorpholin-4-yl]pyrimidin-2-yl}amino)-N- methylbenzenesulfonamide as a white solid.

[0424] LC-MS (ES, m / z): 426.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.85 (s, 1H), 8.15 (s, 1H), 7.92 – 7.78 (m, 2H), 7.75 – 7.61 (m, 2H), 7.21 (q, J = 5.1 Hz, 1H), 4.55 – 4.40 (m, 1H), 4.04 – 3.88 (m, 2H), 3.47 (dd, J = 11.9, 2.1 Hz, 1H), 3.17 (d, J = 13.5 Hz, 1H), 2.38 (d, J = 5.0 Hz, 3H), 1.28 (d, J = 6.6 Hz, 3H), 1.22 (s, 6H).

[0425] Example 29

[0426] Compound 34: Synthesis of 4-{[4-(2,2-diethylmorpholin-4-yl)-5-fluoropyrimidin- 2-yl] amino} benzenesulfonamide according to Scheme 29.

[0427] Scheme 29:

[0428] Step 1: To a 20 mL vial was added a solution of 2,2-diethylmorpholine (500 mg, 3.491 mmol, 1.0 equiv), 2,4-dichloro-5-fluoropyrimidine (582.8 mg, 3.491 mmol, 1.0 equiv) in DCM (5 mL). Then, DIEA (1128 mg, 8.728 mmol, 2.5 equiv) were added to the mixture at 0°C and the mixture stirred for 1 h at room temperature. The resulting solution was diluted with DCM (6 ml) and washed with H2O (3 x 10 mL). The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (0~25% yield). This resulted in 850 mg (89% yield) 4-(2-chloro-5-fluoropyrimidin-4-yl)-2,2-diethylmorpholine as a yellow oil.

[0429] Step 2: To an 8 mL vial was added a solution of 4-(2-chloro-5-fluoropyrimidin-4- yl)-2,2-diethylmorpholine (130 mg, 0.475 mmol, 1.0 equiv) in dioxane (5.2 mL) and H2O (0.52 mL), Then, sulfanilamide (98.1 mg, 0.570 mmol, 1.2 equiv) and Cs2CO3 (464.2 mg, 1.425 mmol, 3.0 equiv) were added at room temperature. Replaced the N2for 2 min. After that, Pd2(dba)3(87 mg, 0.095 mmol, 0.2 equiv) and DavePhos (74.7 mg, 0.190 mmol, 0.4 equiv) were added into thereactor at room temperature, and replaced by N2 for 2 min. The mixture was stirred at 100°C for 1 h. The mixture was cooled to room temperature. The reaction was concentrated under reduced pressure. The residue was purified by reverse phase flash with the following conditions (ACN: H2O with 0.1% NH4HCO3 30%~80%, 30 min. RT = 18 min). This resulted in 4-{[4-(2,2- diethylmorpholin-4-yl)-5-fluoropyrimidin-2-yl] amino}benzenesulfonamide (Compound 34, 72 mg, 37% yield)as a white solid.

[0430] LC-MS (ES, m / z): 410.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.63 (s, 1H), 8.07 – 8.03 (m, 1H), 7.82 – 7.80 (m, 2H), 7.69 – 7.67 (m, 2H), 7.14 (s, 2H), 3.70 (s, 4H), 3.61 (s, 2H), 1.64 – 1.61 (m, 2H), 1.49 – 1.47 (m, 2H), 0.83 – 0.82 (m, 6H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.69.

[0431] Example 30

[0432] Compound 35: Synthesis of 4-({5-fluoro-4-[(5S)-2,2,5-trimethylmorpholin-4- yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide according to Scheme 30.

[0433] Scheme 30:imidine (516.9 mg, 3.096 mmol, 1.0 equiv) and (S)-2,2,5-trimethylmorpholine (400 mg, 3.096 mmol, 1.0 equiv) in DCM (3.2 mL). DIEA (1040.4 mg, 8.050 mmol, 2.6 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 24 h. The reaction was extracted with DCM (2 x 8 mL). The combined organic layers were washed with brine (2 x 8 mL), dried over anhydrous Na2SO4. This resulted in 750 mg (crude) (S)-4-(2-chloro-5-fluoropyrimidin-4-yl)- 2,2,5-trimethylmorpholine as a white solid.

[0435] Step 2: To an 8 mL vial was added a solution of (5S)-4-(2-chloro-5- fluoropyrimidin-4-yl)-2,2,5-trimethylmorpholine (200 mg, 0.770 mmol, 1.0 equiv) and N1- methylsulfanilamide (215.1 mg, 1.155 mmol, 1.5 equiv) in dioxane (4 mL) and H2O (0.4 mL). Cs2CO3(175.9 mg, 2.310 mmol, 3.0 equiv), DavePhos (60.6 mg, 0.154 mmol, 0.2 equiv) andPd2(dba)3 (70.5 mg, 0.077 mmol, 0.1 equiv) were added and the reaction was stirred for 5 h at 100°C then filtered and purified via prep-HPLC: Column: XSelect Prep OBD C18 Column, 30*150 mm, 5 μm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 30% B in 0.2 min, 30% B to35 % B in 10 min; Wavelength: 220 nm; RT1 (min): 10. This resulted in 4-({5-fluoro-4-[(5S)-2,2,5- trimethylmorpholin-4-yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide (Compound 35, 83mg, 25% yield for 2 steps) as a yellow solid.

[0436] LC-MS (ES, m / z): 410.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.66 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.9 Hz, 2H), 7.24 – 7.16 (m, 1H), 4.04 – 3.87 (m, 2H), 3.47 (dd, J = 12.1, 2.1 Hz, 1H), 3.18 (d, J = 13.7 Hz, 1H), 2.38 (d, J = 5.0 Hz, 3H), 1.29 (d, J = 6.7 Hz, 3H), 1.21 (d, J = 1.9 Hz, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.740.

[0437] Example 31

[0438] Compound 36 / 37: Synthesis of (S)-7-(5-fluoro-2-((4-(S- methylsulfonimidoyl)phenyl)amino)pyrimidin-4-yl)-4-methyl-4,7-diazaspiro[2.5]octan-5-one and 7-(5-fluoro-2-((4-(S-methylsulfonimidoyl) phenyl)amino)pyrimidin-4-yl)-4-methyl-4,7- diazaspiro[2.5]octan-5-one according to Scheme 31.

[0439] Scheme 31:p - y - xo-4,7- diazaspiro[2.5]octane-7-carboxylate (430 mg, 1.902 mmol, 1.0 equiv) in DMF (8.6 mL),Cs2CO3(1860.1 mg, 5.709 mmol, 3.0 equiv) and MeI (1350.4 mg, 9.510 mmol, 5.0 equiv) dropwise at 0℃ under nitrogen. The reaction was stirred for 1 h at 0℃ then diluted with EA (300 mL) and washed with H2O (3*50 mL). The organic layer was concentrated under reduced pressure. This resulted in 350 mg of tert-butyl 4-methyl-5-oxo-4,7-diazaspiro[2.5]octane-7-carboxylate as a yellow oil.

[0441] Step 2: To an 8 mL vial was added tert-butyl 4-methyl-5-oxo-4,7- diazaspiro[2.5]octane-7-carboxylate (350 mg, 1.456 mmol, 1.0 equiv) and dioxane (1.75 mL) at 0℃. HCl (gas) in 1,4-dioxane (5.25 mL) was added dropwise and the reaction was stirred for 3 h at room temperature then concentrated under vacuum. This resulted in 460 mg of 4-methyl-4,7- diazaspiro[2.5]octan-5-one as a yellow oil. This was used in the next step directly without further purification.

[0442] Step 3: To an 8 mL vial was added 4-methyl-4,7-diazaspiro[2.5]octan-5-one (202 mg, 1.441 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (240.6 mg, 1.441 mmol, 1.0 equiv) in DCM (1.6 mL) at room temperature. Then DIEA (484.2 mg, 3.747 mmol, 2.6 equiv) was added dropwise and the mixture was stirred for 2 h at room temperature. The reaction was neutralized to pH = 7 with citric acid then extracted with DCM (20 mL) and washed with H2O (2 x 15 mL). The organic layer was dried with anhydrous Na2SO4, filtered and the filtrate concentrated under vacuum. This resulted in 397 mg (77% yield for 3 steps) of 7-(2-chloro-5- fluoropyrimidin-4-yl)-4-methyl-4,7-diazaspiro[2.5]octan-5-one as a yellow solid.

[0443] Step 4: To a 20 mL vial was added a solution of 7-(2-chloro-5-fluoropyrimidin-4- yl)-4-methyl-4,7-diaza-spiro[2.5]octan-5-one (270 mg, 0.997 mmol, 1.0 equiv) and (4- aminophenyl)(imino)(methyl)-λ6-sulfanone (169.8 mg, 0.997 mmol, 1.0 equiv) in dioxane (5.4 mL). K2CO3 (827.1 mg, 5.982 mmol, 6.0 equiv), X-Phos (95.1 mg, 0.199 mmol, 0.2 equiv), and Pd(OAc)2 (22.4 mg, 0.100 mmol, 0.1 equiv) was added under nitrogen and the mixture was stirred at 100°C for 5 h, cooled, filtered and concentrated under vacuum. The residue was purified via column chromatography (MeCN: H2O with 0.1% NH4HCO3, 13%-53%, 20 min) to provide 7-(5- fluoro-2-((4-(S-methylsulfonimidoyl)phenyl)amino)pyrimidin-4-yl)-4-methyl-4,7- diazaspiro[2.5]octan-5-one (Compound 36, 91 mg, 22% yield) as a white solid.

[0444] LC-MS (ES, m / z): 405.1[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.73 (s, 1H), 8.11 (d, J = 6.2 Hz, 1H), 7.91 – 7.73 (m, 4H), 4.45 (s, 2H), 3.99 (s, 1H), 3.79 (s, 2H),3.02 (d, J = 0.9 Hz, 3H), 2.70 (s, 3H), 1.14 (d, J = 6.1 Hz, 2H), 0.93 – 0.81 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -158.3.

[0445] Step 5: 70 mg of 7-(5-fluoro-2-((4-(S-methylsulfonimidoyl)phenyl)amino) pyrimidin-4-yl)-4-methyl-4,7-diaza-spiro[2.5]octan-5-one was purified by Prep Chiral HPLC: CHIRALPAK IF 2*25 cm, 5 μm; Mobile Phase A: MtBE (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: MeOH:DCM=1:1--HPLC; Flow rate: 20 mL / min; Gradient: isocratic 40; Wavelength: 220 / 254 nm; RT2 (min): 22.711; Sample Solvent: EtOH--HPLC; Injection Volume: 1.7 mL; Number Of Runs: 3. This resulted in (S)-7-(5-fluoro-2-((4-(S- methylsulfonimidoyl)phenyl)amino)pyrimidin-4-yl)-4-methyl-4,7-diazaspiro[2.5]octan-5-one (Compound 37, 27 mg, 39% yield) as a white solid.

[0446] LC-MS (ES, m / z): 405.00. [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.71 (s, 1H), 8.11 (d, J = 6.2 Hz, 1H), 7.86 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 4.45 (s, 2H), 3.96 (s, 1H), 3.80 (d, J = 1.2 Hz, 2H), 3.01 (s, 3H), 2.70 (s, 3H), 1.17 – 1.08 (m, 2H), 0.95 – 0.86 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -158.381.

[0447] Example 32

[0448] Compound 38: Synthesis of 4-[(5-fluoro-4-{7-fluoro-5-azaspiro [2.4] heptan-5- yl}pyrimidin-2-yl)amino] benzenesulfonamide according to Scheme 32.

[0449] Scheme 32:

[0450] Step 1: To a 20 mL vial was added a solution of 7-(2-chloro-5-fluoropyrimidin-4- yl)-4-methyl-4,7-diazaspiro [2.5] octan-5-one (200 mg, 0.739 mmol, 1.0 equiv) and sulfanilamide (165.4 mg, 0.961 mmol, 1.3 equiv) in dioxane (6 mL). K2CO3 (306.3 mg, 2.217 mmol, 3.0 equiv), X-Phos (33.2 mg, 0.148 mmol, 0.2 equiv), and Pd(OAc)2 (70.5 mg, 0.074 mmol, 0.1 equiv) was added at room temperature and the mixture stirred at 100°C for 3 h. The reaction was cooled to room temperature, concentrated and purified by reverse phase flash chromatography under the following conditions (ACN: H2O with 0.1% NH4HCO320%~70%, 30 min, RT = 15.6 min). This resulted in 4-[(5-fluoro-4-{7-fluoro-5-azaspiro [2.4] heptan-5-yl}pyrimidin-2-yl)amino] benzenesulfonamide (Compound 38, 47.6 mg, 21% yield) as a white solid.

[0451] LC-MS (ES, m / z): 407.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.10 (m, 1H), 7.81 (m, 2H), 7.69 (m, 2H), 7.15 (s, 2H), 4.44 (s, 2H), 3.79 (s, 2H), 2.70 (s, 3H), 1.13 – 1.10(m, 2H), 0.86 – 0.83 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -158.487.

[0452] Example 33

[0453] Compound 39: Synthesis of (S)-[4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone according to Scheme 33.

[0454] Scheme 33:of methylenecyclobutane (7 g, 102.761 mmol, 1 equiv) and tert-butyl (S)-(1-hydroxypropan-2- yl)carbamate (21.61 g, 123.313 mmol, 1.2 equiv) in ACN (30 mL) at room temperature. Then a solution of NIS (27.74 g, 123.313 mmol, 1.2 equiv) in ACN (30 mL) was added dropwise at room temperature. The mixture was stirred overnight at room temperature then quenched with H2O. The reaction was extracted with EA (60 mL), the organic layer was washed with H2O (2x 30 mL) and dried over anhydrous Na2SO4. After filtration the solution was concentrated and purified via column chromatography (PE / EA= 0~10% yield). This resulted in 11g (28% yield) tert-butyl (S)- (1-(1-(iodomethyl)cyclobutoxy)propan-2-yl)carbamate as a yellow oil.

[0456] Step 2: Into a 250 mL three-necked flask was placed a solution of tert-butyl (S)-(1- (1-(iodomethyl)cyclobutoxy)propan-2-yl)carbamate (11 g, 29.8274 mmol, 1 equiv) and NaH (1.43 g, 59.8533 mmol, 2 equiv) in THF (110 mL). The reaction was stirred overnight at 65°C, quenched with H2O and diluted with DCM (400 mL). The organic layer was washed with H2O (2x 100 mL)and dried with anhydrous Na2SO4. After filtration the solution was concentrated to provide 5.45 g (crude) tert-butyl (S)-7-methyl-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate as a yellow oil.

[0457] Step 3: Into a 100 mL three-necked flask was added a solution of tert-butyl (S)-7- methyl-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (5.45 g, 1 equiv) in DCM (27 mL) at To the above mixture was added HCl (gas) in 1,4-dioxane (77 mL, 15V) dropwise over 1 min at 0℃. The reaction was stirred overnight at 25℃ then concentrated under reduced pressure. This resulted in 5.81 g (crude) (S)-7-methyl-5-oxa-8-azaspiro[3.5]nonane as a yellow oil.

[0458] Step 4: Into a 100 mL three-necked flask was placed a solution of (7S)-7-methyl- 5-oxa-8-azaspiro[3.5]nonane (4.3 g, 30.450 mmol, 1 equiv) and 2,4,5-trichloropyrimidine (4.47 g, 24.360 mmol, 0.8 equiv) in DCM (43 mL) at room temperature. Then DIEA (11.81 g, 91.350 mmol, 3 equiv) was added dropwise and the reaction was stirred overnight. The mixture was concentrated under vacuum and purified by column chromatography (PE / EA= 0% - 20% yield). This resulted in 1.7 g (7.7% yield over 3 steps) of (S)-8-(2,5-dichloropyrimidin-4-yl)-7-methyl-5- oxa-8-azaspiro[3.5]nonane as a yellow oil.

[0459] Step 5: To an 8 ml vial was added a solution of (7S)-8-(2,5-dichloropyrimidin-4- yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (100 mg, 0.347 mmol, 1 equiv) and (S)-(4- aminophenyl)(imino)methyl-λ6-sulfanone (88.61 mg, 0.520 mmol, 1.5 equiv) in dioxane (2 mL) at room temperature. p-TsOH (298.78 mg, 1.735 mmol, 5 equiv) and H2O (0.2 mL) was added. The reaction was stirred overnight at 100°C, cooled, concentrated and purified by preparative HPLC: Column: YMC-Actus Triart C18 ExRS Colum, 30*150 nm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3+0.1 NH3.H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min ; Gradient: 5% B to 5% B in 2 min, 5% B to 40% B in 0.2 min, 40% B to 43% B in 10 min; Wavelength: 220 nm; RT1(min): 9.5. This resulted in (S)-[4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone (Compound 39, 15 mg, 10% yield) as a white solid.

[0460] LC-MS (ES, m / z): 422.05 [M+H]+; 1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.88 (s, 1H), 8.17 (s, 1H), 7.88 (d, J = 8.9 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 4.50 – 4.39 (m, 1H), 4.32 (d, J = 13.5 Hz, 1H), 3.71 (dd, J = 11.8, 3.2 Hz, 1H), 3.50 (dd, J = 11.6, 1.7 Hz, 1H), 3.19 (dd, J = 13.6, 1.7 Hz, 1H), 2.25 – 2.09 (m, 1H), 2.12 – 1.93 (m, 2H), 1.94 – 1.85 (m, 1H), 1.83 – 1.73 (m, 1H), 1.72 – 1.58 (m, 1H), 1.31 (d, J = 6.7 Hz, 3H).

[0461] Example 34

[0462] Compound 40: Synthesis of (R)-[4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone according to Scheme 34.

[0463] Scheme 34: O S NH2O O NH (1.5 eq) S)-8-(2,5-dichloropyrimidin-4-yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (100 mg, 0.347 mmol, 1 equiv) and (R)-(4- aminophenyl)(imino)methyl-λ6-sulfanone (88.61 mg, 0.520 mmol, 1.5 equiv) in dioxane (2 mL). p-TsOH (298.78 mg, 1.735 mmol, 5 equiv) was added and the reaction was stirred overnight at 100°C. The mixture was cooled, concentrated and purified by prep-HPLC: Column: Xselect CSH C18 OBD Column 30*150mm 5μm, n; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: isocratic 37-42; Wavelength: 220 nm; RT1(min): 10.69. This resulted in (R)-[4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone (Compound 40, 29 mg, 19% yield) as a white solid.

[0465] LC-MS (ES, m / z): 422.05 [M+H]+; 1H: (400 MHz, DMSO-d6, ppm) δ 9.88 (s, 1H), 8.16 (s, 1H), 7.88 (d, J = 8.9 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 4.49 – 4.40 (m, 1H), 4.31 (d, J = 13.4 Hz, 1H), 4.01 (d, J = 1.4 Hz, 1H), 3.70 (dd, J = 11.7, 3.2 Hz, 1H), 3.49 (dd, J = 11.7, 1.7 Hz, 1H), 3.19 (dd, J = 13.5, 1.9 Hz, 1H), 3.01 (d, J = 1.0 Hz, 3H), 2.24 – 2.11 (m, 1H), 2.09 – 1.86 (m, 3H), 1.84 – 1.71 (m, 1H), 1.69 – 1.57 (m, 1H), 1.30 (d, J = 6.7 Hz, 3H).

[0466] Example 35

[0467] Compound 41: Synthesis of (S)-[4-({5-fluoro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone according to Scheme 35.

[0468] Scheme 35:solution of (7S)-8-(2-chloro-5-fluoropyrimidin-4-yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (60 mg, 0.221 mmol, 1.0 equiv) in dioxane (1.2 mL) and H2O (0.12 mL). (S)-(4-aminophenyl)(imino)methyl-λ6-sulfanone (45.1 mg, 0.265 mmol, 1.2 equiv), Cs2CO3(143.9 mg, 0.442 mmol, 2.0 equiv), DavePhos (17.4 mg, 0.044 mmol, 0.2 equiv) and Pd2(dba)3(20.2 mg, 0.022 mmol, 0.1 equiv) were added at room temperature. The reaction was stirred for 2 h at 100°C then cooled, filtered and purified by prep-HPLC with the following conditions: Column: YMC-Actus Triart C18 ExRS Colum, 30*150 nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: isocratic 32-37; Wavelength: 220 / 254 nm; RT1(min): 12. This resulted in (S)-[4-({5-fluoro-4-[(7S)-7- methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6- sulfanone (Compound 41, 21 mg, 23% yield) as a white solid.

[0470] LC-MS (ES, m / z): 406.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.70 (s, 1H), 8.10 (d, J = 6.8 Hz, 1H), 7.92 – 7.83 (m, 2H), 7.83 – 7.74 (m, 2H), 4.44 – 4.27 (m, 2H), 3.99 (s, 1H), 3.71 (dd, J = 11.8, 3.3 Hz, 1H), 3.51 (d, J = 11.7 Hz, 1H), 3.18 (dd, J = 13.6, 1.9 Hz, 1H), 3.01 (s, 3H), 2.11 – 2.01 (m, 2H), 2.01 – 1.87 (m, 2H), 1.86 – 1.75 (m, 1H), 1.70 – 1.59 (m, 1H), 1.31 (d, J = 6.7 Hz, 3H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -157.150.

[0471] Example 36

[0472] Compound 42: Synthesis of (R)-[4-({5-fluoro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6-sulfanone according to Scheme 36.

[0473] Scheme 36:

[0474] Step 1: To a 4 mL vial was added a solution of (7S)-8-(2-chloro-5-fluoropyrimidin- 4-yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (60 mg, 0.221 mmol, 1.0 equiv) in dioxane (1.2 mL) and H2O (0.12 mL). (R)-(4-aminophenyl)(imino)methyl-λ6-sulfanone (45.1 mg, 0.265 mmol, 1.2 equiv), Cs2CO3(143.9 mg, 0.442 mmol, 2.0 equiv), DavePhos (17.4 mg, 0.044 mmol, 0.2 equiv) and Pd2(dba)3(20.2 mg, 0.022 mmol, 0.1 equiv) were added at room temperature and the reaction stirred for 2 h at 100°C. The mixture was cooled, concentrated, filtered and the filtrate purified by prep-HPLC with the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150 nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 32% B in 2.5 min, 32% B to 36% B in 10 min; Wavelength: 254 nm / 220 nm; RT1 (min): 10.8. This resulted in) (R)-[4-({5-fluoro-4-[(7S)- 7-methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)phenyl](imino)methyl-λ6- sulfanone (Compound 42, 25 mg, 27.5% yield) as a white solid.

[0475] LC-MS (ES, m / z): 406.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.70 (s, 1H), 8.10 (d, J = 6.9 Hz, 1H), 7.91 – 7.83 (m, 2H), 7.82 – 7.75 (m, 2H), 4.46 – 4.28 (m, 2H), 3.99 (s, 1H), 3.71 (dd, J = 11.8, 3.3 Hz, 1H), 3.51 (d, J = 11.8 Hz, 1H), 3.24 – 3.12 (m, 1H), 3.01 (s, 3H), 2.13 – 2.00 (m, 2H), 2.00 – 1.87 (m, 2H), 1.87 – 1.75 (m, 1H), 1.71 – 1.58 (m, 1H), 1.31 (d, J = 6.7 Hz, 3H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -157.145.

[0476] Example 37

[0477] Compound 43: Synthesis of {4-[(5-fluoro-4-{6-oxa-9-azaspiro[4.5]decan-9-yl} pyrimidin-2-yl)amino]phenyl}(imino)methyl-λ6-sulfanone according to Scheme 37:

[0478] Scheme 37:

[0079] Step : o a 0 m v a was added a so ut on o 6-oxa-9-azasp ro[ .5]decane (500 mg, 3.541 mmol, 1.0 equiv) in THF (10 mL) and 2,4-dichloro-5-fluoropyrimidine (591.2 mg, 3.541 mmol, 1.0 equiv) under nitrogen followed by TEA (1074.9 mg, 10.623 mmol, 3.0 equiv) dropwise. The reaction was stirred for 2 h at RT then concentrated under reduced pressure. This provided 9-(2-chloro-5-fluoropyrimidin -4-yl)-6-oxa-9-azaspiro[4.5]decane (900 mg, 94% yield).

[0480] Step 2: To an 8 ml vial was added a solution of 9-(2-chloro-5-fluoropyrimidin-4- yl)-6-oxa-9-azaspiro [4.5]decane (100 mg, 0.368 mmol, 1.0 equiv) in 1,4-dioxane (2 mL), (4- aminophenyl) (imino)methyl-λ6-sulfanone (75.2 mg, 0.442 mmol, 1.2 equiv), Cs2CO3(239.8 mg, 0.736 mmol, 2.0 equiv), X-Phos (35.1 mg, 0.074 mmol, 0.2 equiv) and Pd(OAc)2 (8.3 mg, 0.037 mmol, 0.1 equiv) under nitrogen. The reaction was stirred for 12 h at 100°C, cooled and concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in 0.1% NH4HCO3 Water, 30% to 60% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under reduced pressure. This provided {4-[(5-fluoro-4-{6-oxa-9-azaspiro[4.5]decan- 9-yl} pyrimidin-2-yl)amino]phenyl}(imino)methyl-λ6-sulfanone (Compound 43, 50.9 mg, 34% yield) as a white solid.

[0481] LC-MS (ES, m / z): 406.2[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.67 (s, 1H), 8.08 (d, J = 6.7 Hz, 1H), 7.89 – 7.81 (m, 2H), 7.81 – 7.73 (m, 2H), 3.96 (s, 1H), 3.72 (p, J = 2.5 Hz, 4H), 3.63 (s, 2H), 3.01 (d, J = 1.0 Hz, 3H), 1.77 – 1.49 (m, 8H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.35.

[0482] Example 38

[0483] Compound 44: Synthesis of 4-[(5-chloro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl} pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide according to Scheme 38.

[0484] Scheme 38:

[0485] Step 1: To a 20 mL vial was added a solution of 8-(2,5-dichloropyrimidin-4-yl)-5- oxa-8-azaspiro[3.5]nonane (55 mg, 0.201 mmol, 1.0 equiv) and N1-methylsulfanilamide (44.8 mg, 0.241 mmol, 1.2 equiv) in 1,4-dioxane (5.5 mL). Then, p-toluenesulfonic acid (172.7 mg, 1.005 mmol, 5.0 equiv) was added and the reaction was stirred for 16 h at 100°C under nitrogen then cooled, diluted with MeCN (5 mL), filtered; and washed with MeCN (2 x 5 mL). The filtrate was concentrated and purified via prep-HPLC with the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L HCOOH), 35% to 65% gradient in 30 min; detector, UV 210 nm.) to afford 4-[(5-chloro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl} pyrimidin-2-yl)amino]- N-methylbenzenesulfonamide (Compound 44, 83 mg, 97% yield) as a white solid.

[0486] LC-MS (ES, m / z): 424 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.93 (s, 1H), 8.20 (s, 1H), 7.94 – 7.86 (m, 2H), 7.71 – 7.65 (m, 2H), 7.24 (q, J = 5.1 Hz, 1H), 3.67 (d, J = 9.5 Hz, 4H), 3.57 (dd, J = 5.8, 3.5 Hz, 2H), 2.39 (d, J = 5.0 Hz, 3H), 2.08 (s, 1H), 2.07 – 2.02 (m, 1H), 1.96 (dt, J = 11.6, 9.1 Hz, 2H), 1.78 (q, J = 10.0 Hz, 1H), 1.72 – 1.58 (m, 1H).

[0487] Example 39

[0488] Compound 45: Synthesis of (S)-4-((5-chloro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)-N-methylbenzenesulfonamide according to Scheme 39.

[0489] Scheme 39:

[0490] Step 1: To a 500 mL three-necked flask at 0°C containing (S)-6-methyl-4-oxa-7- azaspiro[2.5]octane (2.04 g, 16.039 mmol, 1 equiv) in water (100 mL) was added DIEA (16.58 g,128.312 mmol, 8 equiv) and 2,4,5-trichloropyrimidine (2.33 g, 12.831 mmol, 0.8 equiv) in DCM (60 mL) and the reaction stirred overnight at 25°C. The mixture was extracted with DCM (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified via column chromatography (PE / EA = 0~5%). This provided 1.8 g (41% yield) of (S)-7-(2,5- dichloropyrimidin-4-yl)-6-methyl-4-oxa-7-azaspiro[2.5]octane as a yellow oil.

[0491] Step 2: To an 8 ml vial was added a solution of (S)-7-(2,5-dichloropyrimidin-4-yl)- 6-methyl-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.365 mmol, 1 equiv) and N1- methylsulfanilamide (81.52 mg, 0.438 mmol, 1.2 equiv) in dioxane (3 mL) at room temperature. p-TsOH (314.06 mg, 1.825 mmol, 5 equiv) was added and the mixture was stirred overnight at 100°C. The reaction was filtered and purified by Column: C18; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 43% B to 83% B in 20 min; Wavelength: 220 nm; RT1(min): 10.3. This resulted in 88mg (Yield: 56% yield) (S)-4- ((5-chloro-4-(6-methyl-4-oxa-7-azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)-N- methylbenzenesulfonamide as a white solid.

[0492] LC-MS (ES, m / z): 424.05 [M+H]+;1H: (400 MHz, DMSO-d6, ppm) δ 9.85 (s, 1H), 8.16 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.22 (d, J = 5.3 Hz, 1H), 4.60 (d, J = 7.3 Hz, 1H), 3.82 (dd, J = 11.4, 3.0 Hz, 2H), 3.66 (d, J = 11.2 Hz, 1H), 3.57 (d, J = 13.6 Hz, 1H), 2.38 (d, J = 5.0 Hz, 3H), 1.35 (d, J = 6.8 Hz, 3H), 0.90 – 0.78 (m, 1H), 0.76 – 0.57 (m, 3H).

[0493] Example 40

[0494] Compound 46: Synthesis of (S)-4-((5-chloro-4-(7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl)pyrimidin-2-yl)amino)benzenesulfonamide according to Scheme 40.

[0495] Scheme 40:ution of (S)-8-(2,5-dichloropyrimidin- 4-yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (100 mg, 0.347 mmol, 1.0 equiv) and sulfanilamide (71.7 mg, 0.416 mmol, 1.2 equiv) in dioxane (2 mL) at room temperature. p-TsOH (298.8 mg, 1.735 mmol, 5.0 equiv) and 2 drops of H2O were added. The reaction was stirred for 18 h at 100°C then cooled and purified by prep-HPLC: Xselect CSH C18 OBD Column 30*150mm 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: isocratic 43-48; Wavelength: 220 nm; RT1 (min): 10.58. This provided (S)-4-((5-chloro-4-(7-methyl-5-oxa-8-azaspiro[3.5]nonan-8- yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 46, 35 mg, 23% yield) as a white solid.

[0497] LC-MS (ES, m / z): 424.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.82 (s, 1H), 8.16 (s, 1H), 7.84 (d, J = 8.9 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 7.18 (s, 2H), 4.48 – 4.39 (m, 1H), 4.31 (d, J = 13.5 Hz, 1H), 3.69 (dd, J = 11.7, 3.2 Hz, 1H), 3.49 (dd, J = 11.7, 1.8 Hz, 1H), 3.18 (dd, J = 13.5, 1.9 Hz, 1H), 2.21 – 2.10 (m, 1H), 2.09 – 1.92 (m, 2H), 1.92 – 1.84 (m, 1H), 1.83 – 1.71 (m, 1H), 1.71 – 1.60 (m, 1H), 1.29 (d, J = 6.7 Hz, 3H).

[0498] Example 41

[0499] Compound 47: Synthesis of 4-({5-fluoro-4-[(7S)-7-methyl-5-oxa-8- azaspiro[2.6]nonan-8-yl]pyrimidin-2-yl}amino)benzenesulfonamide according to Scheme 41.

[0500] Scheme 41:was added a solution of tert- butyl N-[(2S)-1-hydroxypropan-2-yl] carbamate (20 g, 114.137 mmol, 1 equiv) in DMSO (400 mL), 1,1-bis(bromomethyl)cyclopropane (28.62 g, 125.55 mmol, 1.1 equiv) and t-BuONa (32.91 g, 342.411 mmol, 3.0 equiv). The mixture was stirred at 120°C for 6 h then diluted with EA (500 mL). The organic layer was washed with water (3x300 ml), dried over anhydrous Na2SO4; filteredand concentrated under reduced pressure. The residue was purified via column chromatography (PE / EA=0~20%). This provided 4 g (14% yield) of tert-butyl (7S)-7-methyl-5-oxa-8- azaspiro[2.6]nonane-8-carboxylate as a yellow oil.

[0502] Step 2: To an 8 ml vial was added a solution of tert-butyl (7S)-7-methyl-5-oxa-8- azaspiro [2.6] nonane-8-carboxylate (200 mg, 0.829 mmol, 1 equiv) in dioxane (2 mL). This was cooled to 0°C and HCl (gas) in 1,4-dioxane (2 mL) was added under nitrogen. The reaction was stirred at room temperature for 3 then concentrated under reduced pressure to provide 160 mg of (7S)-7-methyl-5-oxa-8-azaspiro [2.6] nonane as a yellow oil.

[0503] Step 3: To an 8 ml vial was added a solution of (7S)-7-methyl-5-oxa-8- azaspiro[2.6]nonane (160 mg, 1.133 mmol, 1 equiv) and 2,4-dichloro-5-fluoropyrimidine (208.09 mg, 1.246 mmol, 1.1 equiv) in DCM (1.6 mL), The mixture was cooled to 0°C and DIEA (439.32 mg, 3.399 mmol, 3.0 equiv) was added dropwise over 30 min. The mixture was stirred at room temperature for 2 h. The reaction was diluted with DCM (10 mL). The organic layer was washed with brine (3x10 mL), dried over anhydrous Na2SO4 filtered and concentrated under reduced pressure. The residue was used in the next step directly without further purification. This resulted in 93 mg of (7S)-8-(2-chloro-5-fluoropyrimidin-4-yl)-7-methyl-5-oxa-8-azaspiro[2.6]nonane as a white solid.

[0504] Step 4: To an 8 ml vial was added a solution of (7S)-8-(2-chloro-5-fluoropyrimidin- 4-yl)-7-methyl-5-oxa-8-azaspiro[2.6]nonane (80 mg, 0.294 mmol, 1 equiv) and sulfanilamide (152.10 mg, 0.882 mmol, 3.0 equiv) in dioxane (1.6 mL). p-TsOH (253.50 mg, 1.470 mmol, 5.0 equiv) was added under nitrogen and the mixture was stirred at 100°C for 24 h then cooled to room temperature and concentrated under reduced pressure. The residue was purified via prep-HPLC under the following conditions (Column: XBridge Prep Shield RP18OBD Column, 19*250 mm, 5μm; Mobile Phase A:Water (10mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: isocratic 33-38; Wavelength: 220 / 254 nm; RT1(min): 15). This provided 4- ({5-fluoro-4-[(7S)-7-methyl-5-oxa-8-azaspiro[2.6]nonan-8-yl]pyrimidin-2- yl}amino)benzenesulfonamide (Compound 47, 25 mg, 21% yield) as a white solid.

[0505] LC-MS (ES, m / z): 408 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.54 (s, 1H), 8.01 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 7.15 (s, 2H), 4.69 (d, J = 8.2 Hz, 1H), 4.12 – 3.97 (m, 1H), 3.97 – 3.81 (m, 2H), 3.81 – 3.66 (m, 2H), 3.17 (d, J =11.9 Hz, 1H), 1.17 (d, J = 6.4 Hz, 3H), 0.74 (d, J = 9.4, 4.6 Hz, 1H), 0.61 – 0.34 (m, 3H);19F- NMR (376 MHz, DMSO-d6, ppm): -155.964, -156.031.

[0506] Example 42

[0507] Compound 48: Synthesis of (S)-4-((5-fluoro-4-(7-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl)pyrimidin-2-yl)amino)benzenesulfonamide according to Scheme 42.

[0508] Scheme 42:

[0509] Step 1: To a 4 mL vial was added a solution of (S)-8-(2-chloro-5-fluoropyrimidin- 4-yl)-7-methyl-5-oxa-8-azaspiro[3.5]nonane (110 mg, 0.377 mmol, 1.0 equiv) and 4- aminobenzenesulfonamide (129.9 mg, 0.754 mmol, 2.0 equiv) in dioxane (2.2 mL) in H2O (0.22 mL). Cs2CO3(368.6 mg, 1.131 mmol, 3.0 equiv), DavePhos (29.7 mg, 0.075 mmol, 0.2 equiv) and Pd2(dba)3 (34.5 mg, 0.038 mmol, 0.1 equiv) were added under nitrogen. The mixture was stirred for 3 h at 100°C. The reaction mixture was filtered and purified via prep-HPLC: Column: XBridge Prep Shield RP18 OBD Column, 30*150 mm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 42% B in 0.2 min, 42% B to 45% B in 10 min; Wavelength: 220 nm; RT1 (min): 10. This provided (S)-4-((5-fluoro-4-(7-methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl)pyrimidin-2- yl)amino)benzenesulfonamide (Compound 48, 86 mg, 52% yield) as a white solid.

[0510] LC-MS (ES, m / z): 408.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.64 (s, 1H), 8.08 (d, J = 6.9 Hz, 1H), 7.82 (d, J = 9.3 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.15 (s, 2H), 4.43 – 4.24 (m, 2H), 3.70 (dd, J = 11.9, 3.3 Hz, 1H), 3.50 (d, J = 11.8 Hz, 1H), 3.17 (dd, J = 13.5, 1.9 Hz, 1H), 2.12 – 2.00 (m, 2H), 1.99 – 1.87 (m, 2H), 1.86 – 1.74 (m, 1H), 1.71 – 1.59 (m, 1H), 1.30 (d, J = 6.7 Hz, 3H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -157.335.

[0511] Example 43

[0512] Compound 49: Synthesis of 4-[(5-fluoro-4-{6-oxa-9-azaspiro[3.6]decan-9- yl}pyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 43.

[0513] Scheme 43:

[0514] Step 1: To an 8 mL vial was added a solution of 6-oxa-9-azaspiro [3.6] decane (200 mg, 1.416 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (236.5 mg, 1.416 mmol, 1.0 equiv) in DCM (1.6 mL). DIEA (475.9 mg, 3.682 mmol, 2.6 equiv) was added at 0°C. The mixture was warmed to room temperature and stirred for 1 h then diluted with DCM (8 mL). The organic layer was washed with brine (2 x 8 mL), dried over anhydrous Na2SO4and concentrated. This resulted in 300 mg of 9-(2-chloro-5-fluoropyrimidin-4-yl)-6-oxa-9-azaspiro [3.6] decane as an off- white solid.

[0515] Step 2: To an 8 mL vial was added a solution of 9-(2-chloro-5-fluoropyrimidin-4- yl)-6-oxa-9-azaspiro [3.6] decane (100 mg, 0.368 mmol, 1.0 equiv) in dioxane (2 mL). Then, sulfanilamide (95.1 mg, 0.552 mmol, 1.5 equiv), K2CO3 (152.6 mg, 1.104 mmol, 3.0 equiv), X- Phos (35.1 mg, 0.074 mmol, 0.2 equiv) and Pd(OAc)2(8.3 mg, 0.037 mmol, 0.1 equiv) was added and the reaction stirred for 1 h at 100°C, cooled to room temperature and filtered. The residue was purified via prep-HPLC under the following conditions: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5 μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 35% B in 2.5 min, 35% B to 40% B in 10 min; Wavelength: 254nm / 220nm; RT1(min): 10.5. This provided 4-[(5-fluoro-4-{6- oxa-9-azaspiro[3.6]decan-9-yl}pyrimidin-2-yl)amino]benzenesulfonamide (Compound 49, 50 mg, 25% yield for 2 steps) as a white solid.

[0516] LC-MS (ES, m / z): 408.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.55 (s, 1H), 8.03 (d, J = 7.0 Hz, 1H), 7.91 – 7.79 (m, 2H), 7.74 – 7.62 (m, 2H), 7.14 (s, 2H), 3.92 (s, 2H), 3.79 (s, 4H), 3.64 (s, 2H), 1.97 – 1.63 (m, 6H);19F-NMR (376 MHz, DMSO-d6, ppm): δ - 157.03.

[0517] Example 44

[0518] Compound 50: Synthesis of 4-[(5-fluoro-4-{6-oxa-9-azaspiro[4.5]decan-9- yl}pyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 44.

[0519] Scheme 44: lution of 9-(2-chloro-5-fluoropyrimidin-4-yl)-6-oxa-9-azaspiro[4.5]decane (100 mg, 0.368 mmol, 1.0 equiv) in 1,4-dioxane (2 mL), sulfanilamide (69.7 mg, 0.405 mmol, 1.1 equiv), Cs2CO3 (56 mg, 0.736 mmol, 2.0 equiv), X-Phos (35.1 mg, 0.074 mmol, 0.2 equiv) and Pd(OAc)2(8.3 mg, 0.037 mmol, 0.1 equiv) under nitrogen. The reaction was stirred for 12 h at 100°C under nitrogen then concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in 0.1% NH4HCO3Water, 30% to 60% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under reduced pressure. This resulted in 4-[(5-fluoro-4-{6-oxa-9-azaspiro[4.5]decan-9-yl}pyrimidin-2- yl)amino]benzenesulfonamide (Compound 50, 17.2 mg, 11% yield) as a white solid.

[0521] LC-MS (ES, m / z): 408.1 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.61 (s, 1H), 8.08 (d, J = 6.7 Hz, 1H), 7.81 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 7.11 (s, 2H), 3.72 (p, J = 2.5 Hz, 4H), 3.63 (s, 2H), 1.76 – 1.52 (m, 8H);19F-NMR: 19F NMR (376 MHz, DMSO-d6, ppm): δ -156.51.

[0522] Example 45

[0523] Compound 51: Synthesis of 4-({5-fluoro-4-[(6R)-6-methyl-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)benzenesulfonamide according to Scheme 45.

[0524] Scheme 45:

[0525] Step 1: To a 4 mL vial under nitrogen was added 6-methyl-5-oxa-8- azaspiro[3.5]nonane (200 mg, 1.416 mmol, 1 equiv) and 2,4-dichloro-5-fluoropyrimidine (236.46 mg, 1.416 mmol, 1 equiv) in DCM (2 mL). DIEA (475.93 mg, 3.682 mmol, 2.6 equiv) was added dropwise to the solution at 0oC. The mixture was stirred for 2 h at room temperature then diluted with DCM (20 mL), washed with brine (3 x 20 ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. This provided (370 mg, 96% yield) of 8-(2-chloro-5- fluoropyrimidin-4-yl)-6-methyl-5-oxa-8-azaspiro[3.5]nonane as a yellow oil.

[0526] Step 2: To a 20 mL vial was added a solution of 8-(2-chloro-5-fluoropyrimidin-4- yl)-6-methyl-5-oxa-8-azaspiro[3.5]nonane (340 mg, 1.251 mmol, 1 equiv) in dioxane (7 mL) and H2O (0.7 mL). Sulfanilamide (258.57 mg, 1.501 mmol, 1.2 equiv), Cs2CO3 (815.39 mg, 2.502 mmol, 2 equiv), DavePhos (98.49 mg, 0.250 mmol, 0.2 equiv) and Pd2(dba)3 (114.58 mg, 0.125 mmol, 0.1 equiv) were added at room temperature under nitrogen. The reaction was stirred for 2 h at 100°C then cooled and was purified via column chromatography (ACN: H2O with 0.1% NH4HCO3, 25%~65%, 20 min) to provide (260 mg, 51% yield) of 4-[(5-fluoro-4-{6-methyl-5- oxa-8-azaspiro[3.5]nonan-8-yl}pyrimidin-2-yl)amino]benzenesulfonamide as a white solid.

[0527] Step 3: 4-[(5-fluoro-4-{6-methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl}pyrimidin-2- yl)amino]benzenesulfonamide (90 mg, 0.218 mmol, 1 equiv) was purified by prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 μm; Mobile Phase A: HEX(0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL / min; Gradient: isocratic 10; Wavelength: 220 / 254 nm; RT1(min): 47.81; RT2(min): 52.044; Sample Solvent: EtOH; Injection Volume: 0.3 mL; Number Of Runs: 24

[0528] This provided 4-({5-fluoro-4-[(6R)-6-methyl-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl}amino)benzenesulfonamide (Compound 51, 25 mg, 27% yield) as a white solid.

[0529] LC-MS (ES, m / z): 408.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.87 – 7.77 (m, 2H), 7.74 – 7.65 (m, 2H), 7.16 (s, 2H), 4.45 (d, J = 13.2 Hz, 1H), 4.24 (d, J = 12.7 Hz, 1H), 3.73 – 3.62 (m, 1H), 2.98 – 2.90 (m, 1H), 2.79 – 2.70(m, 1H), 2.06 – 1.88 (m, 4H), 1.79 (q, J = 10.1 Hz, 1H), 1.67 – 1.63 (m, 1H), 1.13 (d, J = 6.2 Hz, 3H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.515.

[0530] Example 46

[0531] Compound 52: Synthesis of 4-[(5-fluoro-4-{5-oxa-8-azaspiro[3.5]nonan-8- yl}pyrimidin-2-yl)amino]-N-methylbenzenesulfonamide according to Scheme 46.

[0532] Scheme 46:

[0533] Step 1: To an 8 ml vial under nitrogen was added 8-(2-chloro-5-fluoropyrimidin-4- yl)-5-oxa-8-azaspiro[3.5]nonane (50 mg, 0.194 mmol, 1.0 equiv), N1-methylsulfanilamide (54.2 mg, 0.291 mmol, 1.5 equiv), X-Phos (18.5 mg, 0.039 mmol, 0.2 equiv), Cs2CO3 (189.7 mg, 0.582 mmol, 3.0 equiv) and Pd(OAc)2(4.4 mg, 0.019 mmol, 0.1 equiv) in 1,4-dioxane (2.5 mL) under nitrogen at room temperature. The reaction was stirred for 16 h at 100°C. The mixture was cooled to room temperature then filtered and concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 30% to 60% gradient in 30 min; detector, UV 210 nm) to afford 4-[(5-fluoro-4-{5-oxa-8-azaspiro[3.5]nonan-8-yl}pyrimidin-2-yl)amino]-N- methylbenzenesulfonamide (Compound 52, 38.3 mg, 47% yield) as a white solid.

[0534] LC-MS (ES, m / z): 408 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.69 (s, 1H), 8.10 (d, J = 6.7 Hz, 1H), 7.91 – 7.82 (m, 2H), 7.67 – 7.63 (m, 2H), 7.20 (d, J = 5.3 Hz, 1H), 3.75 – 3.63 (m, 6H), 2.38 (d, J = 4.7 Hz, 3H), 1.98 (t, J = 7.9 Hz, 4H), 1.80 (d, J = 8.0 Hz, 1H), 1.65 (p, J = 9.2 Hz, 1H);19F-NMR (282 MHz, DMSO-d6, ppm) δ -156.4.

[0535] Example 47

[0536] Compound 53: Synthesis of (S)-4-((5-fluoro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)-N-methylbenzenesulfonamide according to Scheme 47.

[0537] Scheme 47: lution of (S)-7-(2-chloro-5-fluoropyrimidin-4-yl)-6-methyl-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.388 mmol, 1 equiv) and N1- methylsulfanilamide (86.72 mg, 0.466 mmol, 1.2 equiv) in dioxane (3 mL) and H2O (0.3 mL) at room temperature. Cs2CO3(379.32 mg, 1.164 mmol, 3 equiv), DavePhos (30.54 mg, 0.078 mmol, 0.2 equiv) and Pd2(dba)3 (35.54 mg, 0.039 mmol, 0.1 equiv) were added under nitrogen. The mixture was stirred for 2h at 100°C then filtered and purified by prep-HPLC: Column: XBridge Prep Shield RP18 OBD Column, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3+0.1%NH3.H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 1.5 min, 5% B to 40% B in 2 min, 40% B to 44% B in 10 min; Wavelength: 220nm / 254nm; RT1(min): 10.1. This provided (S)-4-((5-fluoro-4-(6-methyl-4-oxa-7-azaspiro[2.5]octan-7- yl)pyrimidin-2-yl)amino)-N-methylbenzenesulfonamide (Compound 53, 80 mg, 49% yield) as a white solid.

[0539] LC-MS (ES, m / z): 408.15 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.68 (s, 1H), 8.09 (d, J = 6.8 Hz, 1H), 7.84 (d, J = 9.0 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.30 – 7.07 (m, 1H), 4.53 (d, J = 7.7 Hz, 1H), 3.91 – 3.76 (m, 2H), 3.68 (dd, J = 11.3, 1.2 Hz, 1H), 3.56 (d, J = 13.7 Hz, 1H), 2.37 (s, 3H), 1.35 (d, J = 6.8 Hz, 3H), 0.93 – 0.83 (m, 1H), 0.79 – 0.63 (m, 2H), 0.61 – 0.51 (m, 1H).19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.815.

[0540] Example 48

[0541] Compound 54: Synthesis of 4-[(4-{4-ethyl-5-oxo-4,7-diazaspiro[2.5]octan-7-yl}- 5-fluoropyrimidin-2-yl)amino] benzenesulfonamide according to Scheme 48.

[0542] Scheme 48:

[0543] Step 1: To a 20 mL vial was added a solution of tert-butyl 5-oxo-4,7- diazaspiro[2.5]octane-7-carboxylate (450 mg, 1.989 mmol, 1.0 equiv) and Cs2CO3(1943.9 mg, 5.967 mmol, 3.0 equiv) in DMF (9 mL). The solution was stirred for 5 min at room temperature under nitrogen then cooled to 0°C. Ethyl iodide (1550.9 mg, 9.945 mmol, 5.0 equiv) was added dropwise over 5 min at 0°C. The reaction was stirred for 1 h at 0°C then quenched with water at room temperature. The reaction was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. This provided tert-butyl 4-ethyl-5-oxo-4,7-diazaspiro[2.5]octane-7- carboxylate (500 mg, 88% yield) as an off-white oil.

[0544] Step 2: To a 25 mL round-bottom flask was added tert-butyl 4-ethyl-5-oxo-4,7- diazaspiro[2.5]octane-7-carboxylate (200 mg, 0.786 mmol, 1.0 equiv) and dioxane (1 mL) at room temperature. To the above mixture was added HCl (gas) in 1,4-dioxane (3 mL, 98.738 mmol, 125.6 equiv) at room temperature. The reaction was stirred for 3 h at room temperature then concentrated under reduced pressure. The residue was used in the next step without further purification.

[0545] Step 3: To a 20 mL vial was added a solution of 4-ethyl-4,7-diazaspiro[2.5]octan- 5-one (100 mg, 0.648 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (108.3 mg, 0.648 mmol, 1.0 equiv) in EtOH (2 mL). This was stirred for 5 min at room temperature under nitrogen and then Et3N (328.1 mg, 3.240 mmol, 5.0 equiv) was added dropwise at 0°C. The reaction was stirred for 3 h at 0°C then concentrated under reduced pressure to afford 7-(2-chloro-5-fluoropyrimidin-4-yl)-4-ethyl-4,7-diazaspiro[2.5]octan-5-one (200 mg, 90% yield) as a light yellow solid. The crude reaction was used in the next step directly without further purification.

[0546] Step 4: To a 40 mL vial was added 7-(2-chloro-5-fluoropyrimidin-4-yl)-4-ethyl- 4,7-diazaspiro[2.5]octan-5-one (110 mg, 0.386 mmol, 1.0 equiv), sulfanilamide (199.6 mg, 1.158 mmol, 3.0 equiv), Pd(OAc)2 (8.7 mg, 0.039 mmol, 0.1 equiv), X-Phos (36.8 mg, 0.077 mmol, 0.2 equiv), Cs2CO3(377.6 mg, 1.158 mmol, 3.0 equiv) and dioxane (5.5 mL) at room temperature under nitrogen. The reaction was stirred for 12 h at 100°C then cooled and concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10µm; mobile phase, MeCN in Water (0.1% FA), 35% to 65% gradient in 30 min; detector, UV 210 / 254 nm to afford 4-[(4-{4-ethyl-5-oxo-4,7-diazaspiro[2.5]octan-7-yl}-5-fluoropyrimidin-2-yl)amino] benzenesulfonamide (Compound 54, 26 mg, 15% yield) as a light yellow solid.

[0547] LC-MS (ES, m / z): 421.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.09 (d, J = 5.9 Hz, 1H), 7.83 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.14 (s, 2H), 4.45 (s, 2H), 3.73 (d, J = 2.0 Hz, 2H), 3.23 (q, J = 7.0 Hz, 2H), 1.09 (d, J = 5.6 Hz, 2H), 1.01 (dd, J = 13.8, 6.6 Hz, 5H);19F-NMR (376 MHz, DMSO, ppm): δ -159.17.

[0548] Example 49

[0549] Compound 55: Synthesis of 4-[(4-{4-acetyl-4,7-diazaspiro[2.5]octan-7-yl}-5- fluoropyrimidin-2-yl)amino]benzenesulfonamide according to Scheme 49.

[0550] Scheme 49:

[0551] Step 1: To a 20 mL vial was added a solution of tert-butyl 4,7- diazaspiro[2.5]octane-7-carboxylate (500 mg, 2.355 mmol, 1.0 equiv) in DCM (5 mL). Then, acetyl chloride (203.4 mg, 2.591 mmol, 1.1 equiv) and DIEA (913.2 mg, 7.065 mmol, 3.0 equiv) were added at room temperature. The reaction was stirred for 2 h then concentrated and purified via column chromatography (ACN: H2O with 0.1% NH4HCO3, 25%~65%, 20 min) to afford tert- butyl 4-acetyl-4,7-diazaspiro[2.5]octane-7-carboxylate (500 mg, 84% yield).

[0552] Step 2: To a 20 mL vial under nitrogen was added a solution of tert-butyl 4-acetyl- 4,7-diazaspiro[2.5]octane-7-carboxylate (500 mg, 1.966 mmol, 1.0 equiv) in HCl (gas) in 1,4- dioxane (5 mL). The mixture was stirred for 2 h at room temperature, filtered and concentrated under reduced pressure to afford 1-{4,7-diazaspiro[2.5]octan-4-yl}ethanone (500 mg). The crude product was used for the next step without further purification.

[0553] Step 3: To an 8 ml vial under nitrogen was added a mixture of 1-{4,7- diazaspiro[2.5]octan-4-yl}ethanone (500 mg, 3.242 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoro- pyrimidine (541.3 mg, 3.242 mmol, 1.0 equiv) in DCM (5 mL). DIEA (1089.5 mg, 8.429 mmol, 2.6 equiv) was added dropwise to the solution at 0°C. The mixture was stirred for 2 h at 110°C then diluted with DCM (20 mL), washed with brine (3 x 20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. This resulted in 1-[7-(2-chloro-5-fluoropyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]ethanone (300 mg, 33% yield) as a yellow solid

[0554] Step 4: To an 8 ml vial was added a solution of 1-[7-(2-chloro-5-fluoropyrimidin- 4-yl)-4,7-diazaspiro[2.5] octan-4-yl]ethanone (150 mg, 0.527 mmol, 1.0 equiv) in 1,4-dioxane (2 mL). Sulfanilamide (108.9 mg, 0.632 mmol, 1.2 equiv), K2CO3 (145.6 mg, 1.054 mmol, 2.0 equiv), X-Phos (50.2 mg, 0.105 mmol, 0.2 equiv) and Pd(OAc)2(11.8 mg, 0.053 mmol, 0.1 equiv) were added at room temperature under nitrogen. The reaction was stirred for 2 h at 100°C then cooled, filtered, concentrated and purified via prep-HPLC with the following conditions (Column: Xselect CSH C18 OBD Column 30*150mm 5μm, n; Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: 5% B to 5% B in 5 min, 25% B to 45% B in 30 min; Wavelength: 220 nm; RT1(min): 10.92; Number Of Runs: 2) to afford 4-[(4-{4-acetyl-4,7-diazaspiro[2.5]octan-7-yl}-5- fluoropyrimidin-2-yl)amino]benzenesulfonamide (Compound 55, 55 mg, 25% yield) as a white solid.

[0555] LC-MS (ES, m / z): 420.95 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.64 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.84 – 7.77 (m, 2H), 7.73 – 7.68 (m, 2H), 7.00 (s, 2H), 3.69 (d, J = 36.6 Hz, 6H), 2.16 (s, 2H), 2.08 (s, 1H), 0.98 (dd, J = 58.1, 34.4 Hz, 4H).

[0556] Example 50

[0557] Compound 56 / 57 / 58: Synthesis of 4-((5-chloro-4-[(6R)-6-(hydroxymethyl)-5-oxa- 8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide, 4-((5-chloro-4-[(6R)-6- (hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide and 4-((5-chloro-4-[(6S)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2- ylamino)benzenesulfonamide according to Scheme 50.

[0558] Scheme 50:

[0559] Step 1: In a 250 mL round-bottom flask a solution of 5-oxa-8-azaspiro [3.5] nonan- 6-ylmethanol (635 mg, 4.039 mmol, 1.0 equiv) in THF (60 mL) was treated with 2,4,5- trichloropyrimidine (1.11 g, 6.06 mmol, 1.5 equiv) at room temperature under nitrogen then Et3N (2.04 g, 20.2 mmol, 5.0 equiv)was added dropwise at 0°C. The reaction was stirred for 1 h at 0- 20°C under nitrogen then concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 10% to 100% gradient in 20 min; detector, UV 210 nm. The eluent of product was concentrated and dried by lyophilization. This resulted in [8-(2,5-dichloropyrimidin -4-yl) -5-oxa-8-azaspiro [3.5] nonan-6-yl] methanol (1 g, 81% yield) as a brown oil.

[0560] Step 2: To a 60 mL vial was added [8-(2,5-dichloropyrimidin-4-yl)-5-oxa-8- azaspiro [3.5] nonan-6-yl] methanol (100 mg, 0.329 mmol, 1.0 equiv), sulfanilamide (283 mg, 1.65 mmol, 5.0 equiv) in dioxane (10 mL) and p-TsOH (283 mg, 1.65 mmol, 5.0 equiv) at room temperature under nitrogen. The reaction was stirred for 16 h at 100°C under nitrogen then cooled to room temperature, filtered, and the filter cake was washed with acetonitrile (3 x 30 mL). The filtrate was concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 5% to 30% gradient in 20 min; detector, UV 210 nm. The eluent of product was concentrated and freeze dried, this resulted in 4-((5-chloro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro [3.5] nonan-8-yl] pyrimidin-2-ylamino) benzenesulfonamide (Compound 56, 26.2 mg, 18% yield) as a white solid.

[0561] LC-MS (ES, m / z):440.11[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.86 (s, 1H), 8.19 (s, 1H), 7.89 – 7.81 (m, 2H), 7.75 – 7.68 (m, 2H), 7.16 (s, 2H), 4.86 (t, J = 5.6 Hz, 1H), 4.50 (dd, J = 12.9, 1.9 Hz, 1H), 4.29 (dt, J = 12.9, 2.3 Hz, 1H), 3.60 (dd, J = 10.4, 6.7 Hz, 1H), 3.51 (dt, J = 9.9, 4.7 Hz, 1H), 3.41 (dt, J = 11.4, 5.9 Hz, 1H), 2.89 (dd, J = 13.1, 1.9 Hz, 1H), 2.80 (dd, J = 13.0, 10.6 Hz, 1H), 2.10 – 1.98 (m, 1H), 1.95 (dd, J = 8.0, 3.9 Hz, 1H), 1.94 – 1.84 (m, 2H), 1.78 (q, J = 10.2 Hz, 1H), 1.65 (p, J = 9.3 Hz, 1H).

[0562] Step 3: 4-((5-chloro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-ylamino) benzenesulfonamide (150 mg, 0.341 mmol, 1 equiv) was separated by Prep-SFC (Column: CHIRALPAK IA, 5*25 cm, 5 μm; Mobile Phase A: Hex: DCM = 3: 1 (0.5% 2M NH3-MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL / min; Gradient: isocratic; Wavelength: 220 / 254 nm; RT1 (min): 20.403; RT2 (min): 26.003; Sample Solvent: EtOH--HPLC; Injection Volume: 8 mL; Number Of Runs: 20). The eluent of product was concentrated and dried by lyophilization to afford 4-((5-chloro-4-[(6S)-6- (hydroxymethyl)-5-oxa- 8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide (Compound 57, 54.4 mg, 38% yield) as a white solid.

[0563] LC-MS (ES, m / z): 440.11[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.86 (s, 1H), 8.18 (d, J = 1.5 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H), 7.17 (s, 2H), 4.86 (t, J = 5.6 Hz, 1H), 4.50 (dd, J = 13.0, 1.9 Hz, 1H), 4.29 (dt, J = 12.9, 2.3 Hz, 1H), 3.66 – 3.56 (m, 1H), 3.51 (dt, J = 10.2, 5.0 Hz, 1H), 3.41 (dt, J = 11.5, 6.1 Hz, 1H), 2.89 (d, J = 13.2 Hz, 1H), 2.80 (dd, J = 12.9, 10.5 Hz, 1H), 2.19 – 1.72 (m, 5H), 1.64 (q, J = 9.5 Hz, 1H).

[0564] And 4-((5-chloro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-ylamino)benzenesulfonamide (Compound 58, 51 mg, 33% yield) as a white solid.

[0565] LC-MS: (ES, m / z):440.10[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.86 (s, 1H), 8.19 (s, 1H), 7.89 – 7.81 (m, 2H), 7.74 – 7.67 (m, 2H), 7.17 (s, 2H), 4.85 (t, J = 5.6 Hz, 1H), 4.50 (dd, J = 12.8, 1.9 Hz, 1H), 4.29 (d, J = 12.9 Hz, 1H), 3.51 (dt, J = 10.1, 4.9 Hz, 1H), 3.41 (dt, J = 11.5, 6.1 Hz, 1H), 2.89 (dd, J = 12.9, 1.8 Hz, 1H), 2.80 (dd, J = 13.0, 10.6 Hz, 1H), 2.13 (s, 1H), 2.10 – 1.93 (m, 2H), 1.93 – 1.84 (m, 1H), 1.79 (t, J = 10.7 Hz, 1H), 1.64 (q, J = 9.6 Hz, 1H).

[0566] Example 51

[0567] Compound 59 / 60 / 61: Synthesis of 4-((5-fluoro-4-[(6-(hydroxymethyl) -5-oxa-8- azaspiro [3.5] nonan-8-yl] pyrimidin-2-ylamino)benzenesulfonamide, 4-((5-fluoro-4-[(6S)-6- (hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide and 4-({5-fluoro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2- yl}amino) benzenesulfonamide according to Scheme 51.

[0568] Scheme 51:6-ylmethanol (500 mg, 3.180 mmol, 1.0 equiv) in EtOH (50 mL) was treated with Et3N (1609.2 mg, 15.900 mmol, 5.0 equiv) at room temperature under nitrogen, followed by the addition of 2,4- dichloro- 5-fluoropyrimidine (796.5 mg, 4.770 mmol, 1.5 equiv) at 0°C. The reaction was stirred for 2 h at 0-20°C under nitrogen atmosphere. The reaction was concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10mmol / L NH4HCO3), 10% to 100% gradient in 20 min; detector, UV 210 nm. This resulted in [8-(2-chloro-5-fluoropyrimidin-4-yl)-5-oxa-8- azaspiro[3.5]nonan-6-yl] methanol (300 mg, 33% yield) as a pale yellow oil.

[0570] Step 2 In a 60 mL vial a stirred solution of [8-(2-chloro-5-fluoropyrimidin-4-yl) - 5-oxa-8-azaspiro [3.5] nonan-6-yl] methanol (100 mg, 0.348 mmol, 1.0 equiv) and sulfanilamide (179.6 mg, 1.044 mmol, 3.0 equiv) in dioxane (10 mL) was added p-TsOH (478.8 mg, 2.784 mmol, 8.0 equiv) at room temperature under nitrogen. The reaction was stirred for 16 h at 100°C under nitrogen then cooled, filtered and the filter cake washed with acetonitrile (3x30 mL). The filtrate was concentrated and the residue purified via reverse-phase flash chromatography under thefollowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 5% to 30% gradient in 20 min; detector, UV 210 nm. This provided 4-((5-fluoro-4-[(6-(hydroxymethyl) -5-oxa-8-azaspiro [3.5] nonan -8-yl] pyrimidi n-2-ylamino) benzenesulfonamide (Compound 59, 30 mg, 20% yield) as a white solid.

[0571] LC-MS (ES, m / z): 424.14[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.71 – 9.66 (m, 1H), 8.10 (dd, J = 7.0, 1.8 Hz, 1H), 7.85 – 7.79 (m, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.15 (s, 2H), 4.43 (dd, J = 19.1, 13.2 Hz, 2H), 3.53 (ddd, J = 24.7, 11.0, 6.0 Hz, 2H), 3.39 (dd, J = 11.0, 6.4 Hz, 1H), 3.00 (d, J = 13.0 Hz, 1H), 2.88 (dd, J = 13.0, 10.7 Hz, 1H), 2.11 – 1.99 (m, 4H), 1.99 – 1.82 (m, 1H), 1.80 (d, J = 10.5 Hz, 1H), 1.65 (p, J = 9.1 Hz, 1H);19F-NMR (376 MHz, DMSO- d6, ppm): δ -156.43.

[0572] Step 3: 4-((5-fluoro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-ylamino)benzenesulfonamide (100 mg, 0.236 mmol, 1.0 equiv) was separated by Prep-SFC (Column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 μm; Mobile Phase A: MtBE (0.5% 2M NH3-MeOH)--HPLC, Mobile Phase B: EtOH; Gradient: isocratic 5; Wavelength: 220 / 254 nm; RT1 (min): 7; RT2 (min): 7.88; Sample Solvent: EtOH; Injection Volume: 0.4 mL; Number Of Runs: 50). The eluent was concentrated and dried by lyophilization to afford 4-((5-fluoro-4-[(6S)- 6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide (Compound 60, 17.8 mg, 17% yield) as a white solid.

[0573] LC-MS (ES, m / z): 424.20[M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.64 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.83 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 8.6 Hz, 2H), 7.14 (s, 2H), 5.00 – 4.70 (m, 1H), 4.43 (t, J = 13.6 Hz, 2H), 3.63 – 3.42 (m, 3H), 3.06 – 2.79 (m, 2H), 1.98 (dq, J = 19.7, 10.0 Hz, 4H), 1.81 – 1.59 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.6.

[0574] And 4-({5-fluoro-4-[(6R)-6-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl} amino)benzenesulfonamide (Compound 61, 23.5 mg, 23% yield) as a white solid. LC-MS (ES, m / z): 424.15[M+H]+:1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.64 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.6 Hz, 2H), 7.14 (s, 2H), 4.43 (t, J = 13.5 Hz, 2H), 3.56-3.41(m, 4H), 2.99 (d, J = 13.1 Hz, 1H), 2.87 (t, J = 11.9 Hz, 1H), 1.98 (dq, J = 19.7, 10.1 Hz, 4H), 1.82 (t, J = 12.0 Hz, 1H), 1.64 (q, J = 9.1 Hz, 1H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.5.

[0575] Example 52

[0576] Compound 62: Synthesis of (4-[(5-fluoro-4-(1-oxa-4-azaspiro[5.5]undecan- 4- ylpyrimidin-2-yl)amino]phenyl(imino)methyl-λ6-sulfanone according to Scheme 52.

[0577] Scheme 52:

[0578] Step 1: To a 20 mL vial was added a solution of 1-oxa-4-azaspiro[5.5]undecane (400 mg, 2.577 mmol, 1.0 equiv) and 2,4-dichloro-5-fluoropyrimidine (430.2 mg, 2.577 mmol, 1.0 equiv) in THF (8 mL). TEA (782.2 mg, 7.731 mmol, 3.0 equiv) was added dropwise at 0oC under nitrogen and the reaction stirred for 2 h at 25°C under nitrogen then concentrated and the residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% NH4HCO3), 45% to 75% gradient in 30 min; detector, UV 254 / 210 nm to afford 4-(2-chloro-5-fluoropyrimidin-4-yl)-1-oxa-4- azaspiro[5.5]undecane (534 mg, 71% yield) as a white solid.

[0579] Step 2: To a 20 mL vial was added a solution of 4-(2-chloro-5-fluoropyrimidin-4- yl)-1-oxa-4-azaspiro[5.5] undecane (200 mg, 0.700 mmol, 1.0 equiv) and (4- aminophenyl)(imino)methyl-λ6-sulfanone (143 mg, 0.840 mmol, 1.2 equiv) in dioxane (40 mL). Cs2CO3 (456.4 mg, 1.400 mmol, 2.0 equiv), XPhos (66.7 mg, 0.140 mmol, 0.2 equiv) and Pd(OAc)2 (15.7 mg, 0.070 mmol, 0.1 equiv) were added at 25°C under nitrogen. The reaction was stirred for 1 h at 100°C under nitrogen then cooled, concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: column, XB-C18 silica gel; mobile phase, MeCN in Water (0.1N NH4HCO3, 30% to 60% yield) gradient in 30 min; detector, UV 254 / 210 nm to afford (4-[(5-fluoro-4-(1-oxa-4-azaspiro[5.5]undecan- 4- ylpyrimidin-2- yl)amino]phenyl(imino)methyl-λ6-sulfanone (Compound 62, 99.5 mg, 32% yield) as a white solid.

[0580] LC-MS (ES, m / z): 420 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.07 (d, J = 6.7 Hz, 1H), 7.91 – 7.74 (m, 4H), 3.96 (s, 1H), 3.80 – 3.65 (m, 4H), 3.59 (s, 2H),3.01 (s, 3H), 1.70 (d, J = 11.8 Hz, 2H), 1.57 – 1.22 (m, 8H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.3.

[0581] Example 53

[0582] Compound 63: Synthesis of (S)-4-((5-chloro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)-N-ethylbenzenesulfonamide according to Scheme 53.

[0583] Scheme 53:

[0584] Step 1: In a 500 mL three-necked flask, DIEA (16.58 g, 128.3 mmol, 8 equiv) and DCM (60 mL) were added to the solution of (S)-6-methyl-4-oxa-7-azaspiro[2.5]octane (2.04 g, 16 mmol, 1 equiv) in water (100 mL) at 0°C. To the above mixture was added a solution of 2,4,5- trichloropyrimidine (2.33 g, 12.8 mmol, 0.8 equiv) in DCM dropwise over 1 min at 0°C. The reaction was stirred overnight at 25°C. The mixture was extracted with DCM (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified via column chromatography (PE / EA= 0~5% yield). This provided (S)-7-(2,5-dichloropyrimidin-4-yl)-6- methyl-4-oxa-7-azaspiro[2.5]octane (1.8 g, 41% yield) as a yellow oil.

[0585] Step 2: To an 8 ml vial was added a solution of (S)-7-(2,5-dichloropyrimidin-4-yl)- 6-methyl-4-oxa-7-azaspiro[2.5]octane (110 mg, 0.4 mmol, 1 equiv) and 4-amino-N- ethylbenzenesulfonamide (96.42 mg, 0.48 mmol, 1.2 equiv) in dioxane (3.3 mL) at room temperature. p-TsOH (345.47 mg, 2 mmol, 5 equiv) and 2 drops of H2O were added. The reaction was stirred overnight at 100°C then concentrated and the residue purified by prep-HPLC: XBridge Prep Shield RP18 OBD Column, 19*250 mm, 5μm; Mobile Phase A: Water (10mmol / L NH4HCO3), Mobile Phase B: ACN; Gradient: 5% B to 5% B in 2 min, 5% B to 38% B in 2.5 min, 38% B to 68% B in 10 min; Wavelength: 220 / 254 nm; RT1(min): 10.23. This provided (S)-4-((5- chloro-4-(6-methyl-4-oxa-7-azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)-N- ethylbenzenesulfonamide (Compound 63, 45 mg, 25% yield) as a white solid.

[0586] LC-MS (ES, m / z): 438.15[M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.83 (s, 1H), 8.16 (s, 1H), 7.83 (d, J = 8.9 Hz, 2H), 7.67 (d, J = 8.9 Hz, 2H), 7.32 (t, J = 5.7 Hz, 1H), 4.60 (d, J = 7.4 Hz, 1H), 3.88 – 3.74 (m, 2H), 3.66 (dd, J = 11.3, 1.6 Hz, 1H), 3.57 (d, J = 13.6 Hz, 1H), 2.83 – 2.68 (m, 2H), 1.35 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 0.90 – 0.78 (m, 1H), 0.75 – 0.67 (m, 1H), 0.67 – 0.57 (m, 2H).

[0587] Example 54

[0588] Compound 64: Synthesis of 4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8-azaspiro[3.5] nonan-8-yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide according to Scheme 54.

[0589] Scheme 54:

[0590] Step 1: To an 8 ml vial under nitrogen was added a solution of (7S)-8-(2,5- dichloropyrimidin-4-yl)-7-methyl-5-oxa-8-azaspiro [3.5] nonane (100 mg, 0.347 mmol, 1.0 equiv) and N1-methylsulfanilamide (77.6 mg, 0.416 mmol, 1.2 equiv) in dioxane (1 ml) at room temperature. TsOH (282.2 mg, 1.640 mmol, 5.0 equiv) was added. The mixture was stirred overnight at 100°C then cooled, concentrated and the residue purified via prep-HPLC under the following conditions: Column: XSelect Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 2 min, 5% B to 48% B in 0.2 min, 48% B to 51% B in 10 min; Wavelength: 220 nm; RT1(min): 10.8. This provided 4-({5-chloro-4-[(7S)-7-methyl-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide (Compound 64, 45 mg, 29% yield) as a white solid.

[0591] LC-MS (ES, m / z): 438.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.88 (s, 1H), 8.16 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.32 – 7.16 (m, 1H), 4.44 (d, J = 7.3 Hz, 1H), 4.31 (d, J = 13.5 Hz, 1H), 3.75 – 3.62 (m, 1H), 3.49 (d, J = 11.7 Hz, 1H), 3.18 (d, J = 13.5 Hz, 1H), 2.39 (d, J = 4.8 Hz, 3H), 2.21 – 2.11 (m, 1H), 2.10 – 1.89 (m, 3H), 1.76 – 1.64 (m, 2H), 1.30 (d, J = 6.6 Hz, 3H).

[0592] Example 55

[0593] Compound 65: Synthesis of (S)-N-ethyl-4-((5-fluoro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)benzenesulfonamide according to Scheme 55.

[0594] Scheme 55: solution of (6S)-7-(2-chloro-5-fluoropyrimidin-4-yl)-6-methyl-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.388 mmol, 1 equiv) and 4-amino-N- ethylbenzenesulfonamide (93.26 mg, 0.466 mmol, 1.2 equiv) in dioxane (3 mL) and H2O (0.3 mL) at room temperature. Cs2CO3(379.32 mg, 1.164 mmol, 3 equiv), DavePhos (30.54 mg, 0.078 mmol, 0.2 equiv) and Pd2(dba)3(35.54 mg, 0.039 mmol, 0.1 equiv) were added under nitrogen. The mixture was stirred for 2 h at 100°C then filtered, concentrated and purified via prep-HPLC: Column: Xselect CSH Prep C18 OBD Colum, 30*150nm, 5μm; Mobile Phase A: Water(10 mmol / L NH4HCO3+0.1%NH3.H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 5% B to 5% B in 1.5 min, 5% B to 45% B in 2 min, 45% B to 46% B in 10 min; Wavelength: 220nm / 254nm; RT1(min): 10. This provided (S)-N-ethyl-4-((5-fluoro-4-(6-methyl-4-oxa-7- azaspiro[2.5]octan-7-yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 65, 93 mg, 56% yield) as a white solid.

[0596] LC-MS (ES, m / z): 422.15 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.65 (s, 1H), 8.08 (d, J = 6.7 Hz, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.30 (s, 1H), 4.53 (d, J = 7.7 Hz, 1H), 3.83 (dd, J = 11.8, 3.6 Hz, 2H), 3.62 (dd, J = 49.4, 12.5 Hz, 2H), 2.74 (dp, J = 11.0, 3.7, 2.9 Hz, 2H), 1.35 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 0.92 – 0.80 (m, 1H), 0.78 – 0.63 (m, 2H), 0.63 – 0.45 (m, 1H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.867.

[0597] Example 56

[0598] Compound 66: Synthesis of 4-[(5-fluoro-4-(1-oxa-4-azaspiro[5.5]undecan-4- ylpyrimidin-2-yl)amino] benzenesulfonamide according to Scheme 56.

[0599] Scheme 56:

[0600] Step 1: To an 8 ml vial was added a solution of 4-(2-chloro-5-fluoropyrimidin-4- yl)-1-oxa-4-azaspiro[5.5] undecane (100 mg, 0.350 mmol, 1.0 equiv) and sulfanilamide (72.3 mg, 0.420 mmol, 1.2 equiv) in dioxane (2 mL). TsOH (361.6 mg, 2.100 mmol, 6.0 equiv) was added at 25°C under nitrogen. The reaction was stirred for 16 h at 100°C under nitrogen then cooled, concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: column, XB-C18 silica gel; mobile phase, MeCN in Water (0.1% NH4HCO3, 30% to 60% yield) gradient in 30 min; detector, UV 254 / 210 nm to afford 4-[(5-fluoro-4-(1-oxa-4- azaspiro[5.5]undecan-4-ylpyrimidin-2-yl)amino] benzenesulfonamide (Compound 66, 22.2 mg, 14% yield) as a white solid.

[0601] LC-MS (ES, m / z): 422 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm):δ 9.60 (s, 1H), 8.06 (d, J = 6.1 Hz, 1H), 7.75 (dd, J = 36.8, 7.1 Hz, 4H), 7.14 (s, 2H), 3.86 – 3.51 (m, 6H), 1.70 (s, 2H), 1.60 – 1.10 (m, 8H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.4.

[0602] Example 57

[0603] Compound 67: Synthesis of 4-({5-fluoro-4-[(7S)-7-methyl-5-oxa-8-azaspiro [3.5] nonan-8-yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide according to Scheme 57.

[0604] Scheme 57:n was added a solution of (7S)-8-(2-chloro- 5-fluoropyrimidin-4-yl)-7-methyl-5-oxa-8-azaspiro [3.5] nonane (70 mg, 0.258 mmol, 1.0 equiv) and 4-amino-N-methylbenzenesulfonamide (62.4 mg, 0.335 mmol, 1.3 equiv) in dioxane (1.4 mL). TsOH (323.7 mg, 1.290 mmol, 5.0 equiv) was added. The mixture was stirred overnight at 100°Cthen cooled, concentrated and the residue purified via reverse-phase flash chromatography under the following conditions: column, C18; column, C18; MeCN : H2O with 0.1% NH4HCO3, 20% to 60% gradient in 20 min; detector, UV 210 nm. RT1(min): 10. This afforded 4-({5-fluoro-4-[(7S)- 7-methyl-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)-N-methylbenzenesulfonamide (Compound 67, 25 mg, 22% yield) as a white solid.

[0606] LC-MS (ES, m / z): 422.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.71 (s, 1H), 8.10 (d, J = 6.9 Hz, 1H), 7.95 – 7.78 (m, 2H), 7.72 – 7.52 (m, 2H), 7.29 – 7.14 (m, 1H), 4.45 – 4.26 (m, 2H), 3.77 – 3.65 (m, 1H), 3.57 – 3.44 (m, 1H), 3.24 – 3.18 (m, 1H), 2.38 (d, J = 5.1 Hz, 3H), 2.13 – 2.03 (m, 2H), 2.03 – 1.87 (m, 2H), 1.87 – 1.72 (m, 1H), 1.73– 1.73 (m, 1H), 1.31 (d, J = 6.7 Hz, 3H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -157.12.

[0607] Example 58

[0608] Compound 68 / 69 / 70: Synthesis of 4-({5-fluoro-4-[6-(fluoromethyl)-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)benzenesulfonamide, 4-({5-fluoro-4-[(6S)-6- (fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)benzenesulfonamide and 4-({5-fluoro-4-[(6R)-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2- yl}amino)benzenesulfonamide according to Scheme 58.

[0609] Scheme 58:xa-8- azaspiro[3.5]nonan-6-yl}methanol (2 g, 8.09 mmol, 1.0 equiv) and DCM (60 mL) at room temperature. DAST (6.52 g, 40.4 mmol, 5.0 equiv) was added dropwise at 0°C. The reaction was stirred for an additional 16 h at 25°C then diluted with DCM (50 mL). The reaction was quenched by the addition of aqueous NaHCO3(100 mL) at 0°C and extracted with DCM (3 x 100 mL). Thecombined organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was dissolved in MeOH (30 mL) and purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in H2O (0.1 % NH4HCO3),50% to 80% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under vacuum. This resulted in 8-benzyl-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonane (1.2 g, 54% yield) as a yellow oil.

[0611] Step 2: Into a 100 mL round bottom flask was added a solution of 8-benzyl-6- (fluoromethyl)-5-oxa-8-azaspiro [3.5]nonane (1 g, 4.01 mmol, 1.0 equiv) in MeOH (50 mL) and Pd(OH)2(0.1 g,w / w=10% yield) added under nitrogen. The mixture was hydrogenated at room temperature for 3 h under a hydrogen atmosphere using a balloon. The reaction mixture was filtered through a Celite pad and acidified to pH 4 with 4M HCl in dioxane and concentrated under reduced pressure. The product, 6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonane, (50 mg) was used in the next step directly without further purification.

[0612] Step 3: To a 50 mL 3-necked round-bottom flask was added 6-(fluoromethyl)-5- oxa-8-azaspiro[3.5]nonane (500 mg, 2.20 mmol, 1.0 equiv, 70% yield) and EtOH (25 mL) at room temperature.2,4-dichloro-5-fluoropyrimidine (734 mg, 4.40 mmol, 2.0 equiv) was added and TEA (890 mg, 8.79 mmol, 4.0 equiv) added dropwise at 20°C. The reaction was stirred for additional 2 h at 20°C then concentrated under vacuum. The residue was dissolved in MeOH (10 mL) and purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in H2O (0.1 % NH4HCO3), 40% to 70% gradient in 30 min; detector, UV 210 nm. This resulted in 8-(2-chloro-5-fluoropyrimidin-4-yl)-6-(fluoromethyl)-5- oxa-8-azaspiro[3.5]nonane (50 mg, 8% yield) as a brown oil.

[0613] Step 4: Into a 8 mL 1-necked round-bottom flask was added 8-(2-chloro-5- fluoropyrimidin-4-yl)-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonane (50 mg, 0.173 mmol, 1.0 equiv) and dioxane (2.5 mL) at room temperature. To the above mixture was added Cs2CO3(169 mg, 0.519 mmol, 3.0 equiv), Pd(OAc)2 (3.9 mg, 0.017 mmol, 0.1 equiv), sulfanilamide (32.7 mg, 0.190 mmol, 1.1 equiv) and X-Phos (16.5 mg, 0.035 mmol, 0.2 equiv). The reaction was stirred for 16 h at 100°C under N2atmosphere. The mixture was allowed to cool to room temperature then filtered, with the filter cake being washed with dioxane (3 x 3 mL). The filtrate was concentrated under reduced pressure and dissolved in MeOH (5 mL). The residue was purified via reverse-phaseflash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in H2O (0.1 % NH4HCO3), 20% to 50% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under reduced pressure. This resulted in 4-({5-fluoro-4-[(6R)-6- (fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-yl}amino)benzenesulfonamide (Compound 68, 6.6 mg, 9% yield) as a white solid.

[0614] LC-MS (ES, m / z): 426.05 [M+H]+;1H-NMR- (400 MHz, DMSO-d6, ppm) δ 9.67 (s, 1H), 8.12 (d, J = 6.5 Hz, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.13 (s, 2H), 4.57 (d, J = 4.0 Hz, 1H), 4.49 – 4.40 (m, 2H), 4.31 (dd, J = 13.2, 2.5 Hz, 1H), 3.84 (ddq, J = 21.4, 10.6, 3.7 Hz, 1H), 3.07 – 2.96 (m, 2H), 2.13 – 1.89 (m, 4H), 1.81 (qq, J = 10.1, 3.3 Hz, 1H), 1.67 (dq, J = 10.8, 8.7 Hz, 1H);19F-NMR (376 MHz, DMSO-d6, ppm) δ -156.47.

[0615] Step 5: 4-({5-fluoro-4-[(6R)-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl}amino)benzenesulfonamide (50 mg, 0.118 mmol, 1 equiv) was purified by prep- HPLC under the following conditions, Column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 μm; Mobile Phase A: Hex(0.5% 2M NH3-MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL / min; Gradient: isocratic 30; Wavelength: 220 / 254 nm; RT1(min): 12.213; RT2(min): 14.071; Sample Solvent: EtOH; Injection Volume: 0.5 mL; Number Of Runs: 10 to afford 4-({5- fluoro-4-[(6S)-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2- yl}amino)benzenesulfonamide (Compound 69, 14.1 mg, 56% yield) as a white solid.

[0616] LC-MS (ES, m / z): 442.00 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.69 (s, 1H), 8.12 (d, J = 6.5 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.17 (s, 2H), 4.57 (d, J = 4.0 Hz, 1H), 4.48 – 4.40 (m, 2H), 4.31 (dd, J = 13.3, 2.4 Hz, 1H), 3.84 (ddt, J = 21.6, 11.0, 3.2 Hz, 1H), 3.05 – 2.95 (m, 2H), 2.14 – 1.88 (m, 4H), 1.82 (tq, J = 9.9, 6.8, 4.8 Hz, 1H), 1.66 (dt, J = 10.8, 8.6 Hz, 1H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -73.4,-155.4.

[0617] And 4-({5-fluoro-4-[(6R)-6-(fluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-yl}amino)benzenesulfonamide (Compound 70, 13.6 mg, 54% yield) as a white solid.

[0618] LC-MS (ES, m / z): 426.05 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm): δ 9.69 (s, 1H), 8.12 (d, J = 6.5 Hz, 1H), 7.83 (d, J = 8.9 Hz, 2H), 7.73 – 7.67 (m, 2H), 7.17 (s, 2H), 4.57 (d, J = 4.0 Hz, 1H), 4.48 – 4.40 (m, 2H), 4.31 (dt, J = 12.9, 2.2 Hz, 1H), 3.83 (ddq, J = 21.7, 10.8, 3.7 Hz, 1H), 3.05 – 2.95 (m, 2H), 2.15 – 1.88 (m, 4H), 1.82 (ddt, J = 12.9, 9.8, 4.8 Hz, 1H), 1.66 (dp, J = 11.1, 8.9 Hz, 1H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -73.4, -156.4.

[0619] Example 59

[0620] Compound 71: Synthesis of 4-[(5-chloro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide according to Scheme 59.

[0621] Scheme 59:

[0622] Step 1: To a 250 mL 3-neck flask was placed a solution of 4-nitrobenzenesulfonyl chloride (5 g, 226 mmol, 1.0 equiv) in DCM (100 mL) then 2-methoxy-ethanamine (1.69 g, 22.6 mmol, 1.0 equiv) was added in portions at room temperature. The reaction was stirred for 4 h at 25°C under a nitrogen atmosphere then concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in 0.1% NH4HCO3Water, 30% to 60% gradient in 30 min; detector, UV 210 nm. This resulted in N-(2-methoxyethyl)-4-nitrobenzenesulfonamide (3 g, 49% yield) as a white solid.

[0623] Step 2: Into a 100 mL flask was placed a solution of N-(2-methoxyethyl)-4- nitrobenzenesulfonamide (2.1 g, 7.61 mmol, 1.0 equiv, 94.3% yield) in MeOH (63 mL), then Pd / C (0.63 g, w / w=30% yield) was added under a nitrogen atmosphere. The mixture was hydrogenated at room temperature for 3 h then filtered through a Celite pad and concentrated under reduced pressure. This resulted in 4-amino-N-(2-methoxyethyl)benzenesulfonamide (1.6 g, 86% yield) as a yellow oil.

[0624] Step 3: To a 20 mL vial was added a solution of 7-(2,5-dichloropyrimidin-4-yl)-4- oxa-7-azaspiro[2.5]octane (100 mg, 0.384 mmol, 1.0 equiv) in 1,4-dioxane (5 mL). Then 4-amino-N-(2-methoxyethyl)benzenesul-fonamide (97.4 mg, 0.422 mmol, 1.1 equiv), Cs2CO3 (251 mg, 0.768 mmol, 2.0 equiv), X-Phos (36.6 mg, 0.077 mmol, 0.2 equiv) and Pd(OAc)2 (8.6 mg, 0.038 mmol, 0.1 equiv) were added at room temperature under nitrogen. The reaction was stirred for 12 h at 100°C then cooled and concentrated under reduced pressure. The residue was purified via reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, ACN in 0.1% NH4HCO3Water, 30% to 60% gradient in 30 min; detector, UV 210 nm. The reaction was concentrated under reduced pressure. This resulted in4-[(5-chloro-4-{4-oxa- 7-azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide (Compound 71, 5.9 mg, 3% yield) as a white solid.

[0625] LC-MS (ES, m / z): 454.15 [M+H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.90 (s, 1H), 8.19 (s, 1H), 7.86 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.49 (t, J = 6.1 Hz, 1H), 3.81 (t, J = 4.7 Hz, 2H), 3.74 (d, J = 4.8 Hz, 2H), 3.67 (s, 2H), 3.30 (t, J = 5.8 Hz, 2H), 3.17 (s, 3H), 2.87 (q, J = 5.8 Hz, 2H), 0.73 (d, J = 5.0 Hz, 2H), 0.67 (d, J = 5.0 Hz, 2H).

[0626] Example 60

[0627] Compound 72 / 73 / 74: Synthesis of 4-((5-chloro-4-[6-(methoxymethyl)-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide, 4-((5-chloro-4-[(6S)-6- (methoxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzene-sulfonamide and 4-((5-chloro-4-[(6R)-6-(methoxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2- ylamino)benzenesulfonamide according to Scheme 60.

[0628] Scheme 60:xa-8- azaspiro[3.5]nonane (250 mg, 1.46 mmol, 1.0 equiv) and 2,4,5-trichloropyrimidine (536 mg, 2.92mmol, 2.0 equiv) in EtOH (7.5 mL). Then TEA (0.59 g, 5.84 mmol, 4.0 equiv) was added at room temperature. The reaction was stirred for 16 h at 15°C under nitrogen then concentrated under reduced pressure. The residue was purified by prep-HPLC with the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (0.1% NH4HCO3), 40% to 80% gradient in 30 min; detector, UV 210 nm) to afford 8-(2,5-dichloropyrimidin-4-yl)-6-(methoxymethyl)-5-oxa-8- azaspiro[3.5]nonane (330 mg, 69% yield) as a light yellow oil.

[0630] Step 2: To a 20 mL vial was added a solution of 8-(2,5-dichloropyrimidin-4-yl)-6- (methoxymethyl)-5-oxa- 8-azaspiro[3.5]nonane (100 mg, 0.314 mmol, 1 equiv) and sulfanilamide (271 mg, 1.57 mmol, 5.0 equiv) in 1,4-dioxane (10 mL). Then p-toluenesulfonic acid (433 mg, 2.51 mmol, 8.0 equiv) was added at room temperature. The reaction was stirred for 24 h at 100°C under nitrogen then cooled, filtered, and the filter cake was washed with acetonitrile (3 x 3 mL). The filtrate was concentrated under reduced pressure and purified via prep-HPLC under the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L HCOOH), 30% to 70% gradient in 40 min; detector, UV 210 nm) to afford 4-((5-chloro-4-[(6R)- 6-(methoxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide (Compound 72, 37 mg, 25% yield) as a white solid.

[0631] LC-MS (ES, m / z): 454 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.87 (s, 1H), 8.19 (s, 1H), 7.91 – 7.79 (m, 2H), 7.76 – 7.67 (m, 2H), 7.17 (s, 2H), 4.49 (d, J = 13.0 Hz, 1H), 4.20 (d, J = 12.9 Hz, 1H), 3.76 (d, J = 9.3 Hz, 1H), 3.50 – 3.36 (m, 2H), 3.24 (s, 3H), 2.94 – 2.76 (m, 2H), 2.22 – 2.05 (m, 1H), 2.04 – 1.94 (m, 2H), 1.87 (d, J = 10.2 Hz, 1H), 1.78 (d, J = 9.8 Hz, 1H), 1.63 (q, J = 10.3, 9.8 Hz, 1H).

[0632] Step 3: 70 mg of 4-((5-chloro-4-[(6R)-6-(methoxymethyl)-5-oxa-8- azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino)benzenesulfonamide was separated via prep-SFC chromatography under the following conditions (Column: CHIRALPAK IJ, 4.6*150 mm, 5um; Mobile Phase A: Hex(0.5% 2M NH3-MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 20 mL / min; Gradient: isocratic 30; Wavelength: 220 / 254 nm; RT1 (min): 14.741; RT2 (min): 19.367; Sample Solvent: EtOH--HPLC; Injection Volume: 0.5 mL; Number Of Runs: 14) to afford 4-((5-chloro-4-[(6R)-6-(methoxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]pyrimidin-2-ylamino) benzenesulfonamide (Compound 73, 23 mg, 8% yield) as a white solid.

[0633] LC-MS (ES, m / z): 454 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.88 (s, 1H), 8.20 (s, 1H), 7.89 – 7.79 (m, 2H), 7.75 – 7.65 (m, 2H), 7.19 (s, 2H), 4.49 (dd, J = 13.1, 1.9Hz, 1H), 4.20 (d, J = 13.0 Hz, 1H), 3.75 (ddd, J = 10.4, 5.2, 2.5 Hz, 1H), 3.51 – 3.37 (m, 2H), 3.35 (s, 3H), 2.94 – 2.76 (m, 2H), 2.20 – 1.56 (m, 6H).

[0634] And 4-((5-chloro-4-[(6S)-6-(methoxymethyl)-5-oxa-8-azaspiro[3.5]nonan-8- yl]pyrimidin-2-ylamino)benzenesulfonamide (Compound 74, 18 mg, 6% yield) as a white solid.

[0635] LC-MS (ES, m / z): 454 [M+H]+;1H-NMR (300 MHz, DMSO-d6, ppm) δ 9.88 (s, 1H), 8.20 (s, 1H), 7.88 – 7.80 (m, 2H), 7.74 – 7.65 (m, 2H), 7.19 (s, 2H), 4.49 (dd, J = 13.0, 1.8 Hz, 1H), 4.20 (dd, J = 12.6, 2.3 Hz, 1H), 3.75 (ddd, J = 10.7, 5.2, 2.4 Hz, 1H), 3.50 – 3.36 (m, 2H), 3.36 (s, 3H), 2.85 (td, J = 13.3, 11.3 Hz, 2H), 2.18 – 1.57 (m, 6H).

[0636] Example 61

[0637] Compound 75: Synthesis of 4-[(5-fluoro-4-{4-oxa-7-azaspiro[2.5]octan-7- yl}pyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide according to Scheme 61.

[0638] Scheme 61:

[0639] Step 1: To a 40 mL vial under nitrogen was added a solution of 7-(2-chloro-5- fluoropyrimidin-4-yl)-4-oxa-7-azaspiro[2.5]octane (100 mg, 0.41 mmol, 1.0 equiv) in 1,4-dioxane (5 mL) at room temperature. 4-amino-N-(2-methoxyethyl) benzenesulfonamide (94.5 mg, 0.41 mmol, 1.0 equiv), Pd(OAc)2 (9.2 mg, 0.041 mmol, 0.1 equiv), X-Phos (39.1 mg, 0.082 mmol, 0.2 equiv) and Cs2CO3(267 mg, 0.82 mmol, 2.0 equiv) was added under nitrogen. The mixture was stirred for 16 h at 110°C, cooled to room temperature, concentrated and purified via reverse phase flash chromatography under the following conditions: Column, Ultimate XB-C18 Column, 50*250 mm, 10 µm; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 40% to 70% gradient in 30 min; detector, UV 210 / 254 nm. The eluent of product was concentrated and freeze dried to afford 4-[(5-fluoro-4-{4-oxa-7-azaspiro[2.5]octan-7-yl}pyrimidin-2-yl)amino]-N-(2- methoxyethyl)benzenesulfonamide (Compound 75, 9.9 mg, 5% yield) as a white solid.

[0640] LC-MS (ES, m / z):436 [M-H]+;1H-NMR (400 MHz, DMSO-d6, ppm) δ 9.67 (s, 1H), 8.09 (d, J = 6.5 Hz, 1H), 7.86 – 7.79 (m, 2H), 7.70 – 7.61 (m, 2H), 3.81 – 3.75 (m, 4H), 3.70 (s,2H), 3.29 (t, J = 5.9 Hz, 3H), 3.17 (s, 3H), 2.86 (t, J = 5.9 Hz, 2H), 0.74 (d, J = 5.3 Hz, 2H), 0.71 – 0.60 (m, 2H);19F-NMR (376 MHz, DMSO-d6, ppm): δ -156.021.

[0641] Example 62

[0642] Compound 76 / 77: Synthesis of 4-({4-[6-(difluoromethyl)-5-oxa-8- azaspiro[3.5]nonan-8-yl]-5-fluoropyrimidin-2-yl}amino)benzenesulfonamide and 4-({4-[(6R)-6- (difluoromethyl)-5-oxa-8-azaspiro[3.5]nonan-8-yl]-5-fluoropyrimidin-2- yl}amino)benzenesulfonamide according to Scheme 62.

[0643] Scheme 62:

[0644] Step 1: To a 250 mL 3-necked round-bottom flask under nitrogen was added a solution of (COCl)2(0.87 g, 6.82 mmol, 1.5 equiv) in DCM (13 mL) at -78°C. The mixture was stirred for 20 min at -78°C then DMSO (0.64 g, 8.185 mmol, 1.8 equiv) in DCM (13 mL) was added. The reaction mixture was stirred for a further 30 min then tert-butyl 6-(hydroxymethyl)-5- oxa-8-azaspiro[3.5]...

Claims

WHAT IS CLAIMED IS:

1. A compound having a structure according to Formula (I): ), hereof, wherein:X is O or NH; A is an optionally substituted heterocycle or bicyclic heterocycle selected from the group consisting of ;, provided that at least one of Q1, Q2 and Q3 is N; R1 is selected from the group consisting of a halogen, cyano, and C1-C6 alkyl; R2is selected from the group consisting of -NH2, -NHR3, -NR3R4, and C1-C6alkyl, R3 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, wherein the C1-C6 alkyl, C3-C7 cycloalkyl, and C3-C7 heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6alkyl), -NH2, - NH(C1-C6alkyl), and -NH(C1-C6alkyl)2; R4 is selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, heterocycloalkyl, and combinations thereof, wherein the C1-C6alkyl, C3-C7cycloalkyl, and C3-C7heterocycloalkyl is optionally substituted with one or more of deuterium, halogen, -OH, -O(C1-C6alkyl) -NH2, - NH(C1-C6 alkyl), and -NH(C1-C6 alkyl)2; R5 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, or two R5groups are combined to form one or more of =O, a spiro and a bridged C3-C7cycloalkyl,which C1-C6 alkyl and C3-C7 cycloalkyl is optionally substituted with one or more of halogen, - OH, and -O(C1-C6 alkyl); and R6is selected from the group consisting of hydrogen, C1-C6alkyl, and -C(O)C1-C6alkyl.

2. The compound of claim 1, wherein X is O.

3. The compound of claim 1, wherein X is NH.

4. The compound of any one of claims 1-3, wherein R1is a halogen.

5. The compound of any one of claims 1-3, wherein R1is cyano.

6. The compound of any one of claims 1-3, wherein R1 is C1-C6 alkyl.

7. The compound of claim 1, wherein R1is selected from -F, -Cl, cyano and -CH3.

8. The compound of any one of claims 1-7, wherein R2is C1-C6alkyl.

9. The compound of claim 8, wherein R2 is -CH3.

10. The compound of any one of claims 1-7, wherein R2 is -NH2.

11. The compound of any one of claims 1-7, wherein R2is -NHR3.

12. The compound of claim 1 or claim 11, wherein R3 is C1-C6 alkyl.

13. The compound of any one of claim 1 or claims 11-12, wherein R3 is -CH3.

14. The compound of any one of claim 1 or claims 11-12, wherein R3is -CD3.

15. The compound of any one of claim 1 or claims 11-12, wherein R3is an optionally substituted -C2 alkyl.

16. The compound of any one of claims 1, 11-12, or 15 wherein R3is selected from . 17.rein R3 is an optionally substituted C3-C4 alkyl.

18. The compound of any one of claims 1, 11-12, or 17 wherein R3is selected from propyl, isopropyl, butyl, isobutyl, tert-butyl .

19. The compound of claim 1 or claim, l.

20. The compound of any one of claims 1, 11 or 18, wherein R3is cyclopropyl or cyclobutyl.

21. The compound of claim 1 or claim 11, wherein R3 is C3-C7 heterocycloalkyl.

22. The compound of claim 1 or claim 11, wherein R3 is a combination of C1-C6 alkyl and C3-C7 heterocycloalkyl.

23. The compound of claim 1, 11 or 22, wherein R3is a combination of C1-C3alkyl and azetidinyl.

24. The compound of claim 1, 11, 22, or 23, wherein R3 is selected from the group consisting .

25. ein R3is tetrahydrofuranyl.

26. The compound of any one of claims 1-25, wherei .

27. The compound of any one of claims 1-26, wherei28. The compound of any one of claims 1-26, wherein A is selected from the group consisting .

29. The compependently at each occurrence selected from methyl, ethyl, -CH2F, -CHF2, -CH2OH, and -CH2OCH3.

30. The compound of any one of claims 1-26 and 28, wherein two R5groups combine to make a spiro-C3-C7cycloalkyl selected from the group consisting of a spiro-cyclopropyl, a spiro-cyclobutyl, a spiro-cyclopentyl, or a spiro-cyclohexyl, or a bridge-C3-C7 cycloalkyl.

31. The compound of any one of claims 1-26 and 28, wherein A is selected from the group ,32. The compound of any one of claims 1-25, wherein33. The compound of any one of claims 1-25 or 32, wherein34. The compound of any one of claims 1-25, 32, or 33, wherein35. The compound of any one of claims 1-25 or 32, wherein36. The compound of any one of claims 1-25 or 32, wherein37. The compound of any one of claims 1-25, 35, or 36, wherein A is selected from the group38.,39. The compound of any one of claims 1-25 or 38, wherein A is selected from the group consisting40. The compound of any one of claims 1-25, wherein41. The compound of claim 40, wherein Qi is N.

42. The compound of claim 40 or 41, wherein Q2 is O.

43. The compound of claim 40 or 41, wherein Q2 is CH.

44. The compound of any one of claims 40-43, wherein Q3 is N.

45. The compound of any one of claims 40-43, wherein Q3 is C.

46. The compound of any one of claims 1-25 or 40, wherein47. The compound of any one of claims 1-25 or 40-46, wherein A is selected from the group48. The compound of any one of claims 1-25, wherein49. The compound of claim 48, wherein Qi is N.

50. The compound of claim 48, wherein Qi is CH.

51. The compound of any one of claims 48-50, wherein Q2 is N.

52. The compound of any one of claims 48-50, wherein Q2 is CH.

53. The compound of any one of claims 48-52, wherein Q3 is N.

54. The compound of any one of claims 1-25 or 48-53, wherein55. The compound of any one of claims 1-25 or 48-54, wherein A is selected from the group56. The compound of claim 1 having a structure according to Formula (II):or a pharmaceutically acceptable salt thereof.

57. The compound of claim 48 having a structure according to Formula (IIA):or a pharmaceutically acceptable salt thereof.

58. The compound of claim 48 having a structure according to Formula (IIB):or a pharmaceutically acceptable salt thereof.

59. The compound of claim 48 having a structure according to Formula (IIB):or a pharmaceutically acceptable salt thereof.

60. The compound of claim 1 having a structure according to Formula (III):or a pharmaceutically acceptable salt thereof.

61. The compound of claim 60 having a structure according to Formula (IIIA):or a pharmaceutically acceptable salt thereof.

62. The compound of claim 60 having a structure according to Formula (IIIB):or a pharmaceutically acceptable salt thereof.

63. The compound of claim 62 having a structure selected from the group consisting of:or a pharmaceutically acceptable salt thereof.

64. The compound of claim 60 having a structure according to Formula (IIIC):or a pharmaceutically acceptable salt thereof.

65. The compound of claim 1 having a structure according to Formula (IV):or a pharmaceutically acceptable salt thereof.

66. The compound of claim 1 having the structure as shown in Table 1, or a pharmaceutically acceptable salt thereof.

67. A pharmaceutical composition comprising the compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

68. A pharmaceutical dosage form comprising the compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67.

69. A method of targeting cyclin-dependent kinase 2 (CDK2) in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67, or the pharmaceutical dosage form of claim 68.

70. The method of claim 69, wherein the cell is a mammalian cell.

71. The method of claim 69 or claim 70, wherein the cell is a tumor cell.

72. The method of claim 71, wherein the tumor cell is a metastatic tumor cell.

73. A method of inhibiting CDK2 comprising contacting the CDK2 with an effective amount of the compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67, or the pharmaceutical dosage form of claim 68.

74. The method of any one of claims 69-73, wherein the contacting is in a subject.

75. A method of treating a subject having, or at risk of developing, a disease or disorder associated with CDK2, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67, or the pharmaceutical dosage form of claim 68.

76. A method of treating a CDK2-mediated disorder or disease in a subject, the method comprising administering a therapeutically effective amount of a compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67, or the pharmaceutical dosage form of claim 68.

77. The method of claim 75 or claim 76, wherein the disorder is cancer.

78. The method of claim 77, wherein the cancer is selected from the group consisting of adrenal gland cancer, anal cancer, appendiceal cancer, ovarian cancer, uterine cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, cervical cancer, stomach cancer, sarcoma cancer, liver cancer, esophageal cancer, laryngeal cancer, multiple myeloma, colorectal cancer, rectal cancer, skin cancer, pancreatic cancer, brain or spinal cord cancer, leukemia or lymphoma.

79. The method of any one of claims 69-78, wherein the compound is at least two-fold more selective for CDK2 over CDK1, CDK 5, CDK 6, CDK7, and / or CDK9.

80. A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 67, or the pharmaceutical dosage form of claim 68.

81. The method of claim 80, wherein the cancer is characterized by a genomic alteration.

82. The method of claim 80, wherein the cancer is characterized by overexpression of cyclin E1 and / or cyclin E2.

83. The method of claim 81, wherein the genomic alteration is characterized by one or more of amplification of CCNE1 and / or CCNE2, RB1 loss of function mutation, FBXW7 loss of function mutation, MYC amplification, or KRAS mutation.

84. The method of claim 82, wherein the overexpression of cyclin E1 and / or cyclin E2 is the overexpression of RNA and / or protein encoded by CCNE1 and / or CCNE2.

85. The method of claim 82, wherein greater than two copies of CCNE1 and / or CCNE2 are present.

86. The method of claim 83, wherein the RB1 loss of function mutation comprises function- disabling point mutations in the RB1 gene, RB1 gene deletion, and / or epigenetic repression of RB1 transcription.

87. The method of claim 83, wherein the MYC is selected from c-MYC, L-MYC and N- MYC.

88. The method of any one of claims 77-87, wherein the cancer is metastatic cancer.

89. The method of claim 88, wherein the cancer is characterized by metastasis to the brain.

90. The method of claim 80, wherein the cancer selected from the group consisting of adrenal gland cancer, anal cancer, appendiceal cancer, ovarian cancer, uterine cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, cervical cancer, stomach cancer, sarcoma cancer, liver cancer, esophageal cancer, laryngeal cancer, multiple myeloma, colorectal cancer, rectal cancer, skin cancer, pancreatic cancer, brain or spinal cord cancer, leukemia or lymphoma.

91. The method of claim 78 or claim 90, wherein the adrenal gland cancer is adrenocortical carcinoma or pheochromocytoma.

92. The method of claim 78 or claim 90, wherein the breast cancer is HR-positive, HER2- negative breast cancer; HR-positive, HER2- positive breast cancer; triple negative breast cancer (TNBC); or inflammatory breast cancer.

93. The method of claim 78 or claim 90, wherein the breast cancer is drug-naive breast cancer, endocrine resistant breast cancer, trastuzumab resistant breast cancer, breast cancer demonstrating primary or acquired resistance to CDK4 / CDK6 inhibition, platinum-resistant breast cancer or platinum-refractory breast cancer.

94. The method of claim 78 or claim 90, wherein the breast cancer is advanced or metastatic breast cancer.

95. The method of claim 78 or claim 90, wherein the liver cancer is hepatocellular carcinoma.

96. The method of claim 78 or claim 90, wherein the lung cancer is small cell lung cancer, non-small cell lung cancer, or large cell lung cancer.

97. The method of claim 96, wherein the non-small cell lung cancer is squamous cell carcinoma or adenocarcinoma.

98. The method of claim 78 or claim 90, wherein the laryngeal cancer is laryngeal squamous cell carcinoma.

99. The method of claim 78 or claim 90, wherein the skin cancer is melanoma, basal cell carcinoma, squamous cell carcinoma, or Merkel cell cancer.

100. The method of claim 78 or claim 90, wherein the uterine cancer is endometrial cancer or uterine sarcoma.

101. The method of claim 100, wherein the endometrial cancer is platinum-resistant or platinum-refractory endometrial cancer.

102. The method of claim 78 or claim 90, wherein the ovarian cancer is platinum- resistant or platinum-refractory ovarian cancer.

103. The method of claim 78 or claim 90, wherein the brain cancer is selected from glioma, astrocytoma, meningioma, glioblastoma multiforme, medulloblastoma, ependymoma, oligodendroglioma, craniopharyngioma, pituitary adenoma, Schwannoma, anaplastic astrocytoma, germ cell tumor, primitive neuroectodermal tumor, chordoma, haemangioblastoma, optic nerve glioma, subependymoma, and germinoma.

104. The method of any one of claims 74-103, wherein the subject is a human.

105. The method of claim 104, wherein the subject is an adult.

106. The method of claim 104, wherein the subject is pediatric subject 0 to 18 years of age.

107. The method of any one of claims 74-106, wherein the compound, the pharmaceutical composition, or the pharmaceutical dosage form is administered orally, intravenously, or subcutaneously.

108. The method of any one of claims 69-107, wherein the method further comprises administering an effective amount of a second therapeutic agent.

109. The method of claim 108, wherein the second therapeutic agent is an anti- neoplastic agent.

110. The method of claim 109, wherein the anti -neoplastic agent is selected from the group consisting of an antibody, an antibody-drug conjugate, a DNA synthesis inhibitor, a platinum-based agent, topoisomerase I inhibitor, topoisomerase II inhibitor, an alkylating agent, an anti -microtubule agent, an anti-mitotic agent, a taxane-related anti- neoplastic agent, an anti-metabolite, an anti-tumor plant alkaloid, a DNA-intercalating agent, an anti-estrogen agent, a protein kinase inhibitor, a phosphatidylinositol 3 -kinase inhibitor, an immunomodulator, a histone deacetylase inhibitor, a KRAS inhibitor an immunotherapeutic agent, or an epigenetic modulator.

111. The method of claim 110, wherein the antibody-drug conjugate comprises sacituzumab govitecan, mirvetuximab soravtansine, trastuzumab deruxtecan, enfortumab vedotin, or tisotumab vedotin.

112. The method of claim 110, wherein the DNA synthesis inhibitor comprises capecitabine, gemcitabine, nelarabine, or hydroxycarbamide.

113. The method of claim 110, wherein the platinum-based agent comprises carboplatin, oxaliplatin or cisplatin.

114. The method of claim 110, wherein the topoisomerase I inhibitor comprises camptothecin, irinotecan or topotecan.

115. The method of claim 110, wherein the topoisomerase II inhibitor comprises etoposide or teniposide.

116. The method of claim 110, wherein the DNA-intercalating agent comprises doxorubicin or liposomal doxorubicin.

117. The method of claim 110, wherein the alkylating agent comprises temozolomide, dactinomycin, melphalan, altretamine, carmustine, bendamustine, busulfan, lomustine, chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, or procarbazine.

118. The method of claim 110, wherein the anti-microtubule agent comprises estramustine.

119. The method of claim 110, wherein the taxane-related anti-mitotic agent comprises docetaxel, paclitaxel, cabazitaxel, abraxane, or larotaxel.

120. The method of claim 110, wherein the anti-metabolite comprises 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, hydroxyurea, fludarabine, floxuridine, cladribine, pentostatin, or methotrexate.

121. The method of claim 110, wherein the anti-tumor plant alkaloid comprises vinblastine, vincristine, or vinorelbine.

122. The method of claim 110, wherein the anti-estrogen agent comprises tamoxifen, toremifene, raloxifene, lasofoxifene, afimoxifene, arzoxifene, bazedoxifene, fispemifene, ormeloxifene, ospemifene, tesmilifene, trilostane, CHF 4227, fulvestrant, elacestrant, giredestrant, amcenestrant, camizestrant, ataraestane, formestane, exemestane, letrozole, anastrozole, fadrozole; gonadotropin-releasing hormone, leuprolide, leuprolide acetate, enzalutamide, abiraterone acetate, or bicalutamide.

123. The method of claim 110, wherein the protein kinase inhibitor comprises alvocidib, palbociclib, ribociclib, trilaciclib, abemaciclib, crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrectinib, lorlatinib, vemurafenib, dabrafenib, infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547, trametinib, cobimetinib, binimetinib, selumetinib, ulixertinib, MK-8353, LY-3214966, bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib, erlotinib, linifanib, sunitinib, pazopanib, gefitinib, osimertinib, cetuximab, panitumumab, trastuzumab, neratinib, lapatinib, or cabozantinib.

124. The method of claim 110 or 123, wherein the protein kinase inhibitor comprises a CDK4 / 6 inhibitor.

125. The method of claim 124, wherein the CDK4 / 6 inhibitor comprises palbociclib, ribociclib, trilaciclib, or abemaciclib.

126. The method of claim 110, wherein the phosphatidylinositol 3-kinase inhibitor comprises apelisib, duvelisib, copanlisib, or idelalisib.

127. The method of claim 110, wherein the histone deacetylase inhibitor comprises voninostat.

128. The method of claim 110, wherein the KRAS inhibitor can comprise AMG510, MRTX849, JNJ-74699157 / ARS- 3248, Bl 1701963, Bl 1823911, BAY-293, GDC-6036, MRTX1 133, or a RAS(ON) inhibitor.

129. The method of claim 110, wherein the immunotherapeutic agent targets at least one of PD1, PD-L1, PD-L2, CTLA-4, LAG3, TINO, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, 4-1BB, GITR, 0X40, or TGF-beta receptor.

130. The method of claim 129, wherein the immunotherapeutic agent comprises a CTLA-4 inhibitor, a PD1 inhibitor, a PD-L1 inhibitor, a LAG3 inhibitor, or a 4- IBB agonist.

131. The method of claim 130, wherein the CTLA-4 inhibitor comprises tremelimumab or ipilimumab.

132. The method of claim 130, wherein the PD1 inhibitor comprises nivolumab or pembrolizumab.

133. The method of claim 130, wherein the PD-L1 inhibitor comprises atezolizumab, avelumab, or durvalumab.

134. The method of claim 130, wherein the LAG3 inhibitor comprises BMS-986016.

135. The method of claim 110, wherein the epigenetic modulator comprises EZH2a, ARID1A, ARID2, PRMT1-9, BRD4, IDH1 / 2, or BCL6.

Citation Information

Patent Citations

  • Ingestible aggregate and delivery system incorporating the same

    EP0190826A2

  • Confectionery compositions containing magnesium trisilicate adsorbates

    US4647459A

  • Pharmaceutical compositions

    US5275823A

  • Pyrimidine derivatives

    US6908920B2

  • Pyrimidine derivatives

    US7173028B2

Cited By

  • Cyclin-dependent kinase (CDK2) inhibitors

    WO2026176311A1